Cidara Therapeutics (CDTX) S-1 23 Dec 24 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2024
Document Information [Line Items]
Document Type	S-1
Entity Registrant Name	CIDARA THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-1537286
Entity Address, Address Line One	6310 Nancy Ridge Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	(858)
Local Phone Number	752-6170
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001610618
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Jeffrey Stein, Ph.D.
Entity Address, Address Line One	6310 Nancy Ridge Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	(858)
Local Phone Number	752-6170

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 127,386	$ 35,778	$ 32,731
Accounts receivable	1,699	14,075	5,718
Prepaid expenses and other current assets	27,686	1,712	5,577
Current assets from discontinued operations	0	9,290	1,068
Total current assets	156,771	60,855	45,094
Property and equipment, net	561	557	222
Finance lease right-of-use asset, net	722	782	0
Operating lease right-of-use asset	3,035	3,788	1,099
Other assets	1,242	114	114
Noncurrent assets from discontinued operations	0	934	958
Total assets	162,331	67,030	47,487
Current liabilities:
Accounts payable	2,967	3,772	1,447
Accrued liabilities	8,569	14,177	7,672
Accrued indirect tax liabilities	26,289	18,040	11,534
Accrued compensation and benefits	4,933	5,034	4,922
Current contract liabilities	0	430	1,004
Current portion of finance lease liability	259	218	0
Current portion of operating lease liability	1,322	1,082	1,211
Current liabilities from discontinued operations	0	24,665	13,610
Total current liabilities	44,339	67,418	41,400
Long-term finance lease liability	378	575	0
Long-term operating lease liability	1,984	3,002	0
Noncurrent liabilities from discontinued operations	0	4,245	20,525
Total liabilities	46,701	75,240	61,925
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock
Common stock	1	1	1
Additional paid-in capital	674,580	433,220	404,061
Accumulated deficit	(558,951)	(441,431)	(418,500)
Total stockholders' equity (deficit)	115,630	(8,210)	(14,438)
Total liabilities and stockholders' equity (deficit)	162,331	67,030	47,487
Series A Convertible Voting Preferred Stock
Stockholders' equity (deficit):
Preferred stock	0	0
Series X Convertible Preferred Stock
Stockholders' equity (deficit):
Preferred stock	$ 0	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	20,000,000	20,000,000
Common stock, shares issued (in shares)	7,046,633	4,530,113	3,623,591
Common stock, shares outstanding (in shares)	7,046,633	4,530,113	3,623,591
Series A Convertible Voting Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	204,725
Preferred stock, shares issued (in shares)		0
Preferred stock, shares outstanding (in shares)	204,725	0
Preferred stock, shares issued (in shares)	240,000
Series X Convertible Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	4,947,759	4,947,759	4,947,759
Preferred stock, shares issued (in shares)	2,156,713	2,156,713	1,870,713
Preferred stock, shares outstanding (in shares)	2,104,472	2,104,472	1,818,472

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Collaboration revenue	$ 9,217,000	$ 5,090,000	$ 6,220,000	$ 6,512,000	$ 4,293,000	$ 4,743,000	$ 11,310,000	$ 9,036,000	$ 1,275,000	$ 20,527,000	$ 15,548,000	$ 23,283,000	$ 23,496,000
Total revenues	9,217,000	5,090,000	6,220,000	6,512,000	4,293,000	4,743,000	11,310,000	9,036,000	1,275,000	20,527,000	15,548,000	23,283,000	23,496,000
Operating expenses:
Acquired in-process research and development									84,883,000	0
Research and development	10,386,000	8,657,000	9,710,000	8,581,000	6,276,000	5,545,000	18,367,000	11,821,000	25,005,000	28,753,000	20,402,000	36,763,000	30,168,000
Selling, general and administrative	3,299,000	3,181,000	3,653,000	3,783,000	3,645,000	4,675,000	6,834,000	8,320,000	13,307,000	10,133,000	12,103,000	13,580,000	15,227,000
Total operating expenses	13,685,000	11,838,000	13,363,000	12,364,000	9,921,000	10,220,000	25,201,000	20,141,000	123,195,000	38,886,000	32,505,000	50,343,000	45,395,000
Loss from operations	(4,468,000)	(6,748,000)	(7,143,000)	(5,852,000)	(5,628,000)	(5,477,000)	(13,891,000)	(11,105,000)	(121,920,000)	(18,359,000)	(16,957,000)	(27,060,000)	(21,899,000)
Other income, net:
Interest income, net	613,000	623,000	232,000	55,000	(6,000)	(20,000)	855,000	(26,000)	3,998,000	1,468,000	29,000	1,995,000	191,000
Total other income, net	613,000	623,000	232,000	55,000	(6,000)	(20,000)	855,000	(26,000)	3,998,000	1,468,000	29,000	1,995,000	191,000
Net loss from continuing operations before income tax expense	(3,855,000)	(6,125,000)	(6,911,000)	(5,797,000)	(5,634,000)	(5,497,000)	(13,036,000)	(11,131,000)	(117,922,000)	(16,891,000)	(16,928,000)	(25,065,000)	(21,708,000)
Income tax benefit (expense)									0	(8,000)		(15,000)	(14,000)
Net loss from continuing operations									(117,922,000)	(16,899,000)		(25,080,000)	(21,722,000)
Income (loss) from discontinued operations (including loss on disposal of discontinued operations of zero and $1,799 during the three and nine months ended September 30, 2024, respectively), net of income taxes									402,000	(2,819,000)		2,149,000	(11,862,000)
Net loss and comprehensive loss	(9,107,000)	(13,624,000)	3,013,000	14,246,000	(15,759,000)	(18,474,000)	(10,611,000)	(34,233,000)	(117,520,000)	(19,718,000)	(19,987,000)	(22,931,000)	(33,584,000)
Net loss and comprehensive loss	$ (9,107,000)	$ (13,624,000)	$ 3,013,000	$ 14,246,000	$ (15,759,000)	$ (18,474,000)	$ (10,611,000)	$ (34,233,000)	$ (117,520,000)	$ (19,718,000)	$ (19,987,000)	$ (22,931,000)	$ (33,584,000)
Basic net loss per common share from continuing operations (in dollars per share)									$ (22.61)	$ (3.91)		$ (5.74)	$ (6.22)
Diluted net loss per common share from continuing operations (in dollars per share)									(22.61)	(3.91)		(5.74)	(6.22)
Basic net earnings (loss) per common share from discontinued operations (in dollars per share)									0.08	(0.65)		0.49	(3.39)
Diluted net earnings (loss) per common share from discontinued operations (in dollars per share)									0.08	(0.65)		0.49	(3.39)
Basic net loss per common share (in dollars per share)	$ (2.02)	$ (1.65)	$ 0.6	$ 3.22	$ (2.93)	$ (5.42)	$ (2.51)	$ (9.97)	(22.53)	(4.56)	$ (5.78)	(5.25)	(9.61)
Diluted net loss per common share (in dollars per share)	$ (2.02)	$ (1.65)	$ 0.6	$ 3.22	$ (2.93)	$ (5.42)	$ (2.51)	$ (9.97)	$ (22.53)	$ (4.56)	$ (5.78)	$ (5.25)	$ (9.61)
Shares used to compute basic net earnings (loss) per common share (in shares)	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017	5,215,365	4,319,536	3,458,608	4,371,375	3,492,925
Shares used to compute diluted net earnings (loss) per common share (in shares)	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017	5,215,365	4,319,536	3,458,608	4,371,375	3,492,925

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Loss on disposal of discontinued operations	$ 1,799	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (117,520)	$ (19,718)	$ (22,931)	$ (33,584)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of discontinued operations	1,799	0
Stock-based compensation	2,249	2,231	3,061	3,532
Non-cash operating lease expense	753	895	1,158	981
Depreciation and amortization	114	79	112	143
Amortization of costs to obtain a contract with a customer	184	53	77	0
Amortization of finance lease right-of-use asset	60	0	6	0
Non-cash interest expense	44	0	5	1
Changes in assets and liabilities:
Accounts receivable	14,270	2,655	(10,413)	(477)
Inventory	6,097	(2,901)	(6,097)	0
Prepaid expenses, other current assets, and other assets	(26,832)	2,776	3,735	(2,440)
Accounts payable and accrued liabilities	(6,422)	6,204	8,886	(2,371)
Accrued indirect tax liabilities	8,249	3,155	6,506	3,945
Accrued compensation and benefits	(46)	(402)	235	203
Contract liabilities	(29,340)	(3,956)	(5,799)	2,646
Operating lease liabilities	(778)	(781)	(973)	(1,052)
Net cash used in operating activities	(147,119)	(9,710)	(22,432)	(28,473)
Investing activities:
Purchases of property and equipment	(129)	(327)	(505)	(118)
Net cash used in investing activities	(129)	(327)	(505)	(118)
Financing activities:
Proceeds from private placement, net of issuance costs	239,095	0
Proceeds from underwritten public offering, net of issuance costs	0	17,256	17,256	0
Proceeds from public offering of common stock, net of issuance costs	0	8,706	8,707	2,362
Proceeds from exercise of stock options	0	14	21	0
Issuance costs for underwritten public offering		0	0	(720)
Principal repayments of Term Loan		0	0	(2,593)
Payment of finance lease liabilities	(200)	0
Payment for shares withheld to fund payroll taxes	(39)	0
Net cash provided by financing activities	238,856	25,976	25,984	(951)
Net increase in cash and cash equivalents	91,608	15,939	3,047	(29,542)
Cash and cash equivalents at beginning of period	35,778	32,731	32,731	62,273
Cash and cash equivalents at end of period	127,386	48,670	35,778	32,731
Supplemental disclosure of cash flows:
Interest paid		0	0	40
Income taxes paid	95	651	797	0
Non-cash investing activities:
Purchases of property and equipment, included in accounts payable and accrued liabilities	0	178	11	69
Finance lease right-of-use asset obtained in exchange for lease liability			788	0
Right-of-use asset obtained in exchange for lease liability	0	3,847	3,847	0
Non-cash financing activities:
Purchase of shares pursuant to Employee Stock Purchase Plan	$ 55	63	122	140
Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets		$ 0	$ 0	$ 8

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited) - USD ($) $ in Thousands	Total	Private Placement	Underwritten Public Offering	Public Offering	Common Stock	Common Stock Underwritten Public Offering	Common Stock Public Offering	Additional Paid-In Capital	Additional Paid-In Capital Private Placement	Additional Paid-In Capital Underwritten Public Offering	Additional Paid-In Capital Public Offering	Accumulated Deficit	Series A Convertible Voting Preferred Stock	Series A Convertible Voting Preferred Stock Preferred Stock	Series A Convertible Voting Preferred Stock Preferred Stock Private Placement	Series X Convertible Preferred Stock	Series X Convertible Preferred Stock Preferred Stock	Series X Convertible Preferred Stock Preferred Stock Underwritten Public Offering
Balance, beginning (in shares) at Dec. 31, 2021																	1,818,472
Balance, beginning at Dec. 31, 2021	$ 13,104				$ 1			$ 398,019				$ (384,916)					$ 0
Balance, beginning (in shares) at Dec. 31, 2021					3,393,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)							32,208
Issuance of stock, net of issuance costs				$ 500							$ 500
Issuance of common stock upon vesting of restricted stock units (in shares)					27,039
Stock-based compensation	1,165							1,165
Net income (loss)	(18,474)											(18,474)
Balance, ending (in shares) at Mar. 31, 2022																1,818,472	1,818,472
Balance, ending at Mar. 31, 2022	$ (3,705)				$ 1			399,684				(403,390)					$ 0
Balance, ending (in shares) at Mar. 31, 2022	3,452,567				3,452,567
Balance, beginning (in shares) at Dec. 31, 2021																	1,818,472
Balance, beginning at Dec. 31, 2021	$ 13,104				$ 1			398,019				(384,916)					$ 0
Balance, beginning (in shares) at Dec. 31, 2021					3,393,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under Employee Stock Purchase Plan	69
Net income (loss)	(34,233)
Balance, ending (in shares) at Jun. 30, 2022																1,818,472	1,818,472
Balance, ending at Jun. 30, 2022	$ (18,543)				$ 1			400,605				(419,149)					$ 0
Balance, ending (in shares) at Jun. 30, 2022	3,462,024				3,462,024
Balance, beginning (in shares) at Dec. 31, 2021																	1,818,472
Balance, beginning at Dec. 31, 2021	$ 13,104				$ 1			398,019				(384,916)					$ 0
Balance, beginning (in shares) at Dec. 31, 2021					3,393,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under Employee Stock Purchase Plan	69
Net income (loss)	(19,987)
Balance, ending (in shares) at Sep. 30, 2022																1,818,472	1,818,472
Balance, ending at Sep. 30, 2022	$ (2,247)				$ 1			402,655				(404,903)					$ 0
Balance, ending (in shares) at Sep. 30, 2022	3,559,141				3,559,141
Balance, beginning (in shares) at Dec. 31, 2021																	1,818,472
Balance, beginning at Dec. 31, 2021	$ 13,104				$ 1			398,019				(384,916)					$ 0
Balance, beginning (in shares) at Dec. 31, 2021					3,393,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)							170,723
Issuance of stock, net of issuance costs				2,370							2,370
Issuance of common stock upon vesting of restricted stock units (in shares)					41,380
Issuance of common stock under Employee Stock Purchase Plan (in shares)					18,168
Issuance of common stock under Employee Stock Purchase Plan	140							140
Stock-based compensation	3,532							3,532
Net income (loss)	(33,584)											(33,584)
Balance, ending (in shares) at Dec. 31, 2022																1,818,472	1,818,472
Balance, ending at Dec. 31, 2022	$ (14,438)				$ 1			404,061				(418,500)					$ 0
Balance, ending (in shares) at Dec. 31, 2022	3,623,591				3,623,591
Balance, beginning (in shares) at Mar. 31, 2022																1,818,472	1,818,472
Balance, beginning at Mar. 31, 2022	$ (3,705)				$ 1			399,684				(403,390)					$ 0
Balance, beginning (in shares) at Mar. 31, 2022	3,452,567				3,452,567
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)					252
Issuance of common stock under Employee Stock Purchase Plan (in shares)					9,205
Issuance of common stock under Employee Stock Purchase Plan	$ 69							69
Stock-based compensation	852							852
Net income (loss)	(15,759)											(15,759)
Balance, ending (in shares) at Jun. 30, 2022																1,818,472	1,818,472
Balance, ending at Jun. 30, 2022	$ (18,543)				$ 1			400,605				(419,149)					$ 0
Balance, ending (in shares) at Jun. 30, 2022	3,462,024				3,462,024
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)							83,197
Issuance of stock, net of issuance costs				1,208							1,208
Issuance of common stock upon vesting of restricted stock units (in shares)					13,920
Stock-based compensation	$ 842							842
Net income (loss)	14,246											14,246
Balance, ending (in shares) at Sep. 30, 2022																1,818,472	1,818,472
Balance, ending at Sep. 30, 2022	$ (2,247)				$ 1			402,655				(404,903)					$ 0
Balance, ending (in shares) at Sep. 30, 2022	3,559,141				3,559,141
Balance, beginning (in shares) at Dec. 31, 2022																1,818,472	1,818,472
Balance, beginning at Dec. 31, 2022	$ (14,438)				$ 1			404,061				(418,500)					$ 0
Balance, beginning (in shares) at Dec. 31, 2022	3,623,591				3,623,591
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)						554,300	307,936											286,000
Issuance of stock, net of issuance costs			$ 17,256	8,622						$ 17,256	8,622
Issuance of common stock for exercise of options (in shares)					812
Issuance of common stock for exercise of options	$ 14							14
Issuance of common stock upon vesting of restricted stock units (in shares)					14,617
Stock-based compensation	640							640
Net income (loss)	3,013											3,013
Balance, ending (in shares) at Mar. 31, 2023																2,104,472	2,104,472
Balance, ending at Mar. 31, 2023	$ 15,107				$ 1			430,593				(415,487)					$ 0
Balance, ending (in shares) at Mar. 31, 2023	4,501,256				4,501,256
Balance, beginning (in shares) at Dec. 31, 2022																1,818,472	1,818,472
Balance, beginning at Dec. 31, 2022	$ (14,438)				$ 1			404,061				(418,500)					$ 0
Balance, beginning (in shares) at Dec. 31, 2022	3,623,591				3,623,591
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under Employee Stock Purchase Plan	$ 63
Net income (loss)	(10,611)
Balance, ending (in shares) at Jun. 30, 2023																2,104,472	2,104,472
Balance, ending at Jun. 30, 2023	$ 2,417				$ 1			431,527				(429,111)					$ 0
Balance, ending (in shares) at Jun. 30, 2023	4,512,595				4,512,595
Balance, beginning (in shares) at Dec. 31, 2022																1,818,472	1,818,472
Balance, beginning at Dec. 31, 2022	$ (14,438)				$ 1			404,061				(418,500)					$ 0
Balance, beginning (in shares) at Dec. 31, 2022	3,623,591				3,623,591
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)						554,300	310,983											286,000
Issuance of stock, net of issuance costs			17,256	8,698						17,256	8,698
Issuance of common stock for exercise of options (in shares)					812
Issuance of common stock for exercise of options	$ 14							14
Issuance of common stock upon vesting of restricted stock units (in shares)					23,068
Issuance of common stock under Employee Stock Purchase Plan (in shares)					8,060
Issuance of common stock under Employee Stock Purchase Plan	63							63
Stock-based compensation	2,231							2,231
Net income (loss)	(19,718)											(19,718)
Balance, ending (in shares) at Sep. 30, 2023																2,104,472	2,104,472
Balance, ending at Sep. 30, 2023	$ (5,894)				$ 1			432,323				(438,218)					$ 0
Balance, ending (in shares) at Sep. 30, 2023	4,520,814				4,520,814
Balance, beginning (in shares) at Dec. 31, 2022																1,818,472	1,818,472
Balance, beginning at Dec. 31, 2022	$ (14,438)				$ 1			404,061				(418,500)					$ 0
Balance, beginning (in shares) at Dec. 31, 2022	3,623,591				3,623,591
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)						554,300	310,983											286,000
Issuance of stock, net of issuance costs			$ 17,256	8,699						$ 17,256	8,699
Issuance of common stock for exercise of options (in shares)	1,287				1,287
Issuance of common stock for exercise of options	$ 21							21
Issuance of common stock upon vesting of restricted stock units (in shares)					24,487
Issuance of common stock under Employee Stock Purchase Plan (in shares)					15,465
Issuance of common stock under Employee Stock Purchase Plan	122							122
Stock-based compensation	3,061							3,061
Net income (loss)	(22,931)											(22,931)
Balance, ending (in shares) at Dec. 31, 2023													0	0		2,104,472	2,104,472
Balance, ending at Dec. 31, 2023	$ (8,210)				$ 1			433,220				(441,431)		$ 0			$ 0
Balance, ending (in shares) at Dec. 31, 2023	4,530,113				4,530,113
Balance, beginning (in shares) at Mar. 31, 2023																2,104,472	2,104,472
Balance, beginning at Mar. 31, 2023	$ 15,107				$ 1			430,593				(415,487)					$ 0
Balance, beginning (in shares) at Mar. 31, 2023	4,501,256				4,501,256
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)							3,047
Issuance of stock, net of issuance costs											$ 76
Issuance of common stock upon vesting of restricted stock units (in shares)					232
Issuance of common stock under Employee Stock Purchase Plan (in shares)					8,060
Issuance of common stock under Employee Stock Purchase Plan	$ 63							63
Stock-based compensation	795							795
Net income (loss)	(13,624)			$ 76								(13,624)
Balance, ending (in shares) at Jun. 30, 2023																2,104,472	2,104,472
Balance, ending at Jun. 30, 2023	$ 2,417				$ 1			431,527				(429,111)					$ 0
Balance, ending (in shares) at Jun. 30, 2023	4,512,595				4,512,595
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)					8,219
Stock-based compensation	$ 796							796
Net income (loss)	(9,107)											(9,107)
Balance, ending (in shares) at Sep. 30, 2023																2,104,472	2,104,472
Balance, ending at Sep. 30, 2023	$ (5,894)				$ 1			432,323				(438,218)					$ 0
Balance, ending (in shares) at Sep. 30, 2023	4,520,814				4,520,814
Balance, beginning (in shares) at Dec. 31, 2023													0	0		2,104,472	2,104,472
Balance, beginning at Dec. 31, 2023	$ (8,210)				$ 1			433,220				(441,431)		$ 0			$ 0
Balance, beginning (in shares) at Dec. 31, 2023	4,530,113				4,530,113
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)															240,000
Issuance of stock, net of issuance costs		$ 239,095							$ 239,095
Issuance of common stock for exercise of options (in shares)	0
Issuance of common stock upon conversion of Series A Convertible Voting Preferred Stock (in shares)					2,469,250									(35,275)
Issuance of common stock upon vesting of restricted stock units (in shares)					40,220
Issuance of common stock under Employee Stock Purchase Plan (in shares)					7,050
Issuance of common stock under Employee Stock Purchase Plan	$ 55							55
Value of shares withheld to fund payroll taxes	(39)							(39)
Stock-based compensation	2,249							2,249
Net income (loss)	(117,520)											(117,520)
Balance, ending (in shares) at Sep. 30, 2024													204,725	204,725		2,104,472	2,104,472
Balance, ending at Sep. 30, 2024	$ 115,630				$ 1			$ 674,580				$ (558,951)		$ 0			$ 0
Balance, ending (in shares) at Sep. 30, 2024	7,046,633				7,046,633

THE COMPANY AND BASIS OF PRESEN

THE COMPANY AND BASIS OF PRESENTATION	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
THE COMPANY AND BASIS OF PRESENTATION	1. THE COMPANY AND BASIS OF PRESENTATION Description of Business Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company using its proprietary Cloudbreak ® drug-Fc The Company’s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase 1 and Phase 2a clinical trials under a partnership with J&J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, or Janssen. On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, under which the Company reacquired all rights for CD388 from Janssen to develop and commercialize CD388. The Company’s first commercially approved product in the United States, or U.S., was REZZAYO ® The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited in England, and Cidara Therapeutics (Ireland) Limited in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe. Basis of Presentation The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September 30, 2024, the Company had an accumulated deficit of $559.0 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. At September 30, 2024, the Company had cash and cash equivalents of $127.4 million, which the Company expects, together with the $105.0 million gross proceeds from the Private Placement, will provide sufficient liquidity for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Registration Statement on Form S-1. The Company’s ability to execute its current business plan depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company’s ability to execute on its business plan. The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company’s business, operating results and financial condition and the Company’s ability to achieve its intended business objectives. Any of these actions could materially harm the Company’s business, results of operations and future prospects. Unaudited Interim Financial Data The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB. Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2024 and 2023. Reverse Stock Split On April 23, 2024, the Company effected the approved 1-for-20 S-1 paid-in Basis of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company’s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company’s collaboration and license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.	1. THE COMPANY AND BASIS OF PRESENTATION Description of Business Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase 1 and Phase 2a clinical trials under a partnership with J&J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, or Janssen. On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, under which the Company reacquired all rights for CD388 from Janssen to develop and commercialize CD388. The Company’s first commercially approved product in the United States, or U.S., was REZZAYO ® The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe. Sale of Rezafungin On April 24, 2024, the Company and Napp Pharmaceutical Group Limited, or Napp, an affiliate of Mundipharma Medical Company, or Mundipharma, entered into an Asset Purchase Agreement, or the Napp Purchase Agreement, pursuant to which the Company sold to Napp all of the Company’s rezafungin assets and related contracts. The Company completed all conditions of the sale on April 24, 2024. The Company determined that the sale of rezafungin represented a strategic shift that will have a major effect on the Company’s operations and financial results. Accordingly, the sale of rezafungin is classified as discontinued operations. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as income (loss) from discontinued operations in the consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the consolidated balance sheets. See Note 11 Reverse Stock Split On April 23, 2024, the Company effected the approved 1-for-20 S-1 paid-in Basis of Presentation The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December 31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. At December 31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company’s business plan at the time of filing its Annual Report on Form 10-K In April 2024 the Company received total gross proceeds of $240.0 million in the Series A Private Placement and in November 2024 the Company received total gross proceeds of $105.0 million in the Private Placement (see Note 13), which has alleviated substantial doubt about the Company’s ability to continue as a going concern and provides sufficient liquidity for a period of at least one year following the date that these consolidated financial statements are issued as part of this Registration Statement on Form S-1. The Company’s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company’s ability to execute on its business plan. The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company’s business, operating results and financial condition and the Company’s ability to achieve its intended business objectives. Any of these actions could materially harm the Company’s business, results of operations and future prospects. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s consolidated financial statements relate to estimated collaboration expenses related to the Company’s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company’s collaboration and license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment. Restatement of Consolidated Financial Statements The Company evaluated the indirect taxation consequences upon the first commercial sale of REZZAYO in 2023 and determined that it had a liability for indirect taxation in various tax jurisdictions outside of the U.S. based on its supply chain activities in 2023 and prior years. As a result, it was concluded that in prior years the Company did not appropriately account for indirect taxes which led to understatements of accrued liabilities and operating expenses during the impacted periods. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $11.5 million, an increase in operating expenses of $3.9 million, and an increase in beginning accumulated deficit of $7.6 million, for 2022. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $7.6 million, an increase in operating expenses of $3.7 million, and an increase in beginning accumulated deficit of $3.9 million, for 2021. The consolidated financial statements (as restated) also include adjustments to correct certain other previously identified misstatements relating to fiscal year 2022 and the quarters within 2023 that the Company had determined to be immaterial, both individually and in the aggregate. Impact of Restatement See below for reconciliation from the previously reported amounts to the restated amounts in the consolidated balance sheet, consolidated statement of operations and comprehensive loss, consolidated statement of convertible preferred stock and stockholders’ equity (deficit), and consolidated statement of cash flows as of and for the year ended December 31, 2022. The previously reported amounts were derived from the Company’s Annual Report on Form 10-K The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data): Year Ended December 31, 2022 Corrected Consolidated Balance Sheet As Previously Restatement As Restated Operating lease right-of-use $ 1,205 $ (106 ) $ 1,099 Total assets 47,593 (106 ) 47,487 Accrued indirect tax liabilities —  11,534 11,534 Current portion of operating lease liability 1,317 (106 ) 1,211 Total current liabilities 29,972 11,428 41,400 Total liabilities 50,497 11,428 61,925 Accumulated deficit (406,966 ) (11,534 ) (418,500 ) Total stockholders’ deficit (2,904 ) (11,534 ) (14,438 ) Total liabilities and stockholders’ deficit 47,593 (106 ) 47,487 Year Ended December 31, 2022 Corrected Consolidated Statement of Operations and Comprehensive Loss As Previously Restatement As Restated Revenues: Collaboration revenue $ 23,336 $ 160 $ 23,496 Total revenues 23,336 160 23,496 Loss from operations (22,059 ) 160 (21,899 ) Net loss from continuing operations before income tax expense (21,868 ) 160 (21,708 ) Net loss from continuing operations (21,882 ) 160 (21,722 ) Loss from discontinued operations (7,917 ) (3,945 ) (11,862 ) Net loss and comprehensive loss (29,799 ) (3,785 ) (33,584 ) Basic and diluted net loss per common share from continuing operations (6.26 ) (6.22 ) Basic and diluted net loss per common share from discontinued operations (2.27 ) (3.39 ) Basic and diluted net loss per common share (8.53 ) (9.61 ) Shares used to compute basic and diluted net loss per common share 3,492,925 3,492,925 Additional Paid-In Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders’ Equity (Deficit) As Restatement As Restated Balance, December 31, 2021 $ 398,739 $ (720 ) $ 398,019 Issuance costs for underwritten public offering (720 ) 720 —  Balance, December 31, 2022 404,061 —  404,061 Accumulated Deficit As Restatement As Restated Balance, December 31, 2021 $ (377,167 ) $ (7,749 ) $ (384,916 ) Net loss (29,799 ) (3,785 ) (33,584 ) Balance, December 31, 2022 (406,966 ) (11,534 ) (418,500 ) Total Stockholders’ Equity (Deficit) As Restatement As Restated Balance, December 31, 2021 $ 21,573 $ (8,469 ) $ 13,104 Issuance costs for underwritten public offering (720 ) 720 —  Net loss (29,799 ) (3,785 ) (33,584 ) Balance, December 31, 2022 (2,904 ) (11,534 ) (14,438 ) Year Ended December 31, 2022 Corrected Consolidated Statement of Cash Flows As Previously Restatement As Restated Operating activities: Net loss $ (29,799 ) $ (3,785 ) $ (33,584 ) Adjustments to reconcile net loss to net cash used in operating activities: Non-cash 1,082 (101 ) 981 Changes in assets and liabilities: Accrued indirect tax liabilities —  3,945 3,945 Contract liabilities 2,806 (160 ) 2,646 Operating lease liabilities (1,153 ) 101 (1,052 ) The remainder of the notes to the Company’s consolidated

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. Discontinued Operations The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information. Cash and Cash Equivalents The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Accounts Receivable Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development, or R&D, and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, product sales and the associated indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company’s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Inventory The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&D expense in the period incurred. Inventory is comprised of raw materials and work-in-process, freight-in first-in-first-out Property and Equipment The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements. Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally three Finance Lease In accordance with Accounting Standards Codification Leases right-of-use non-lease The Company recognizes amortization of the right-of-use right-of-use right-of-use right-of-use Operating Lease In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use non-lease Income Taxes The Company reports deferred income taxes in accordance with ASC 740, Income Taxes Indirect Taxes The Company’s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in R&D expenses within discontinued operations, and the related interest and penalties are included in selling, general and administrative, or SG&A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in SG&A in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company’s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed at that time. Indirect tax amounts on commercial sales (product revenue) and asset disposals that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included in inventory within discontinued operations. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Collaboration Revenue If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or a collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates catch-up For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. See Note 6 and Note 9 for additional information. Product Revenue In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta Therapeutics, LLC, or Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024 (see Note 9 for additional information). The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation. The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company’s product to the customer. Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue. Cost of Product Revenue Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in Acquired In-process Acquired in-process The Company evaluates license agreements for IPR&D projects to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the license agreement for IPR&D does not meet the definition of a business and the assets have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&D expense in its condensed consolidated statements of operations and comprehensive loss. In those cases, payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Payments made in connection with regulatory and sales-based milestones will be capitalized and amortized to cost of revenue. Research and Development Expenses R&D expenses consist of wages, benefits and stock-based compensation charges for R&D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials. The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events. Selling, General and Administrative Expenses SG&A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities. Preclinical and Clinical Trial Accruals The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals. Stock-Based Compensation The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company’s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company’s common stock during the equivalent period of the calculated expected term of the Company’s stock-based awards. The Company estimated the expected life of employee stock options using the “simplified” method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met. The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited. Net Earnings (Loss) Per Share The Company follows the guidance in ASC 260, Earnings Per Share non-forfeitable if-converted two-class Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted two-class In accordance with ASC 260, if a company had a discontinued operation, the company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares): Nine Months Ended September 30,   2024     2023   Common stock warrants 866 866 Series A Convertible Voting Preferred Stock 14,330,750 —  Series X Convertible Preferred Stock 1,052,236 1,052,236 Common stock options, RSUs and PRSUs issued and outstanding 2,454,822 646,233 Total 17,838,674 1,699,335 Fair Value of Financial Instruments The Company follows ASC 820-10, Fair Value Measurements and Disclosures 820-10, The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature. Recently Issued and Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, In December 2023, the FASB issued ASU 2023-09, The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company’s condensed consolidated financial statements or related disclosures, or do not apply to the Company.	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Accounts Receivable Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development, or R&D, and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, product sales, and the associated indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company’s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December 31, 2023 or 2022. Inventory The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&D expense in the period incurred. Inventory is comprised of raw materials and work-in-process, freight-in first-in-first-out Property and Equipment The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements. Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally three Finance Lease In accordance with Accounting Standards Codification Leases right-of-use non-lease The Company recognizes amortization of the right-of-use right-of-use right-of-use right-of-use Operating Lease In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use non-lease Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk. Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&A, expenses in the accompanying statements of operations and comprehensive loss. Income Taxes The Company reports deferred income taxes in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. Indirect Taxes The Company’s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in R&D expenses within discontinued operations, and the related interest and penalties are included in SG&A expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in SG&A in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company’s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed at that time. Indirect tax amounts on commercial sales (product revenue) and asset disposals that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included in inventory within discontinued operations. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Collaboration Revenue If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or a collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates catch-up For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. Potential future payments for variable consideration, such as regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. In July 2022, the Company entered into a License Agreement with Melinta Therapeutics, LLC, or Melinta, or the Melinta License Agreement. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. The Mundipharma Collaboration Agreement and the Melinta License Agreement were terminated upon the effectiveness of the assignment to Napp on April 24, 2024, and the related revenue amounts have been reclassified to discontinued operations. See Note 8 and Note 11 Product Revenue In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024 (see Note 11 The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation. The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company’s product to the customer. Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue. Cost of Product Revenue Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in Research and Development Costs R&D expenses consist of wages, benefits and stock-based compensation charges for R&D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials. The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events. Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use. Selling, General and Administrative Expenses SG&A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities. Preclinical and Clinical Trial Accruals The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals. Stock-Based Compensation The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company’s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company’s common stock during the equivalent period of the calculated expected term of the Company’s stock-based awards. The Company estimated the expected life of employee stock options using the “simplified” method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met. The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited. Net Earnings (Loss) Per Share The Company follows the guidance in ASC 260, Earnings Per Share non-forfeitable if-converted two-class Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted two-class In accordance with ASC 260, if a company had a discontinued operation, the company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares): December 31, 2023 2022 Common stock warrants 866 625,859 Series X Convertible Preferred Stock 1,052,236 909,236 Common stock options, RSUs and PRSUs issued and outstanding 638,037 465,965 Total 1,691,139 2,001,060 Fair Value of Financial Instruments The Company follows ASC 820-10, Fair Value Measurements and Disclosures 820-10, The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature. Recently Issued and Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company’s consolidated financial statements or related disclosures, or do not apply to the Company.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	3. FAIR VALUE MEASUREMENTS The Company follows ASC 820-10, As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets. None of the Company’s non-financial non-recurring The following tables summarize the Company’s financial instruments measured at fair value on a recurring basis (in thousands): TOTAL LEVEL 1 LEVEL 2 LEVEL 3 September 30, 2024 Assets: Cash and money market accounts $ 127,386 $ 127,386 $ —  $ —  Total assets at fair value $ 127,386 $ 127,386 $ —  $ —  December 31, 2023 Assets: Cash and money market accounts $ 35,778 $ 35,778 $ —  $ —  Total assets at fair value $ 35,778 $ 35,778 $ —  $ —	3. FAIR VALUE MEASUREMENTS The Company follows ASC 820-10, As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets. None of the Company’s non-financial non-recurring The following tables summarize the Company’s financial instruments measured at fair value on a recurring basis (in thousands): TOTAL LEVEL 1 LEVEL 2 LEVEL 3 December 31, 2023 Assets: Cash and money market accounts $ 35,778 $ 35,778 $ —  $ —  Total assets at fair value $ 35,778 $ 35,778 $ —  $ —  December 31, 2022 Assets: Cash and money market accounts $ 32,731 $ 32,731 $ —  $ —  Total assets at fair value $ 32,731 $ 32,731 $ —  $ —

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Equity [Abstract]
STOCKHOLDERS' EQUITY	4. STOCKHOLDERS’ EQUITY Reverse Stock Split On April 23, 2024, the Company effected the Reverse Stock Split of its shares of common stock and decreased its authorized number of shares of common stock from 200,000,000 shares to 20,000,000 shares. All references in this Registration Statement on Form S-1 Controlled Equity Sales Agreement In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald & Co, or Cantor. During the nine months ended September 30, 2024, the Company sold zero shares of its common stock under the Sales Agreement. During the nine months ended September 30, 2023, the Company sold 310,983 shares of its common stock under the Sales Agreement for net proceeds of approximately $8.7 million after deducting placement agent fees. The Company has not sold shares of its common stock under the Sales Agreement since July 2023. The Company will not be able to sell shares of its common stock under the Sales Agreement until April 16, 2025, due to the loss of its Form S-3 2023 Underwritten Public Offering On March 7, 2023, the Company completed concurrent but separate underwritten public offerings with Cantor, the underwriter, to issue and sell 554,300 shares of its common stock, including the exercise in full by Cantor of their option to purchase an additional 72,300 shares of common stock, and 286,000 shares of the Company’s Series X Convertible Preferred Stock. Cantor agreed to purchase the shares of common stock at a price of $25.34 per share and the shares of Series X Convertible Preferred Stock at a price of $12.67 per share. The total gross proceeds from the offerings, including the full exercise by Cantor of its option to purchase additional shares of common stock, were approximately $19.5 million, before deducting underwriting discounts and commissions and offering expenses. The Company received total net proceeds of approximately $17.3 million, after deducting underwriting discounts, commissions, and other expenses payable by the Company. 2024 Series A Private Placement On April 23, 2024, the Company entered into a securities purchase agreement, or the Series A Securities Purchase Agreement, with certain institutional and other accredited investors, or the Series A Purchasers, pursuant to which the Company issued and sold, in a private placement, or the Series A Private Placement, 240,000 shares of Series A Convertible Voting Preferred Stock, par value $0.0001 per share, or the Series A Convertible Preferred Stock, at a purchase price of $1,000 per share. The closing of the Series A Private Placement took place on April 24, 2024, and the Company received total gross proceeds of $240.0 million. The Company received total net proceeds of approximately $239.1 million, after deducting issuance costs payable by the Company. Preferred Stock Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company’s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at September 30, 2024. Series A Convertible Preferred Stock In April 2024, the Company designated 240,000 shares of preferred stock as Series A Convertible Preferred Stock with a par value of $0.0001 per share. On July 18, 2024, the Company’s stockholders approved, for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to 16,800,000 shares of common stock upon conversion of 240,000 shares of Series A Convertible Preferred Stock issued in the Private Placement completed in April 2024. On July 19, 2024, the Company issued 2,469,250 shares of common stock upon automatic conversion of 35,275 shares of Series A Convertible Preferred Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, including that shares of Series A Convertible Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than 9.99% of the Company’s outstanding shares of common stock as of the applicable conversion date. After conversion, the converted shares of Series A Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series A Convertible Preferred Stock. As of September 30, 2024, shares of preferred stock designated as Series A Convertible Preferred Stock totaled 204,725. The specific terms of the Series A Convertible Preferred Stock are as follows: Conversion: Dividends: as-if-converted Liquidation: Voting: as-if-converted The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480, Distinguishing Liabilities from Equity Series X Convertible Preferred Stock In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share. On August 12, 2020, at the request of certain holders, 52,241 shares of the Company’s Series X Convertible Preferred Stock were converted to an aggregate of 26,120 shares of the Company’s common stock. After conversion, the converted shares of Series X Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series X Convertible Preferred Stock. As of September 30, 2024 and December 31, 2023, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759. The specific terms of the Series X Convertible Preferred Stock are as follows: Conversion: Dividends: as-converted Liquidation: Voting: The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC 480, Distinguishing Liabilities from Equity Common Stock On July 18, 2024, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 20,000,000 shares to 50,000,000 shares, which amendment was filed by the Company with the Secretary of State of the State of Delaware on July 18, 2024 and was effective as of such date. The Company had 50,000,000 shares of common stock authorized as of September 30, 2024. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company’s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company’s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, Common Stock Warrants As of September 30, 2024 and December 31, 2023, warrants to purchase 866 shares of the Company’s common stock were outstanding with a weighted average exercise price of $230.95 per share. The warrants had no intrinsic value at September 30, 2024 and December 31, 2023. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant. Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows (in common stock equivalent shares): September 30, 2024 December 31, 2023 Common stock warrants 866 866 Series A Convertible Preferred Stock 14,330,750 —  Series X Convertible Preferred Stock 1,052,236 1,052,236 Common stock options, RSUs and PRSUs issued and outstanding 2,454,822 638,037 Authorized for future stock awards 1,052,406 170,783 Awards available under the ESPP 67,089 49,623 Total 18,958,169 1,911,545	6. STOCKHOLDERS’ EQUITY Reverse Stock Split On April 23, 2024, the Company effected the Reverse Stock Split of its shares of common stock and decreased its authorized number of shares of common stock from 200,000,000 shares to 20,000,000 shares. All references in this Registration Statement on Form S-1 Controlled Equity Sales Agreement In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald & Co, or Cantor. During the years ended December 31, 2023 and 2022, the Company sold 310,983 and 170,723 shares of common stock for net proceeds of approximately $8.7 million and $2.4 million, respectively, after deducting placement agent fees. As of December 31, 2023, the remaining capacity under the Sales Agreement is $37.1 million. 2023 Underwritten Public Offering On March 7, 2023, the Company completed concurrent but separate underwritten public offerings with Cantor, the underwriter, to issue and sell 554,300 shares of its common stock, including the exercise in full by Cantor of their option to purchase an additional 72,300 shares of common stock, and 286,000 shares of the Company’s Series X Convertible Preferred Stock. Cantor agreed to purchase the shares of common stock at a price of $25.34 per share and the shares of Series X Convertible Preferred Stock at a price of $12.67 per share. The total gross proceeds from the offerings, including the full exercise by Cantor of its option to purchase additional shares of common stock, were approximately $19.5 million, before deducting underwriting discounts and commissions and offering expenses. The Company received total net proceeds of approximately $17.3 million, after deducting underwriting discounts, commissions, and other expenses payable by the Company. Preferred Stock Under the amended and restated certificate of incorporation, the Company’s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at December 31, 2023. In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share. On August 12, 2020, at the request of certain holders, 52,241 shares of the Company’s Series X Convertible Preferred Stock were converted to an aggregate of 26,120 shares of the Company’s common stock. As of December 31, 2023 and 2022 shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759. The specific terms of the Series X Convertible Preferred Stock are as follows: Conversion: Dividends: as-converted Liquidation: Voting: restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock. The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC 480, Distinguishing Liabilities from Equity Common Stock The Company had 20,000,000 shares of common stock authorized as of December 31, 2023. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company’s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company’s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, Common Stock Warrants As of December 31, 2023, warrants to purchase 866 shares of the Company’s common stock were outstanding with a weighted average exercise price of $230.95 per share. During the year ended December 31, 2023, 624,993 common stock warrants expired unexercised. As of December 31, 2022, warrants to purchase 625,859 shares of the Company’s common stock were outstanding with a weighted average exercise price of $136.33 per share. The warrants had no intrinsic value at December 31, 2023 and 2022. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant. Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows (in common stock equivalent shares): December 31, 2023 2022 Common stock warrants 866 625,859 Series X Convertible Preferred Stock 1,052,236 909,236 Common stock options, RSUs and PRSUs issued and outstanding 638,037 465,965 Authorized for future stock awards 170,783 223,713 Awards available under the ESPP 49,623 40,572 Total 1,911,545 2,265,345

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following (in thousands): December 31, 2023 2022 Laboratory equipment $ 2,817 $ 2,415 Leasehold improvements 425 425 Computer hardware and software 327 305 Office equipment 36 93 Furniture and fixtures 142 142 3,747 3,380 Less accumulated depreciation and amortization (3,190 ) (3,158 ) Total $ 557 $ 222 Depreciation and amortization of property and equipment of $0.1 million and $0.1 million were recorded for the years ended December 31, 2023 and 2022, respectively.

EQUITY INCENTIVE PLANS

EQUITY INCENTIVE PLANS	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
EQUITY INCENTIVE PLANS	5. EQUITY INCENTIVE PLANS 2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan In May 2024, the Company’s board of directors approved and adopted the Company’s 2024 Equity Incentive Plan, or 2024 EIP. In July 2024, the Company’s stockholders approved the adoption of the 2024 EIP. The 2024 EIP is the successor to and continuation of the Company’s 2015 Equity Incentive Plan, or 2015 EIP, previously approved and adopted in March 2015 by the Company’s board of directors and stockholders. The 2024 EIP became effective on July 18, 2024. Upon the effectiveness of the 2024 EIP, no additional awards were or will be granted under the 2015 EIP, although all outstanding stock awards granted under the 2015 EIP continue to be governed by the terms of the 2015 EIP. Under the 2024 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. In December 2020, the Company’s board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2024 EIP, 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a three incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant. 2015 Employee Stock Purchase Plan In March 2015, the Company’s board of directors and stockholders approved and adopted the ESPP. The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 through and including January 1, 2025, by the lesser of (i) 1% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31, (ii) 24,516 shares, or (iii) such lesser number as determined by the Company’s board of directors. The ESPP allows substantially all employees to purchase the Company’s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period. An employee’s payroll deductions under the ESPP are limited to 15% of the employee’s eligible compensation. During the nine months ended September 30, 2024 and 2023, 7,050 shares and 8,060 shares, respectively, were issued pursuant to the ESPP. As of September 30, 2024, total unrecognized compensation expense related to the ESPP was $0.1 million and is expected to be recognized over approximately 0.6 years. Restricted Stock Units The following table summarizes RSU and PRSU activity during the nine months ended September 30, 2024: Number of RSUs and Weighted Outstanding at December 31, 2023 104,886 $ 22.83 RSUs and PRSUs granted 153,012 12.30 RSUs and PRSUs vested (43,053 ) 24.24 RSUs and PRSUs canceled (17,705 ) 24.68 Outstanding at September 30, 2024 197,140 $ 14.18 The weighted-average grant date fair value of RSUs and PRSUs granted by the Company during the nine months ended September 30, 2023 was $20.10 per share. The total fair value of RSUs and PRSUs vested during the nine months ended September 30, 2024 and 2023 was approximately $1.0 million and $0.7 million, respectively. At September 30, 2024, estimated unrecognized compensation expense related to RSUs and PRSUs granted was approximately $2.3 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.6 years. Stock Options The following table summarizes stock option activity during the nine months ended September 30, 2024: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Total Intrinsic Value Outstanding at December 31, 2023 533,151 $ 44.61 6.72 $ 57 Options granted 1,796,401 11.14 Options exercised —  —  Options canceled (71,870 ) 31.68 Outstanding at September 30, 2024 2,257,682 $ 18.39 9.10 $ 1 Vested and expected to vest at September 30, 2024 2,257,682 $ 18.39 9.10 $ 1 Exercisable at September 30, 2024 420,941 $ 48.19 5.74 $ 1 The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option. The weighted-average grant date fair value of stock options granted by the Company during the nine months ended September 30, 2024 and 2023 was $8.05 and $14.45 per share, respectively. As of September 30, 2024, total unrecognized share-based compensation expense related to unvested stock options was approximately $15.2 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.9 years. Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Nine Months Ended September 30, 2024 2023 Stock compensation expense: Research and development $ 868 $ 629 Selling, general and administrative 1,150 1,038 Stock compensation expense recorded in continuing operations 2,018 1,667 Stock compensation expense recorded in discontinued operations 231 564 Total stock compensation expense $ 2,249 $ 2,231	7. EQUITY INCENTIVE PLANS 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan In December 2020, the Company’s board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment In March 2015, the Company’s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number as determined by the Company’s board of directors. Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a three 2015 Employee Stock Purchase Plan In March 2015, the Company’s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP. The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i) 1% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31, (ii) 24,516 shares, or (iii) such lesser number as determined by the Company’s board of directors. The ESPP allows substantially all employees to purchase the Company’s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period. An employee’s payroll deductions under the ESPP are limited to 15% of the employee’s eligible compensation. During the years ended December 31, 2023 and 2022, 15,465 and 18,168 shares, respectively, were issued pursuant to the ESPP. As of December 31, 2023, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately 0.4 years. Restricted Stock Units The following table summarizes RSU and PRSU activity during the year ended December 31, 2023: Number of RSUs and PRSUs Weighted Average Outstanding at December 31, 2022 61,149 $ 29.36 RSUs and PRSUs granted 75,778 20.04 RSUs and PRSUs vested (24,487 ) 29.64 RSUs and PRSUs canceled (7,554 ) 25.76 Outstanding at December 31, 2023 104,886 $ 22.83 The weighted-average grant date fair value of RSUs and PRSUs granted by the Company during the year ended December 31, 2022 was $16.64 per share. The total fair value of RSUs and PRSUs vested during the years ended December 31, 2023 and 2022 was approximately $0.7 million and $1.6 million, respectively. At December 31, 2023, estimated unrecognized compensation expense related to RSUs and PRSUs granted was approximately $1.7 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2 years. Stock Options The following table summarizes stock option activity during the year ended December 31, 2023: Number of Shares Weighted Average Exercise Weighted Average Remaining Contractual in Years Total Intrinsic Outstanding at December 31, 2022 404,816 $ 55.60 6.65 $ 48 Options granted 161,666 20.40 Options exercised (1,287 ) 16.65 Options canceled (32,044 ) 62.40 Outstanding at December 31, 2023 533,151 $ 44.61 6.72 $ 57 Vested and expected to vest at December 31, 2023 533,151 $ 44.61 6.72 $ 57 Exercisable at December 31, 2023 361,644 $ 55.04 5.71 $ 54 The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option. The weighted-average grant date fair value of stock options granted by the Company during the years ended December 31, 2023 and 2022 was $14.45 and $10.14, respectively, per share. As of December 31, 2023, total unrecognized share-based compensation expense related to unvested stock options was approximately $2.4 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.9 years. The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented: For the years ended December 31, 2023 2022 2015 EIP and 2020 IIP Risk-free interest rate 3.58% - 4.61% 1.39% - 4.02% Expected dividend yield 0% 0% Expected volatility 82% - 83% 70% - 75% Expected term (years) 5.50 - 6.08 5.50 - 6.08 2015 ESPP Risk-free interest rate 4.29% - 5.43% 1.57% - 2.65% Expected dividend yield 0% 0% Expected volatility 64% - 147% 75% - 98% Expected term (years) 0.50 - 2.00 0.50 - 2.00 Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands): Years ended December 31,   2023     2022   Stock compensation expense: Research and development $ 839 $ 809 Selling, general and administrative 1,469 1,945 Stock compensation expense recorded in continuing operations 2,308 2,754 Stock compensation expense recorded in discontinued operations 753 951 Total stock compensation expense $ 3,061 $ 3,705

DEBT

DEBT	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
DEBT	5. DEBT Term Loan On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific W es

SIGNIFICANT AGREEMENTS AND CONT

SIGNIFICANT AGREEMENTS AND CONTRACTS	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SIGNIFICANT AGREEMENTS AND CONTRACTS	6. SIGNIFICANT AGREEMENTS AND CONTRACTS Janssen License Agreement On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, which effectively terminated the Janssen Collaboration Agreement (as defined below), including the license granted by the Company to Janssen. Under the Janssen License Agreement, the Company also assumed responsibility for further clinical development, manufacture, registration and commercialization of DFCs based on the Company’s Cloudbreak platform for the prevention and treatment of influenza, including CD388 and products or compounds containing CD388. Janssen granted the Company an exclusive, worldwide, fee-bearing know-how know-how, The Company paid Janssen an upfront payment of $85.0 million on April 24, 2024. The Company is also obligated to pay Janssen up to $150.0 million in development and regulatory milestone payments with respect to CD388 and up to $455.0 million in commercialization milestone payments with respect to CD388. The Company has no obligation to pay any royalties to Janssen for future sales of any commercialized CD388 product. As the Company had an existing revenue contract with Janssen, or the Janssen Collaboration Agreement, the Company considered the contract modification and consideration payable to a customer guidance in ASC 606. The Company determined this bundled arrangement would be accounted for as a termination of the existing revenue contract and the creation of a new arrangement. No amounts paid or payable to Janssen were recorded against revenue as the consideration payable to Janssen does not exceed the fair value of the distinct assets acquired in the Janssen License Agreement. In accordance with authoritative guidance, the Company was determined to be the accounting acquirer and substantially all of the fair value of the gross assets acquired is concentrated in the IPR&D of CD388. The reacquired license to develop, manufacture, and commercialize activities of CD388 is part of the acquired IPR&D. The transaction was accounted for as an asset acquisition. The acquired IPR&D did not have an alternative future use as of the acquisition date. Therefore the initial purchase price of $85.4 million, inclusive of $0.4 million in direct transaction costs, was expensed as of the acquisition date as acquired IPR&D in the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2024. Prior to the acquisition, the Company had $0.5 million in contract liabilities related to deferred revenue balances and unearned cancelled performance obligations associated with the Janssen Collaboration Agreement. The settlement of the preexisting contract liabilities was recorded as an offset to the Janssen License Agreement’s initial purchase price resulting in $84.9 million expensed as acquired IPR&D in condensed consolidated statements of operations and comprehensive loss. The Company’s contingent future obligation to pay Janssen up to $150.0 million in development and regulatory milestone payments with respect to CD388 and up to $455.0 million in commercialization milestone payments with respect to CD388 will be recognized if and when the contingency is resolved and the consideration is paid or becomes payable. Janssen Collaboration Agreement On March 31, 2021, the Company and Janssen entered into an exclusive, worldwide license and collaboration agreement, or Janssen Collaboration Agreement, to develop and commercialize one or more DFCs based on the Company’s Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date. Collaboration out-of-pocket In September 2023, Janssen delivered its Election to Proceed Notice for CD388, whereby Janssen assumed the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continued to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and was reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement. Following Janssen’s Election to Proceed Notice, Janssen was obligated at its sole expense to diligently continue development and commercialization. Licenses Non-Compete non-compete Financial Terms Research Plan activities. The Company was also eligible to receive up to $695.0 million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single Termination Revenue Recognition Prior to the Janssen Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price is equal to the up-front A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, was as follows: Licenses of Intellectual Property. know-how, know-how Research and Development Services. Clinical Supply Services. Milestone Payments. Royalties. Contract Liabilities The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Janssen Collaboration Agreement during the nine months ended September 30, 2024 (in thousands): Opening balance, December 31, 2023 $ 430 Revenue from performance obligations satisfied during reporting period (370 ) Gain on settlement of unsatisfied performance obligations (60 ) Closing balance, September 30, 2024 $ —  As of September 30, 2024, the aggregate transaction price allocated to performance obligations that are unsatisfied is zero under the Janssen Collaboration Agreement. As of September 30, 2024, the Company recorded no accounts receivable associated with the Janssen Collaboration Agreement. As of December 31, 2023, the Company recorded $1.9 million in accounts receivable associated with the Janssen Collaboration Agreement. The following table presents collaboration revenue under the Janssen Collaboration Agreement (in thousands): Nine Months Ended September 30, 2024 2023 Revenue from Janssen Collaboration Agreement: Point in Time: License of Intellectual Property - upon milestone achieved $ —  $ 2,347 Over Time: Research and Development Services $ 1,273 $ 16,324 Clinical Supply Services 2 1,856 Total Revenue from Janssen Collaboration Agreement $ 1,275 $ 20,527	8. SIGNIFICANT AGREEMENTS AND CONTRACTS Janssen Collaboration Agreement On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company’s Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date. Collaboration Plan clinical trials. Both parties were responsible for conducting certain specified chemistry, manufacturing and controls, or CMC, development activities under the Research Plan. Janssen was solely responsible, and reimbursed the Company, for internal full-time equivalent and out-of-pocket In September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen assumed the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continued to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and was reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement. Following Janssen’s Election to Proceed Notice, Janssen, was obligated at its sole expense to diligently continue development and commercialization. Licenses Non-Compete non-compete Financial Terms mid-single Termination Revenue Recognition As of December 31, 2023, the Company determined the transaction price is equal to the up-front $10.0 million. The transaction price includes the total estimated costs related to research and development and clinical supply services, which can increase or decrease as costs to continue the research and development efforts become known. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows: Licenses of Intellectual Property. know-how, know-how Research and Development Services. Clinical Supply Services. Milestone Payments. re-evaluate Royalties. Contract Liabilities The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Janssen Collaboration Agreement during the year ended December 31, 2023 (in thousands): Opening balance, December 31, 2022 $ 1,004 Payments received in advance 292 Revenue from performance obligations satisfied during reporting period (866 ) Closing balance, December 31, 2023 $ 430 Current portion of contract liabilities $ 430 Long-term portion of contract liabilities —  Total contract liabilities, December 31, 2023 $ 430 As of December 31, 2023, the aggregate transaction price allocated to performance obligations that are unsatisfied is $3.8 million under the Janssen Collaboration Agreement. These amounts are expected to be recognized over 0.5 years which represent the remaining research periods under the Janssen Collaboration Agreement. As of December 31, 2023 and December 31, 2022, the Company recorded $1.9 million and $5.6 million, respectively, in accounts receivable associated with the Janssen Collaboration Agreement. The following table presents collaboration revenue under the Janssen Collaboration Agreement (in thousands): Year Ended Year Ended (As Restated) Revenue from Janssen Collaboration Agreement: Point in Time: License of Intellectual Property - upon milestones achieved $ 2,347 $ 976 Over Time: Research and Development Services 19,011 18,814 Clinical Supply Services 1,925 3,706 Total Revenue from Janssen Collaboration Agreement $ 23,283 $ 23,496

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Finance Lease Obligations The Company has a finance lease for lab equipment which was entered into in November 2023. The finance lease has a term of 36 months, monthly lease payments of $25,009, and an option to purchase the lab equipment for $1 at the end of the finance lease term. As of September 30, 2024, the Company was reasonably certain that it would exercise the option to purchase the lab equipment at the end of the finance lease term. The useful life of the lab equipment is estimated to be 10 years. The rate implicit to the finance lease used in measuring the Company’s finance lease liability was 8.0%. The following table presents information about the amount and timing of cash flows arising from the Company’s finance lease as of September 30, 2024 (in thousands): 2024 $ 75 2025 300 2026 300 2027 25 Total undiscounted finance lease payments 700 Less: Imputed interest (63 ) Present value of finance lease payments $ 637 The balance sheet classification of the Company’s finance lease is as follows (in thousands): Balance Sheet Classification: Finance lease right-of-use $ 788 Accumulated amortization (66 ) Net finance lease right-of-use $ 722 Current portion of finance lease liability $ 259 Long-term finance lease liability 378 Total finance lease liabilities $ 637 As of September 30, 2024, the weighted average remaining finance lease term was 2.3 years. Cash paid for amounts included in the measurement of finance lease liabilities was $0.2 million for the nine months ended September 30, 2024. Finance lease costs were $0.1 million for the nine months ended September 30, 2024. Operating Lease Obligations The Company has an operating lease for laboratory and office space in San Diego, California which was entered into in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015. On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional 36 months and increased the base rent to $133,371 per month effective January 1, 2024, subject to 4% increases every January. The operating lease expires on December 31, 2026 with options for two individual two-year The following table presents information about the amount and timing of cash flows arising from the Company’s operating lease as of September 30, 2024 (in thousands): 2024 $ 400 2025 1,664 2026 1,731 Total undiscounted operating lease payments 3,795 Less: Imputed interest (489 ) Present value of operating lease payments $ 3,306 The balance sheet classification of the Company’s operating lease is as follows (in thousands): Balance Sheet Classification: Operating lease right-of-use $ 3,035 Current portion of operating lease liability $ 1,322 Long-term operating lease liability 1,984 Total operating lease liabilities $ 3,306 As of September 30, 2024, the weighted average remaining operating lease term was 2.3 years. Cash paid for amounts included in the measurement of operating lease liabilities was $1.2 million and $1.0 million for the nine months ended September 30, 2024 and 2023, respectively. Operating lease costs were $1.3 million and $1.2 million for the nine months ended September 30, 2024 and 2023, respectively. These costs are primarily related to the Company’s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days. Contractual Obligations The Company enters into contracts in the normal course of business with vendors for R&D activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period. Reduction in Force On September 9, 2024, management of the Company, as authorized by the board of directors of the Company, approved a reduction in the Company’s workforce (the “Reduction”) of 20 employees, which represented approximately 30% of the Company’s workforce. The Reduction reflects the Company’s focus on the clinical development of CD388, its influenza product candidate. The Reduction was substantially completed by November 1, 2024. As a result of the Reduction, the Company incurred charges of approximately $1.2 million for severance payments and employee benefits included in R&D expenses in the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2024. The Company does not expect to incur additional charges related to the Reduction. As of September 30, 2024, these charges were unpaid and included in accrued compensation and benefits in the condensed consolidated balance sheets. The Company expects these charges to be paid during the fourth quarter of 2024.	10. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company at December 31, 2023 which will have, individually or in the aggregate, a material adverse Finance Lease Obligations The Company has a finance lease for lab equipment which was entered into in November 2023. The finance lease has a term of 36 months, monthly lease payments of $25,009, and an option to purchase the lab equipment for $1 at the end of the finance lease term. As of December 31, 2023, the Company was reasonably certain that it would exercise the option to purchase the lab equipment at the end of the finance lease term. The useful life of the lab equipment is estimated to be 10 years. The rate implicit to the finance lease used in measuring the Company’s finance lease liability was 8.0%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance lease as of December 31, 2023 (in thousands): 2024 $ 275 2025 300 2026 300 2027 25 Total undiscounted finance lease payments 900 Less: Imputed interest (107 ) Present value of finance lease payments $ 793 The balance sheet classification of the Company’s finance lease is as follows (in thousands): Balance Sheet Classification: Finance lease right-of-use $ 788 Accumulated amortization (6 ) Net finance lease right-of-use $ 782 Current portion of finance lease liability $ 218 Long-term finance lease liability 575 Total finance lease liabilities $ 793 As of December 31, 2023, the weighted average remaining finance lease term was 3.1 years. Cash paid for amounts included in the measurement of finance lease liabilities was zero for the year ended December 31, 2023. Finance lease costs were immaterial for the year ended December 31, 2023. Operating Lease Obligations The Company has an operating lease for laboratory and office space in San Diego, California which was entered into in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015. On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional 36 months and increases the base rent to $133,371 per month effective January 1, 2024, subject to 4% increases every January. The operating lease expires on December 31, 2026 with options for two individual two-year The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating lease as of December 31, 2023 (in thousands): 2024 $ 1,600 2025 1,665 2026 1,731 Total undiscounted operating lease payments 4,996 Less: Imputed interest (912 ) Present value of operating lease payments $ 4,084 The balance sheet classification of the Company’s operating lease is as follows (in thousands): Balance Sheet Classification: Operating lease right-of-use $ 3,788 Current portion of operating lease liability $ 1,082 Long-term operating lease liability 3,002 Total operating lease liabilities $ 4,084 As of December 31, 2023, the weighted average remaining operating lease term was 3 years. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.2 million for the years ended December 31, 2023 and 2022, respectively. Operating lease costs were $1.6 million and $1.3 million for the years ended December 31, 2023 and 2022, respectively. These costs are primarily related to the Company’s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days. Contractual Obligations The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.

INCOME TAXES

INCOME TAXES	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	8. INCOME TAXES The Company estimates an annual effective income tax rate based on projected results for the year and applied the rate to net income or (loss) before taxes to calculate income tax expense or (benefit). When applicable, the income tax provision also includes adjustments for discrete tax items. Any refinements made due to subsequent information that affects the estimated annual effective income tax rate are reflected as adjustments in the current period. For the nine months ended September 30, 2024 the Company recognized no income tax expense from continuing operations, and income tax benefit (expense) from continuing operations recognized for the nine months ended September 30, 2023 was immaterial.	9. INCOME TAXES The tax provision for income taxes from continuing operations consisted of the following (in thousands): December 31, 2023 2022 Current tax (benefit) provision: Federal $ (1 ) $ —  State 16 14 Total current tax provision 15 14 Deferred tax provision: Federal —  —  State —  —  Total deferred tax provision —  —  Total tax provision $ 15 $ 14 The Company accounts for income taxes under ASC 740. Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The following table provides a reconciliation between income taxes from continuing operations computed at the federal statutory rate and the provision for income taxes (in thousands): Years Ended December 31,   2023     2022   (As Restated) Federal income taxes at 21% for 2023 and 2022 $ (5,264 ) $ (4,559 ) State income tax, net of federal benefit (241 ) (158 ) Nondeductible expenses 234 365 Tax credits (1,096 ) (1,092 ) Rate change (54 ) 491 Change in valuation allowance 5,861 (22,218 ) Reserve for uncertain tax positions 273 (10,346 ) 162m deferred tax asset limitation 128 82 382 NOL and tax credit limitation —  37,513 Expired stock awards 174 1,052 Other —  (1,116 ) Income tax expense $ 15 $ 14 Current year tax expense is primarily the result of capitalized Internal Revenue Code, or IRC, Section 174 research and development expenditures, effective January 1, 2022, creating taxable income which can be offset with net operating losses and credits that are limited in use by IRC Sections 382 and 383. The income tax expense from discontinued operations for the years ended December 31, 2023 and 2022 of $0.4 million and $0.3 million, respectively, are not included in the above income tax provision from continuing operations. Significant components of the Company’s net deferred tax assets are as follows (in thousands): December 31, 2023 2022 (As Restated) Deferred tax assets: Net operating losses $ 35,506 $ 42,043 Tax credits 9,747 9,327 Intangibles 136 160 Capitalized R&D 25,871 14,706 Stock compensation 1,424 1,385 Lease liabilities 1,112 275 Deferred revenue 5,951 5,620 Accrued indirect tax liabilities 4,114 2,617 Other 725 1,018 Total deferred tax assets 84,586 77,151 Less valuation allowance (83,086 ) (76,713 ) Deferred tax assets, net of valuation allowance 1,500 438 Deferred tax liabilities: Prepaid expenses (214 ) (189 ) Capitalized inventory costs (244 ) — Right-of-use (1,042 ) (249 ) Total deferred tax liabilities (1,500 ) (438 ) Net deferred tax assets $ —  $ —  The deferred income tax assets and liabilities associated with discontinued operations remain in the Company’s consolidated balance sheets rather than being included in the assets and liabilities for discontinued operations, as the sale of rezafungin is structured as a sale of assets. These deferred income tax assets and liabilities associated with discontinued operations will be realized upon the sale of the assets. At December 31, 2023, the Company had federal and state tax net operating loss carryforwards of approximately $153.8 million and $131.2 million, respectively. The federal and state net operating loss carryforwards begin to expire in 2035 and 2029, respectively, unless previously utilized. The Company also has federal research and development credit and orphan drug credit carryforwards totaling $9.5 million and state research and development credit carryforwards totaling $5.3 million. The federal research and development credit and orphan drug credit carryforwards begin to expire in 2035, unless previously utilized. The state research and development credit carryforwards begin to expire in 2029, with the exception of $5.3 million which have no expiration date. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence, including a history of operating losses, management has determined that it is more likely than not that the net deferred tax assets will not be realized. The valuation allowance increased by $6.4 million in 2023 and decreased by $19.7 million in 2022. Future utilization of the Company’s net operating loss and tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to IRC Sections 382 and 383, as a result of ownership changes that may have occurred or that could occur in the future. An ownership change occurs when a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards through 2023 and has adjusted the attributes for their estimated limitation. The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December 31, 2023 and 2022, the unrecognized tax benefits recorded were approximately $11.5 million and $11.0 million, respectively. Approximately $9.7 million of the unrecognized tax benefits would reduce the Company’s annual effective tax rates, if recognized, subject to the valuation allowance. The Company adjusted the uncertain tax position in the current year on certain attributes related to the IRC Section 382/383 analysis performed in the current year. The Company does not anticipate a significant change in the unrecognized tax benefits within the next 12 months. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands): Years Ended December 31,   2023     2022   (As Restated) Balance as of the beginning of the year $ 11,015 $ 23,990 Increases related to current year tax positions 552 497 Decreases related to prior year tax positions (47 ) (13,472 ) Balance as of the end of the year $ 11,520 $ 11,015 The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by the U.S. and state jurisdictions where applicable. There are currently no pending income tax examinations. The Company’s tax years from inception in 2013 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties since inception.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	9. DISCONTINUED OPERATIONS On April 24, 2024, the Company and Napp, entered into the Napp Purchase Agreement, pursuant to which the Company sold to Napp, effective as of April 24, 2024, the following: • all of the Company’s rezafungin assets, including all of the Company’s right to receive future milestones and royalties under the Melinta License Agreement and the Mundipharma Collaboration Agreement, • all rezafungin intellectual property rights, including patents and know-how, • rezafungin and comparator inventory, • specified prepaid assets and specified contracts, in exchange for Napp’s assumption of certain liabilities of the rezafungin business, including the ongoing costs of the ReSPECT Phase 3 clinical trial and the ReSTORE Phase 3 clinical trial in China and the Company’s obligations from and after closing under the Melinta License Agreement, • the Commercial Supply Agreement dated January 23, 2023 between the Company and Melinta, and • the Commercial Supply Agreement, dated December 12, 2022 between the Company and Mundipharma, or the Mundipharma Commercial Supply Agreement. No Company employees were transferred to Napp. The Company, Napp and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Mundipharma Commercial Supply Agreement from the Company to Napp, or the Novation Agreement. In the Novation Agreement, Mundipharma agreed to forgive the Company’s obligation to refund a $11.1 million development milestone advance due as of December 31, 2024, net of royalties, to Mundipharma under the Mundipharma Collaboration Agreement, provided that (a) the Company performs its obligation to provide carryover services under a Transition Services Agreement with Napp, or the TSA, for a period of 45 days following the closing, (b) the Company delivers all of the purchased assets, including product know-how know-how In connection with the Napp Purchase Agreement and as a condition to entering into the Napp Purchase Agreement, the Company entered into an amendment, dated April 23, 2024, to the Melinta License Agreement that, among other changes, modified the future regulatory milestones payable upon receipt of marketing approval of the current rezafungin acetate product. The Melinta License Agreement, as amended, was assigned and novated to Napp at the closing of the asset sale. The action to divest rezafungin was taken because of the Company’s strategy to streamline its portfolio and focus on the Cloudbreak platform and other financial considerations. The Company has determined that the sale of rezafungin represents a strategic shift that had a major effect on its result of operations. Rezafungin met the criteria to be reported as discontinued operations in the period ended September 30, 2024. The Company has separately reported the financial results of rezafungin as discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all periods presented. Assets and liabilities classified as discontinued operations in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023 consist of the following: (In thousands) September 30, 2024 December 31, 2023 Carrying amount of major assets included as part of discontinued operations: Current assets: Accounts receivable $ —  $ 2,171 Inventory —  6,097 Prepaid expenses and other current assets —  1,022 Current assets from discontinued operations —  9,290 Noncurrent assets: Other assets —  934 Noncurrent assets from discontinued operations —  934 Total assets from discontinued operations $ —  $ 10,224 Carrying amount of major liabilities included as part of discontinued operations: Current liabilities: Current contract liabilities —  24,665 Current liabilities from discontinued operations —  24,665 Noncurrent liabilities: Long-term contract liabilities —  4,245 Noncurrent liabilities from discontinued operations —  4,245 Total liabilities from discontinued operations $ —  $ 28,910 Inventory consisted of the following (in thousands): September 30, 2024 December 31, 2023 Raw materials $ —  $ 2,691 Work-in-process —  3,406 Total inventory $ —  $ 6,097 The Company’s capitalized inventory consisted of costs incurred subsequent to FDA approval of REZZAYO in March 2023. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&D expense in the period incurred. There were no inventory write downs during the nine months ended September 30, 2024. The results of operations from discontinued operations during the nine months ended September 30, 2024 and 2023 have been reflected as income (loss) from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consist of the following: Nine Months Ended September 30, (In thousands) 2024 2023 Major line items constituting pretax income (loss) of discontinued operations Revenues: Total revenues $ 29,263 $ 25,795 Operating expenses: Cost of product revenue 9,030 387 Research and development 10,572 25,061 Selling, general and administrative 7,460 2,795 Total operating expenses 27,062 28,243 Income (loss) from operations 2,201 (2,448 ) Other expense, net: Loss on disposal of discontinued operations (1,799 ) —  Total other expense, net (1,799 ) —  Income (loss) from discontinued operations before income tax expense 402 (2,448 ) Income tax expense —  (371 ) Income (loss) from discontinued operations, net of income taxes $ 402 $ (2,819 ) The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. The total net cash used in operating activities from discontinued operations was $18.1 million and $9.3 million for the nine months ended September 30, 2024 and 2023, respectively. There were no investing or financing activities from discontinued operations for the nine months ended September 30, 2024 and 2023. Napp Purchase Agreement In connection with the execution of the Napp Purchase Agreement, the Company modified its existing collaboration and license arrangements and Commercial Supply Agreements with Mundipharma and Melinta. As a result of the modified revenue contracts and the termination of these revenue arrangements, the Company concluded the Napp Purchase Agreement and the other aforementioned arrangements represented a bundled arrangement with a single commercial objective that required assessment under the guidance for revenue recognition. As a result, the Company identified the distinct performance obligations within the arrangements (including whether the distinct performance obligations were within the scope of ASC 606), determined the transaction price and the standalone selling prices of the distinct performance obligations, and allocated the transaction price using the relative standalone selling price method to the distinct performance obligations. Revenue Recognition On April 24, 2024, as of the execution date of the Napp Purchase Agreement (and all other bundled arrangements), the Company determined the transaction price is equal to $21.2 million for the sale of all rezafungin assets, including the Company’s right to receive future milestones and royalties from Mundipharma and Melinta, all rezafungin intellectual property rights, including patents and know-how, The $21.2 million transaction price was allocated to the distinct performance obligations on the basis of their respective relative standalone selling prices. All Rezafungin assets know-how, Specified Prepaid Assets and Contracts Transition Services 76-day 0.1 Mundipharma Collaboration Agreement On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections. Collaboration GLP-compliant Licenses The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co-exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin. Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license Financial Terms up-front Termination Revenue Recognition Prior to the Mundipharma Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, was as follows: Licenses of Intellectual Property. know-how, know-how Research and Development Services. Clinical Supply Services. Milestone Payments. Royalties. immaterial No Melinta License Agreement On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contained or incorporated rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory. Licenses non-human Non-Compete Commercialization. Continued Development and Regulatory Activities. close-out The Company remained the holder of the rezafungin IND and new drug application, or NDA, before the Melinta License Agreement was assigned. Both regulatory applications were to transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated sNDA for the Prophylaxis Indication, after which Melinta would have been responsible for performing all activities that may have been necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta’s sole expense, subject to Melinta’s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket Supply and Transfer of CMC activities. Financial Terms. mid-teens. Termination. Revenue Recognition Prior to the Melinta License Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, was as follows: Licenses of Intellectual Property. know-how, know-how Research and Development Services. Clinical Supply Services. Milestone Payments. Royalties. Costs to Obtain a Contract with a Customer The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $2.0 million upon execution of the Melinta License Agreement, and capitalized an additional $0.5 million upon achievement of a milestone, in accordance with ASC 340, Other Assets and Deferred Costs Contract Liabilities The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Mundipharma Collaboration Agreement and Melinta License Agreement during the nine months ended September 30, 2024 (in thousands): Opening balance, December 31, 2023 $ 28,910 Revenue from performance obligations satisfied during reporting period (28,910 ) Closing balance, September 30, 2024 $ —  Current portion of contract liabilities $ —  Long-term portion of contract liabilities —  Total contract liabilities, September 30, 2024 $ —  As of September 30, 2024, the aggregate transaction price allocated to performance obligations that are unsatisfied is zero under both the Mundipharma Collaboration Agreement and the Melinta License Agreement. As of September 30, 2024, the Company recorded no accounts receivable associated with the Mundipharma Collaboration Agreement and Melinta License Agreement. As of September 30, 2024, the Company recorded accounts receivable associated with the Napp Purchase Agreement of $1.7 million. As of December 31, 2023, the Company recorded $13.9 million and $0.4 million in accounts receivable associated with the Mundipharma Collaboration Agreement and Melinta License Agreement, respectively. The following table presents collaboration revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition (in thousands): Nine Months Ended September 30, 2024 Mundipharma Melinta Revenue from Collaboration, License and Purchase Agreements: Point in Time: Rezafungin Assets, including Sale of IP and Inventory $ 20,833 $ — License of Intellectual Property - upon milestone achieved 813 —  Product Revenue 2,826 —  Royalty Revenue 37 125 Over Time: Research and Development Services 3,895 457 Clinical Supply Services 175 —  Transition Services 102 —  Total Revenue from Collaboration, License and Purchase Agreements $ 28,681 $ 582 Nine Months Ended September 30, 2023 Mundipharma Melinta Revenue from Collaboration, License and Purchase Agreements: Point in Time: License of Intellectual Property - upon milestone achieved $ —  $ 17,257 Clinical Drug Supply 26 —  Product Revenue —  1,468 Royalty Revenue —  70 Over Time: Research and Development Services 4,870 1,859 Clinical Supply Services 245 —  Total Revenue from Collaboration, License and Purchase Agreements $ 5,141 $ 20,654	11. DISCONTINUED OPERATIONS On April 24, 2024, the Company and Napp, entered into the Napp Purchase Agreement, pursuant to which the Company sold to Napp, effective as of April 24, 2024, the following: • all of the Company’s rezafungin assets, including all of the Company’s right to receive future milestones and royalties under the Melinta License Agreement and the Mundipharma Collaboration Agreement, • all rezafungin intellectual property rights, including patents and know-how, • rezafungin and comparator inventory, • specified prepaid assets and specified contracts, in exchange for Napp’s assumption of certain liabilities of the rezafungin business, including the ongoing costs of the ReSPECT Phase 3 clinical trial and the ReSTORE Phase 3 clinical trial in China and the Company’s obligations from and after closing under the Melinta License Agreement, • the Commercial Supply Agreement dated January 23, 2023 between the Company and Melinta, and • the Commercial Supply Agreement, dated December 12, 2022 between the Company and Mundipharma, or the Mundipharma Commercial Supply Agreement. No Company employees were transferred to Napp. The Company, Napp and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Mundipharma Commercial Supply Agreement from the Company to Napp, or the Novation Agreement. In the Novation Agreement, Mundipharma agreed to forgive the Company’s obligation to refund a $11.1 million development milestone advance due as of December 31, 2024, net of royalties, to Mundipharma under the Mundipharma Collaboration Agreement, provided that (a) the Company performs its obligation to provide carryover services under a Transition Services Agreement with Napp, or the TSA, for a period of 45 days following the closing, (b) the Company delivers all of the purchased assets, including product know-how know-how In connection with the Napp Purchase Agreement and as a condition to entering into the Napp Purchase Agreement, the Company entered into an amendment, dated April 23, 2024, to the Melinta License Agreement that, among other changes, modified the future regulatory milestones payable upon receipt of marketing approval of the current rezafungin acetate product. The Melinta License Agreement, as amended, was assigned and novated to Napp at the closing of the asset sale. The action to divest rezafungin was taken because of the Company’s strategy to streamline its portfolio and focus on the Cloudbreak platform and other financial considerations. The Company has determined that the sale of rezafungin represents a strategic shift that had a major effect on its result of operations. Rezafungin met the criteria to be reported as discontinued operations at the time of the sale. The Company has separately reported the financial results of rezafungin as discontinued operations in the consolidated statements of operations and comprehensive loss for all periods presented. Assets and liabilities classified as discontinued operations in the condensed consolidated balance sheets as of December 31, 2023 and 2022 consist of the following: December 31, 2023 December 31, 2022 (In thousands) (As Restated) Carrying amount of major assets included as part of discontinued operations: Current assets: Accounts receivable $ 2,171 $ 116 Inventory 6,097 —  Prepaid expenses and other current assets 1,022 952 Current assets from discontinued operations 9,290 1,068 Noncurrent assets: Other assets 934 958 Noncurrent assets from discontinued operations 934 958 Total assets from discontinued operations $ 10,224 $ 2,026 Carrying amount of major liabilities included as part of discontinued operations: Current liabilities: Current contract liabilities $ 24,665 $ 13,610 Current liabilities from discontinued operations 24,665 13,610 Noncurrent liabilities: —  Long-term contract liabilities 4,245 20,525 Noncurrent liabilities from discontinued operations 4,245 20,525 Total liabilities from discontinued operations $ 28,910 $ 34,135 Inventory consisted of the following (in thousands): December 31, 2023 2022 Raw materials $ 2,691 $ —  Work-in-process 3,406 —  Total inventory $ 6,097 $ —  The Company’s capitalized inventory consisted of costs incurred subsequent to FDA approval of REZZAYO in March 2023. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&D expense in the period incurred. There were no inventory write downs during the year ended December 31, 2023. The results of operations from discontinued operations during the years ended December 31, 2023 and 2022 have been reflected as income (loss) from discontinued operations, net of income taxes in the consolidated statements of operations and comprehensive loss and consist of the following: Years ended December 31, (In thousands) 2023 2022 (As Restated) Major line items constituting pretax income (loss) of discontinued operations Revenues: Total revenues $ 40,622 $ 40,952 Operating expenses: Cost of product revenue 1,523 —  Research and development 31,769 47,237 Selling, general and administrative 4,753 5,319 Total operating expenses 38,045 52,556 Income (loss) from discontinued operations before income tax expense 2,577 (11,604 ) Income tax expense (428 ) (258 ) Income (loss) from discontinued operations, net of income taxes $ 2,149 $ (11,862 ) The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. The total net cash used in operating activities from discontinued operations was $10.5 million and $3.9 million for the years ended December 31, 2023 and 2022, respectively. There were no investing or financing activities from discontinued operations for the years ended December 31, 2023 and 2022. Mundipharma Collaboration Agreement On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections. Collaboration GLP-compliant Licenses the Mundipharma Territory, subject to the Company’s retained right in Japan before the Mundipharma Collaboration Agreement was terminated The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co-exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin. Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party’s territory. Financial Terms up-front Termination Revenue Recognition Prior to the Mundipharma Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front Licenses of Intellectual Property. know-how, know-how Research and Development Services. Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the R&D services was best measured in an amount proportional to the R&D expenses incurred and the total estimated R&D expenses. Clinical Supply Services. Milestone Payments. Royalties. Melinta License Agreement On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contained or incorporated rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory. Licenses non-human Non-Compete for development or commercialization, or commercialized any product in the echinocandin class of drugs in the Melinta Territory without the other party’s prior written consent, subject to certain provisions in connection with a change of control of a party. Commercialization. Continued Development and Regulatory Activities. close-out The Company remained the holder of the rezafungin IND and new drug application, or NDA, before the Melinta License Agreement was assigned. Both regulatory applications were to transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated sNDA for the Prophylaxis Indication, after which Melinta would have been responsible for performing all activities that may have been necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta’s sole expense, subject to Melinta’s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket Supply and Transfer of CMC activities. Financial Terms. mid-teens. Termination. Revenue Recognition Prior to the Melinta License Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&D efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, was as follows: Licenses of Intellectual Property. know-how, know-how Research and Development Services. Clinical Supply Services. Milestone Payments. Royalties. Costs to Obtain a Contract with a Customer The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $2.0 million upon execution of the Melinta License Agreement, and capitalized an additional $0.5 million upon achievement of a milestone, in accordance with ASC 340, Other Assets and Deferred Costs $1.8 million, respectively, and is included within the results of operations from discontinued operations. As of December 31, 2023, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $0.2 million. Contract Liabilities The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Mundipharma Collaboration Agreement and Melinta License Agreement during the year ended December 31, 2023 (in thousands): Opening balance, December 31, 2022 $ 34,135 Payments received in advance 1,463 Payments receivable 1,488 Revenue from performance obligations satisfied during reporting period (8,176 ) Closing balance, December 31, 2023 $ 28,910 Current portion of contract liabilities $ 24,665 Long-term portion of contract liabilities 4,245 Total contract liabilities, December 31, 2023 $ 28,910 As of December 31, 2023, the aggregate transaction price allocated to performance obligations that are unsatisfied is $11.5 million and $3.7 million under the Mundipharma Collaboration Agreement and Melinta License Agreement, respectively. These amounts were expected to be recognized over 2 years which represent the remaining research periods under each of the Mundipharma Collaboration Agreement and Melinta License Agreement. As of December 31, 2023, the Company recorded $13.9 million and $0.4 million in accounts receivable associated with the Mundipharma Collaboration Agreement and Melinta License Agreement, respectively. $1.7 million and $0.4 million of the accounts receivable associated with the Mundipharma Collaboration Agreement and Melinta License Agreement, respectively, were included in discontinued operations. As of December 31, 2022, the Company recorded $0.2 million in accounts receivable associated with the Mundipharma Collaboration Agreement, of which $0.1 million was included in discontinued operations. The following table presents collaboration revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition (in thousands): Year Ended December 31, 2023 Mundipharma Melinta Revenue from Collaboration, License and Purchase Agreements: Point in Time: License of Intellectual Property - upon milestones achieved $ 3,252 $ 17,257 Clinical Drug Supply 26 —  Product Revenue 2,867 1,468 Royalty Revenue —  168 Over Time: Research and Development Services 12,303 2,441 Clinical Supply Services 840 —  Total Revenue from Collaboration, License and Purchase Agreements $ 19,288 $ 21,334 Year Ended December 31, 2022 Mundipharma Melinta Revenue from Collaboration and License Agreements: Point in Time: License of Intellectual Property - upon transfer of license $ —  $ 25,885 License of Intellectual Property - upon milestones achieved 3,252 —  Clinical Drug Supply 484 —  Over Time: Research and Development Services 9,595 811 Clinical Supply Services 925 —  Total Revenue from Collaboration and License Agreements $ 14,256 $ 26,696

SELECTED QUARTERLY FINANCIAL DA

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2023
Quarterly Financial Information Disclosure [Abstract]
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	12. SELECTED QUARTERLY FINANCIAL DATA ( UNAUDITED Restatement of Interim Financial Information (Unaudited) Due to the misstatements described in Note 1 above, the Company has restated, and recast for the discontinued operations and reverse stock split, its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023. March 31, 2023 March 31, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 47,976 $ —  $ 47,976 $ 36,488 $ —  $ 36,488 Restricted Cash —  —  —  1,482 —  1,482 Accounts receivable 25,703 295 25,998 8,649 —  8,649 Prepaid expenses and other current assets 5,245 (143 ) 5,102 4,038 —  4,038 Current assets from discontinued operations 564 168 732 1,350 —  1,350 Total current assets 79,488 320 79,808 52,007 —  52,007 Property and equipment, net 270 —  270 239 —  239 Operating lease right-of-use 917 (81 ) 836 2,030 (184 ) 1,846 Other assets 102 —  102 155 —  155 Noncurrent assets from discontinued operations 959 —  959 864 —  864 Total assets $ 81,736 $ 239 $ 81,975 $ 55,295 $ (184 ) $ 55,111 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable 3,980 46 4,026 2,861 —  2,861 Accrued liabilities 9,078 30 9,108 9,234 720 9,954 Accrued indirect tax liabilities —  11,795 11,795 —  7,942 7,942 Accrued compensation and benefits 5,843 —  5,843 3,079 —  3,079 Current contract liabilities 699 —  699 4,514 —  4,514 Current portion of operating lease liability 1,001 (81 ) 920 1,190 (100 ) 1,090 Current portion of term loan —  —  —  1,481 —  1,481 Current liabilities from discontinued operations 15,062 29 15,091 9,746 —  9,746 Total current liabilities 35,663 11,819 47,482 32,105 8,562 40,667 Long-term contract liabilities 92 (9 ) 83 337 —  337 Long-term operating lease liability —  —  —  1,004 (84 ) 920 Noncurrent liabilities from discontinued operations 19,144 159 19,303 16,892 —  16,892 Total liabilities 54,899 11,969 66,868 50,338 8,478 58,816 March 31, 2023 March 31, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Commitments and contingencies Stockholders’ equity (deficit): Preferred stock (1) Series X Convertible Preferred stock (2) —  —  —  —  —  —  Common stock (3) 1 —  1 1 —  1 Additional paid-in 430,593 —  430,593 400,404 (720 ) 399,684 Accumulated deficit (403,757 ) (11,730 ) (415,487 ) (395,448 ) (7,942 ) (403,390 ) Total stockholders’ equity (deficit) 26,837 (11,730 ) 15,107 4,957 (8,662 ) (3,705 ) Total liabilities and stockholders’ equity (deficit) $ 81,736 $ 239 $ 81,975 $ 55,295 $ (184 ) $ 55,111 (1) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022 (2) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at March 31, 2023 and March 31, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at March 31, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at March 31, 2022 (3) Common stock, $0.0001 par value; 20,000,000 shares authorized at March 31, 2023 and March 31, 2022; 4,501,256 shares issued and outstanding at March 31, 2023 and 3,452,567 shares issued and outstanding at March 31, 2022 June 30, 2023 June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 50,430 $ —  $ 50,430 $ 24,637 $ —  $ 24,637 Restricted cash —  — —  370 —  370 Accounts receivable 5,310 —  5,310 4,113 —  4,113 Prepaid expenses and other current assets 3,230 —  3,230 5,909 —  5,909 Current assets from discontinued operations 3,270 434 3,704 1,517 —  1,517 Total current assets 62,240 434 62,674 36,546 —  36,546 Property and equipment, net 297 —  297 201 —  201 Operating lease right-of-use 4,388 (81 ) 4,307 1,765 (162 ) 1,603 Other assets 101 —  101 150 —  150 Noncurrent assets from discontinued operations 960 —  960 862 —  862 Total assets $ 67,986 $ 353 $ 68,339 $ 39,524 $ (162 ) $ 39,362 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable 1,899 —  1,899 3,091 —  3,091 Accrued liabilities 10,022 —  10,022 8,567 —  8,567 Accrued indirect tax liabilities —  13,431 13,431 —  10,582 10,582 Accrued compensation and benefits 3,582 —  3,582 3,464 —  3,464 Current contract liabilities 369 —  369 4,444 —  4,444 Current portion of operating lease liability 942 (81 ) 861 1,233 (104 ) 1,129 Current portion of term loan —  —  —  370 —  370 Current liabilities from discontinued operations 14,606 —  14,606 10,286 —  10,286 Total current liabilities 31,420 13,350 44,770 31,455 10,478 41,933 Long-term contract liabilities —  —  —  195 —  195 Long-term operating lease liability 3,601 —  3,601 679 (58 ) 621 Noncurrent liabilities from discontinued operations 17,551 —  17,551 15,156 —  15,156 Total liabilities 52,572 13,350 65,922 47,485 10,420 57,905 June 30, 2023 June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Commitments and contingencies Stockholders’ equity (deficit): Preferred stock (4) Series X Convertible Preferred stock (5) —  —  —  —  —  —  Common stock (6) 1 —  1 1 —  1 Additional paid-in 431,527 —  431,527 400,605 —  400,605 Accumulated deficit (416,114 ) (12,997 ) (429,111 ) (408,567 ) (10,582 ) (419,149 ) Total stockholders’ equity (deficit) 15,414 (12,997 ) 2,417 (7,961 ) (10,582 ) (18,543 ) Total liabilities and stockholders’ equity (deficit) $ 67,986 $ 353 $ 68,339 $ 39,524 $ (162 ) $ 39,362 (4) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and June 30, 2022 (5) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at June 30, 2023 and June 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at June 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at June 30, 2022 (6) Common stock, $0.0001 par value; 20,000,000 shares authorized at June 30, 2023 and June 30, 2022; 4,512,595 shares issued and outstanding at June 30, 2023 and 3,462,024 shares issued and outstanding at June 30, 2022 September 30, 2023 September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 48,670 $ —  $ 48,670 $ 53,078 $ —  $ 53,078 Accounts receivable 2,670 —  2,670 4,917 —  4,917 Prepaid expenses and other current assets 2,794 —  2,794 3,932 —  3,932 Current assets from discontinued operations 3,570 757 4,327 1,972 —  1,972 Total current assets 57,704 757 58,461 63,899 —  63,899 Property and equipment, net 580 —  580 173 —  173 Operating lease right-of-use 4,131 (81 ) 4,050 1,491 (137 ) 1,354 Other assets 103 —  103 132 —  132 Noncurrent assets from discontinued operations 950 —  950 1,163 —  1,163 Total assets $ 63,468 $ 676 $ 64,144 $ 66,858 $ (137 ) $ 66,721 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable 3,661 —  3,661 4,244 —  4,244 Accrued liabilities 11,772 —  11,772 8,162 —  8,162 Accrued indirect tax liabilities —  14,689 14,689 —  11,314 11,314 Accrued compensation and benefits 4,457 —  4,457 4,117 —  4,117 Current contract liabilities 750 —  750 3,254 —  3,254 Current portion of operating lease liability 1,051 (81 ) 970 1,277 (108 ) 1,169 Current liabilities from discontinued operations 13,929 —  13,929 11,995 —  11,995 Total current liabilities 35,620 14,608 50,228 33,049 11,206 44,255 Long-term contract liabilities —  —  —  98 —  98 Long-term operating lease liability 3,306 —  3,306 344 (29 ) 315 Noncurrent liabilities from discontinued operations 16,504 —  16,504 24,300 —  24,300 Total liabilities 55,430 14,608 70,038 57,791 11,177 68,968 September 30, 2023 September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Commitments and contingencies Stockholders’ equity (deficit): Preferred stock (7) Series X Convertible Preferred stock (8) —  —  —  —  —  —  Common stock (9) 1 —  1 1 —  1 Additional paid-in 432,323 —  432,323 402,655 —  402,655 Accumulated deficit (424,286 ) (13,932 ) (438,218 ) (393,589 ) (11,314 ) (404,903 ) Total stockholders’ equity (deficit) 8,038 (13,932 ) (5,894 ) 9,067 (11,314 ) (2,247 ) Total liabilities and stockholders’ equity (deficit) $ 63,468 $ 676 $ 64,144 $ 66,858 $ (137 ) $ 66,721 (7) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and September 30, 2022 (8) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at September 30, 2023 and September 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at September 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at September 30, 2022 (9) Common stock, $0.0001 par value; 20,000,000 shares authorized at September 30, 2023 and September 30, 2022; 4,520,814 shares issued and outstanding at September 30, 2023 and 3,559,141 shares issued and outstanding at September 30, 2022 Three Months Ended March 31, 2023 Three Months Ended March 31, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 5,915 $ 305 $ 6,220 $ 4,583 $ 160 $ 4,743 Total revenues 5,915 305 6,220 4,583 160 4,743 Operating expenses: Research and development 9,415 295 9,710 5,545 —  5,545 General and administrative 3,653 —  3,653 4,675 —  4,675 Total operating expenses 13,068 295 13,363 10,220 —  10,220 Income (loss) from operations (7,153 ) 10 (7,143 ) (5,637 ) 160 (5,477 ) Other income (expense), net: Interest income (expense), net 232 —  232 (20 ) —  (20 ) Total other income (expense), net 232 —  232 (20 ) —  (20 ) Net income (loss) from continuing operations (6,921 ) 10 (6,911 ) (5,657 ) 160 (5,497 ) Income (loss) from discontinued operations 10,130 (206 ) 9,924 (12,624 ) (353 ) (12,977 ) Net income (loss) and comprehensive income (loss) 3,209 (196 ) 3,013 (18,281 ) (193 ) (18,474 ) Allocation of earnings to participating securities (677 ) 41 (636 ) —  —  —  Net income (loss) attributable to common stockholders $ 2,532 $ (155 ) $ 2,377 $ (18,281 ) $ (193 ) $ (18,474 ) Basic and diluted net earnings (loss) per common share from continuing operations (10) $ (1.39 ) $ (1.39 ) $ (1.66 ) $ (1.61 ) Basic and diluted net earnings (loss) per common share from discontinued operations (10) $ 2.03 $ 1.99 $ (3.71 ) $ (3.81 ) Basic and diluted net earnings (loss) per common share (10) $ 0.64 $ 0.60 $ (5.37 ) $ (5.42 ) Shares used to compute basic and diluted net earnings (loss) per common share 3,932,050 3,932,050 3,406,994 3,406,994 (10) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Three Months Ended June 30, 2023 Three Months Ended June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 5,395 $ (305 ) $ 5,090 $ 4,293 $ —  $ 4,293 Total revenues 5,395 (305 ) 5,090 4,293 —  4,293 Operating expenses: Research and development 8,952 (295 ) 8,657 6,276 —  6,276 General and administrative 3,181 —  3,181 3,645 —  3,645 Total operating expenses 12,133 (295 ) 11,838 9,921 —  9,921 Loss from operations (6,738 ) (10 ) (6,748 ) (5,628 ) —  (5,628 ) Other income (expense), net: Interest income (expense), net 623 —  623 (6 ) —  (6 ) Total other income (expense), net 623 —  623 (6 ) —  (6 ) Net loss before income tax expense (6,115 ) (10 ) (6,125 ) (5,634 ) —  (5,634 ) Income tax expense (40 ) —  (40 ) —  —  —  Net income (loss) from continuing operations (6,155 ) (10 ) (6,165 ) (5,634 ) —  (5,634 ) Income (loss) from discontinued operations (6,202 ) (1,257 ) (7,459 ) (7,485 ) (2,640 ) (10,125 ) Net loss and comprehensive loss $ (12,357 ) $ (1,267 ) $ (13,624 ) $ (13,119 ) $ (2,640 ) $ (15,759 ) Basic and diluted net earnings (loss) per common share from continuing operations (11) $ (1.37 ) $ (1.37 ) $ (1.63 ) $ (1.63 ) Basic and diluted net earnings (loss) per common share from discontinued operations (11) $ (1.38 ) $ (1.65 ) $ (2.17 ) $ (2.93 ) Basic and diluted net earnings (loss) per common share (11) $ (2.75 ) $ (3.02 ) $ (3.80 ) $ (4.56 ) Shares used to compute basic and diluted net earnings (loss) per common share 4,505,813 4,505,813 3,456,786 3,456,786 (11) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 11,310 $ —  $ 11,310 $ 8,876 $ 160 $ 9,036 Total revenues 11,310 —  11,310 8,876 160 9,036 Operating expenses: Research and development 18,367 —  18,367 11,821 —  11,821 General and administrative 6,834 —  6,834 8,320 —  8,320 Total operating expenses 25,201 —  25,201 20,141 —  20,141 Loss from operations (13,891 ) —  (13,891 ) (11,265 ) 160 (11,105 ) Other income (expense), net: Interest income (expense), net 855 —  855 (26 ) —  (26 ) Total other income (expense), net 855 —  855 (26 ) —  (26 ) Loss before income tax expense (13,036 ) —  (13,036 ) (11,291 ) 160 (11,131 ) Income tax expense (40 ) —  (40 ) —  —  —  Net income (loss) from continuing operations $ (13,076 ) $ — $ (13,076 ) $ (11,291 ) $ 160 $ (11,131 ) Income (loss) from discontinued operations 3,928 (1,463 ) 2,465 (20,109 ) (2,993 ) (23,102 ) Net loss and comprehensive loss $ (9,148 ) $ (1,463 ) $ (10,611 ) $ (31,400 ) $ (2,833 ) $ (34,233 ) Basic and diluted net earnings (loss) per common share $ (3.10 ) $ (3.10 ) $ (3.29 ) $ (3.24 ) Basic and diluted net earnings (loss) per common share $ 0.93 $ 0.59 $ (5.86 ) $ (6.73 ) Basic and diluted net earnings (loss) per common share (12) $ (2.17 ) $ (2.51 ) $ (9.15 ) $ (9.97 ) Shares used to compute basic and diluted net earnings (loss) per common share 4,220,511 4,220,511 3,432,017 3,432,017 (12) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 9,217 $ —  $ 9,217 $ 6,512 $ —  $ 6,512 Total revenues 9,217 —  9,217 6,512 —  6,512 Operating expenses: Research and development 10,386 —  10,386 8,581 —  8,581 General and administrative 3,299 —  3,299 3,783 —  3,783 Total operating expenses 13,685 —  13,685 12,364 —  12,364 Income (loss) from operations (4,468 ) —  (4,468 ) (5,852 ) —  (5,852 ) Other income, net: Interest income, net 613 —  613 55 —  55 Total other income, net 613 —  613 55 —  55 Net income (loss) before income tax expense (3,855 ) —  (3,855 ) (5,797 ) —  (5,797 ) Income tax expense 32 —  32 —  —  —  Net income (loss) from continuing operations (3,823 ) —  (3,823 ) (5,797 ) —  (5,797 ) Income (loss) from discontinued operations (4,349 ) (935 ) (5,284 ) 20,775 (732 ) 20,043 Net income (loss) and comprehensive income (loss) (8,172 ) (935 ) (9,107 ) 14,978 (732 ) 14,246 Allocation of earnings to participating securities —  —  —  (3,081 ) 150 (2,931 ) Net income (loss) attributable to common stockholders $ (8,172 ) $ (935 ) $ (9,107 ) $ 11,897 $ (582 ) $ 11,315 Basic and diluted net earnings (loss) per common share from continuing operations (13) $ (0.85 ) $ (0.85 ) $ (1.31 ) $ (1.31 ) Basic and diluted net earnings (loss) per common share from discontinued operations (13) $ (0.96 ) $ (1.17 ) $ 4.70 $ 4.53 Basic and diluted net earnings (loss) per common share (13) $ (1.81 ) $ (2.02 ) $ 3.39 $ 3.22 Shares used to compute basic and diluted net earnings (loss) per common share 4,514,381 4,514,381 3,510,974 3,510,974 (13) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 20,527 $ —  $ 20,527 $ 15,388 $ 160 $ 15,548 Product revenue —  —  —  —  —  —  Total revenues 20,527 —  20,527 15,388 160 15,548 Operating expenses: Cost of product revenue —  —  —  —  —  —  Research and development 28,753 —  28,753 20,402 —  20,402 General and administrative 10,133 —  10,133 12,103 —  12,103 Total operating expenses 38,886 —  38,886 32,505 —  32,505 Loss from operations (18,359 ) —  (18,359 ) (17,117 ) 160 (16,957 ) Other income, net: Interest income, net 1,468 —  1,468 29 —  29 Total other income, net 1,468 —  1,468 29 —  29 Net loss before income tax expense (16,891 ) —  (16,891 ) (17,088 ) 160 (16,928 ) Income tax expense (8 ) —  (8 ) —  —  —  Net income (loss) from continuing operations (16,899 ) — (16,899 ) (17,088 ) 160 (16,928 ) Income (loss) from discontinued operations (421 ) (2,398 ) (2,819 ) 666 (3,725 ) (3,059 ) Net income (loss) and comprehensive income (loss) $ (17,320 ) $ (2,398 ) $ (19,718 ) $ (16,422 ) $ (3,565 ) $ (19,987 ) Basic and diluted net earnings (loss) per common share $ (3.91 ) $ (3.91 ) $ (4.94 ) $ (4.89 ) Basic and diluted net earnings (loss) per common share $ (0.10 ) $ (0.65 ) $ 0.19 $ (0.89 ) Basic and diluted net earnings (loss) per common share (14) $ (4.01 ) $ (4.56 ) $ (4.75 ) $ (5.78 ) Shares used to compute basic and diluted net earnings (loss) per common share 4,319,536 4,319,536 3,458,608 3,458,608 (14) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Three Months Ended March 31, 2023 Three Months Ended March 31, 2022 Corrected Condensed Consolidated Statement of As Restatement As As Restatement As Operating activities: Net income (loss) $ 3,209 $ (196 ) $ 3,013 $ (18,281 ) $ (193 ) $ (18,474 ) Adjustments to reconcile net loss to net cash used in operating Stock-based compensation 640 —  640 1,338 —  1,338 Non-cash 288 (26 ) 262 258 (24 ) 234 Depreciation and amortization 32 —  32 39 —  39 Amortization of costs to obtain a contract with a customer 475 —  475 —  —  —  Non-cash —  —  —  1 —  1 Changes in assets and liabilities: Accounts receivable (19,993 ) (295 ) (20,288 ) (3,427 ) —  (3,427 ) Prepaid expenses, other current assets, and other assets 872 (24 ) 848 (1,120 ) —  (1,120 ) Accounts payable and accrued liabilities 3,116 76 3,192 657 —  657 Accrued indirect tax liabilities —  261 261 —  353 353 Accrued compensation and benefits 921 —  921 (1,953 ) —  (1,953 ) Contract liabilities (142 ) 178 36 (844 ) (160 ) (1,004 ) Operating lease liabilities (316 ) 26 (290 ) (276 ) 24 (252 ) Net cash used in operating activities (10,898 ) —  (10,898 ) (23,608 ) —  (23,608 ) Investing activities: Purchases of property and equipment (94 ) —  (94 ) (84 ) —  (84 ) Net cash used in investing activities (94 ) —  (94 ) (84 ) —  (84 ) Financing activities: Proceeds from underwritten public offering, net of issuance costs 17,593 —  17,593 —  —  —  Proceeds from public offering of common stock, net of issuance costs 8,630 —  8,630 500 —  500 Proceeds from exercise of stock options 14 —  14 —  —  —  Principal repayments of Term Loan —  —  —  (1,111 ) —  (1,111 ) Net cash provided by (used in) financing activities 26,237 —  26,237 (611 ) —  (611 ) Net increase (decrease) in cash and cash equivalents 15,245 —  15,245 (24,303 ) —  (24,303 ) Cash and cash equivalents at beginning of period 32,731 —  32,731 62,273 — 62,273 Cash and cash equivalents at end of period $ 47,976 $ —  $ 47,976 $ 37,970 $ — $ 37,970 Supplemental disclosure of cash flows: Interest paid $ —  $ —  $ —  $ 25 $ —  $ 25 Non-cash Purchases of property and equipment, included in accounts payable $ 55 $ —  $ 55 $ 16 $ —  $ 16 Non-cash Issuance costs incurred but not yet paid, included in accounts payable $ 337 $ —  $ 337 $ —  $ 720 $ 720 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 Corrected Condensed Consolidated Statement of As Restatement As As Restatement As Operating activities: Net loss $ (9,148 ) $ (1,463 ) $ (10,611 ) $ (31,400 ) $ (2,833 ) $ (34,233 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 1,435 —  1,435 2,016 —  2,016 Non-cash 664 (25 ) 639 523 (47 ) 476 Depreciation and amortization 57 —  57 77 —  77 Amortization of costs to obtain a contract with a customer 40 —  40 —  —  —  Non-cash —  —  —  1 —  1 Changes in assets and liabilities: Accounts receivable 350 —  350 524 —  524 Inventory (1,954 ) (434 ) (2,388 ) —  —  —  Prepaid expenses, other current assets, and other assets 2,120 —  2,120 (2,567 ) —  (2,567 ) Accounts payable and accrued liabilities 2,870 —  2,870 (483 ) —  (483 ) Accrued indirect tax liabilities —  1,897 1,897 —  2,993 2,993 Accrued compensation and benefits (1,277 ) —  (1,277 ) (1,324 ) —  (1,324 ) Contract liabilities (2,613 ) —  (2,613 ) (2,252 ) (160 ) (2,412 ) Operating lease liabilities (620 ) 25 (595 ) (559 ) 47 (512 ) Net cash used in operating activities (8,076 ) —  (8,076 ) (35,444 ) —  (35,444 ) Investing activities: Purchases of property and equipment (201 ) —  (201 ) (100 ) —  (100 ) Net cash used in investing activities (201 ) —  (201 ) (100 ) —  (100 ) Financing activities: Proceeds from underwritten public offering, net of issuance costs 17,256 —  17,256 —  —  —  Proceeds from public offering of common stock, net of issuance costs 8,706 —  8,706 500 —  500 Proceeds from exercise of stock options 14 —  14 —  —  —  Principal repayments of Term Loan —  —  —  (2,222 ) —  (2,222 ) Net cash provided by (used in) financing activities 25,976 —  25,976 (1,722 ) —  (1,722 ) Net increase (decrease) in cash and cash equivalents 17,699 —  17,699 (37,266 ) —  (37,266 ) Cash and cash equivalents at beginning of period 32,731 — 32,731 62,273 — 62,273 Cash and cash equivalents at end of period $ 50,430 $ — $ 50,430 $ 25,007 $ — $ 25,007 Supplemental disclosure of cash flows: Interest paid $ —  $ —  $ —  $ 38 $ —  $ 38 Income taxes paid $ 588 $ —  $ 588 $ —  $ —  $ —  Non-cash Operating lease right-of-use $ 3,847 $ —  $ 3,847 $ —  $ —  $ —  Non-cash Purchase of shares pursuant to Employee Stock Purchase Plan $ 63 $ —  $ 63 $ 69 $ —  $ 69 Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities $ —  $ —  $ —  $ 720 $ —  $ 720 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Corrected Condensed Consolidated Statement As  Restatement  As As  Restatement  As Operating activities: Net loss $ (17,320 ) $ (2,398 ) $ (19,718 ) $ (16,422 ) $ (3,565 ) $ (19,987 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 2,231 —  2,231 2,859 —  2,859 Non-cash 921 (26 ) 895 796 (72 ) 724 Depreciation and amortization 79 —  79 114 —  114 Amortization of costs to obtain a contract with a customer 53 —  53 1,772 —  1,772 Non-cash —  —  —  1 —  1 Changes in assets and liabilities: Accounts receivable 2,978 (323 ) 2,655 314 —  314 Inventory (2,467 ) (434 ) (2,901 ) —  —  —  Prepaid expenses, other current assets, and other assets 2,776 —  2,776 (1,662 ) —  (1,662 ) Accounts payable and accrued liabilities 6,204 —  6,204 (1,037 ) —  (1,037 ) Accrued indirect tax liabilities —  3,155 3,155 —  3,725 3,725 Accrued compensation and benefits (402 ) —  (402 ) (670 ) —  (670 ) Contract liabilities (3,956 ) —  (3,956 ) 7,314 (160 ) 7,154 Operating lease liabilities (807 ) 26 (781 ) (850 ) 72 (778 ) Net cash used in operating activities (9,710 ) —  (9,710 ) (7,471 ) —  (7,471 ) Investing activities: Purchases of property and equipment (327 ) —  (327 ) (109 ) —  (109 ) Net cash used in investing activities (327 ) —  (327 ) (109 ) —  (109 ) Financing activities: Proceeds from underwritten public offering, net of issuance costs 17,256 —  17,256 —  —  —  Proceeds from public offering of common stock, net of issuance costs 8,706 —  8,706 1,698 —  1,698 Proceeds from exercise of stock options 14 —  14 —  —  —  Issuance costs for underwritten public offering —  —  —  (720 ) —  (720 ) Principal repayments of Term Loan —  —  —  (2,593 ) —  (2,593 ) Net cash provided by (used in) financing activities 25,976 —  25,976 (1,615 ) —  (1,615 ) Net increase (decrease) in cash and cash equivalents 15,939 —  15,939 (9,195 ) —  (9,195 ) Cash and cash equivalents at beginning of period 32,731 —  32,731 62,273 —  62,273 Cash and cash equivalents at end of period $ 48,670 $ —  $ 48,670 $ 53,078 $ —  $ 53,078 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Corrected Condensed Consolidated Statement As  Restatement  As As  Restatement  As Supplemental disclosure of cash flows: Interest paid $ —  $ —  $ —  $ 40 $ —  $ 40 Income taxes paid $ 651 $ —  $ 651 $ —  $ —  $ —  Non-cash Purchases of property and equipment, included in accounts payable and accrued liabilities $ 178 $ —  $ 178 $ —  $ —  $ —  Operating lease right-of-use $ 3,847 $ —  $ 3,847 $ —  $ —  $ —  Non-cash Purchase of shares pursuant to Employee Stock Purchase Plan $ 63 $ —  $ 63 $ 69 $ —  $ 69 Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets $ — $ —  $ —  $ 10 $ —  $ 10 Corrected Condensed Consolidated Statements of Convertible Preferred Stock and Series X Convertible Common Stock Additional Paid-In Accumulated (As Total (As Restated) (In thousands, except share data) Shares Amount Shares Amount Balance, December 31, 2022 (As Restated) 1,818,472 $ —  3,623,591 $ 1 $ 404,061 $ (418,500 ) $ (14,438 ) Underwritten public offering, net of issuance costs 286,000 —  554,300 —  17,256 —  17,256 Public offering of common stock, net of issuance costs —  —  307,936 —  8,622 —  8,622 Issuance of common stock for exercise of options —  —  812 —  14 —  14 Issuance of common stock for restricted share units vested —  —  14,617 —  —  —  —  Stock-based compensation —  —  —  —  640 —  640 Net income (As Restated) —  —  —  —  —  3,013 3,013 Balance, March 31, 2023 (As Restated) 2,104,472 —  4,501,256 1 430,593 (415,487 ) 15,107 Public offering of common stock, net of issuance costs —  —  3,047 —  76 —  76 Issuance of common stock for restricted share units vested —  —  232 —  —  —  —  Issuance of common stock under Employee Stock Purchase Plan —  —  8,060 —  63 —  63 Stock-based compensation —  —  —  —  795 —  795 Net loss (As Restated) —  —  —  —  —  (13,624 ) (13,624 ) Balance, June 30, 2023 (As Restated) 2,104,472 —  4,512,595 1 431,527 (429,111 ) 2,417 Issuance of common stock for restricted share units vested —  —  8,219 —  —  —  —  Stock-based compensation —  —  —  —  796 —  796 Net loss (As Restated) —  —  —  —  —  (9,107 ) (9,107 ) Balance, September 30, 2023 (As Restated) 2,104,472 $ —  4,520,814 $ 1 $ 432,323 $ (438,218 ) $ (5,894 ) Corrected Condensed Consolidated Statements of Convertible Preferred Stock and Series X Convertible Common Stock Additional Paid-In (As Accumulated (As Total (As Restated) (In thousands, except share data) Shares Amount Shares Amount Balance, December 31, 2021 (As Restated) 1,818,472 $ —  3,393,320 $ 1 $ 398,019 $ (384,916 ) $ 13,104 Public offering of common stock, net of issuance costs —  —  32,208 —  500 —  500 Issuance of common stock for restricted share units vested —  —  27,039 —  —  —  —  Stock-based compensation —  —  —  —  1,165 —  1,165 Net loss (As Restated) —  —  —  —  —  (18,474 ) (18,474 ) Balance, March 31, 2022 (As Restated) 1,818,472 —  3,452,567 1 399,684 (403,390 ) (3,705 ) Issuance of common stock for restricted share units vested —  —  252 —  —  —  —  Issuance of common stock under Employee Stock Purchase Plan —  —  9,205 —  69 —  69 Stock-based compensation —  —  —  —  852 —  852 Issuance costs for underwritten public offering (As Restated) —  —  —  —  —  —  —  Net loss (As Restated) —  —  —  —  —  (15,759 ) (15,759 ) Balance, June 30, 2022 (As Restated) 1,818,472 —  3,462,024 1 400,605 (419,149 ) (18,543 ) Public offering of common stock, net of issuance costs —  —  83,197 —  1,208 —  1,208 Issuance of common stock for restricted share units vested —  —  13,920 —  —  —  —  Stock-based compensation —  —  —  —  842 —  842 Net income (As Restated) —  —  —  —  —  14,246 14,246 Balance, September 30, 2022 (As Restated) 1,818,472 $ —  3,559,141 $ 1 $ 402,655 $ (404,903 ) $ (2,247 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS (UNAUDITED) Securities Purchase Agreement (Common Stock and Pre-Funded Warrants) On November 20, 2024, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain institutional accredited investors named therein, or the Purchasers, pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement, or the Private Placement, (i) an aggregate of 3,892,274 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $14.912 per share, which is based on the average Nasdaq Official Closing Price of the common stock for the five trading days immediately preceding the signing of the Purchase Agreement, and (ii) in lieu of shares of common stock to certain Purchasers, pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded Warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per warrant share). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The Private Placement closed on November 26, 2024, or the Closing Date. The Company received aggregate gross proceeds from the Private Placement of approximately $105.0 million, before deducting estimated offering expenses payable by the Company. The pre-funded warrants issued in the Private Placement provide that the holder of the pre-funded warrants will not have the right to exercise any portion of its pre-funded warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the Company’s outstanding shares of common stock immediately after giving effect to such exercise, or the Beneficial Ownership Limitation; provided, however, that the holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days’ notice to the Company, but not to any percentage in excess of 19.99%.	13. SUBSEQUENT EVENTS Janssen License Agreement On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, related to DFCs based on the Company’s Cloudbreak platform for the prevention and treatment of influenza, or the Influenza Program, including CD388, the Company’s most advanced DFC program, which has completed a Phase As a condition to the effectiveness of the Janssen License Agreement, the Company paid Janssen an upfront payment of $85.0 million in April 2024. The Company will also be obligated to pay Janssen up to $150.0 million in development and regulatory milestone payments with respect to CD388 Product and up to $455.0 million in commercialization milestone payments with respect to CD388 Product. The Company has no obligation to pay any royalties to Janssen on the sale of any Product and no obligation to pay any milestone payment or other amount to Janssen with respect to the development, registration, manufacture or commercialization of any Compound other than CD388 or any Product other than CD388 Product. Series A Securities Purchase Agreement On April 23, 2024, the Company entered into a securities purchase agreement, or the Series A Securities Purchase Agreement, with certain institutional and other accredited investors, or the Series A Purchasers, pursuant to which the Company issued and sold, in a private placement, or the Series A Private Placement, 240,000 shares of Series A Convertible Voting Preferred Stock, par value $0.0001 per share, or the Series A Preferred Stock, at a purchase price of $1,000 per share. The closing of the Series A Private Placement took place on April 24, 2024, or the Series A Closing Date, and the Company received total gross proceeds of $240.0 million. Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock, which was filed with the Secretary of State of the State of Delaware on the Series A Closing Date, or the Certificate of Designation, each share of Series A Preferred Stock is, subject to the Stockholder Approval (as defined below) and certain beneficial ownership conversion limitations, automatically convertible into shares of common stock, par value $0.0001 per share, of the Company. Subject to the terms and limitations contained in the Certificate of Designation, the Series A Preferred Stock issued in the Series A Private Placement was not convertible until the Company’s stockholders approved the issuance of all common stock issuable upon conversion of the Series A Preferred Stock, or the Conversion Shares, and an amendment to the Company’s certificate of incorporation to increase the authorized number of shares of common stock to enable the issuance or reservation for issuance, as applicable, of all of the Conversion Shares, or the Stockholder Approval. On the first Trading Day (as defined in the Certificate of Designation) following the announcement of the Stockholder Approval, each share of Series A Preferred Stock automatically converted into common stock, at the conversion price of $14.20 per share, rounded down to the nearest whole share, subject to the terms and limitations contained in the Certificate of Designation, including that shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than 9.99% of the Company’s outstanding shares of common stock as of the applicable conversion date. CIDARA THERAPEUTICS, INC. Stockholder Approval On July 18, 2024, the Company held its 2024 Annual Meeting of Stockholders where the Company’s stockholders approved various proposals including (i) adoption of a new 2024 Equity Incentive Plan, or the 2024 EIP, (ii) an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 20,000,000 shares to 50,000,000 shares, which amendment was filed by the Company with the Secretary of State of the State of Delaware on July 18, 2024 and was effective as of such date, and (iii) for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to 16,800,000 shares of common stock upon conversion of 240,000 shares of Series A Convertible Preferred Stock issued in the Series A Private Placement completed in April 2024. Issuance of Common Stock On July 19, 2024, the Company issued 2,469,250 shares of common stock upon automatic conversion of 35,275 shares of Series A Convertible Preferred Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, including that shares of Series A Convertible Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than 9.99% of the Company’s outstanding shares of common stock as of the applicable conversion date. Reduction in Force On September 9, 2024, management of the Company, as authorized by the board of directors of the Company, approved a reduction in the Company’s workforce (the “Reduction”) of 20 employees, which represented approximately 30% of the Company’s workforce. The Reduction reflects the Company’s focus on the clinical development of CD388, its influenza product candidate. The Reduction was substantially completed by November 1, 2024. Securities Purchase Agreement (Common Stock and Pre-Funded On November 20, 2024, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain institutional accredited investors named therein, or the Purchasers, pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement, or the Private Placement, (i) an aggregate of 3,892,274 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $14.912 per share, which is based on the average Nasdaq Official Closing Price of the common stock for the five trading days immediately preceding the signing of the Purchase Agreement, and (ii) in lieu of shares of common stock to certain Purchasers, pre-funded pre-funded pre-funded The Private Placement closed on November 26, 2024, or the Closing Date. The Company received aggregate gross proceeds from the Private Placement of approximately $105.0 million, before deducting estimated offering expenses payable by the Company. The pre-funded pre-funded pre-funded

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September 30, 2024, the Company had an accumulated deficit of $559.0 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. At September 30, 2024, the Company had cash and cash equivalents of $127.4 million, which the Company expects, together with the $105.0 million gross proceeds from the Private Placement, will provide sufficient liquidity for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Registration Statement on Form S-1. The Company’s ability to execute its current business plan depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company’s ability to execute on its business plan. The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company’s business, operating results and financial condition and the Company’s ability to achieve its intended business objectives. Any of these actions could materially harm the Company’s business, results of operations and future prospects.	Basis of Presentation The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December 31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. At December 31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company’s business plan at the time of filing its Annual Report on Form 10-K In April 2024 the Company received total gross proceeds of $240.0 million in the Series A Private Placement and in November 2024 the Company received total gross proceeds of $105.0 million in the Private Placement (see Note 13), which has alleviated substantial doubt about the Company’s ability to continue as a going concern and provides sufficient liquidity for a period of at least one year following the date that these consolidated financial statements are issued as part of this Registration Statement on Form S-1. The Company’s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company’s ability to execute on its business plan. The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company’s business, operating results and financial condition and the Company’s ability to achieve its intended business objectives. Any of these actions could materially harm the Company’s business, results of operations and future prospects.
Unaudited Interim Financial Data	Unaudited Interim Financial Data The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB. Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2024 and 2023.
Basis of Consolidation	Basis of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company’s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company’s collaboration and license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s consolidated financial statements relate to estimated collaboration expenses related to the Company’s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company’s collaboration and license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Segment Information	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Acquisitions	Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.
Discontinued Operations	Discontinued Operations The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.	Cash and Cash Equivalents The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development, or R&D, and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, product sales and the associated indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company’s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The	Accounts Receivable Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development, or R&D, and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, product sales, and the associated indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company’s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December 31, 2023 or 2022.
Inventory	Inventory The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&D expense in the period incurred. Inventory is comprised of raw materials and work-in-process, freight-in first-in-first-out	Inventory The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&D expense in the period incurred. Inventory is comprised of raw materials and work-in-process, freight-in first-in-first-out
Property and Equipment	Property and Equipment The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements. Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally three	Property and Equipment The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements. Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally three
Finance Lease and Operating Lease	Finance Lease In accordance with Accounting Standards Codification Leases right-of-use non-lease The Company recognizes amortization of the right-of-use right-of-use right-of-use right-of-use Operating Lease In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use non-lease	Finance Lease In accordance with Accounting Standards Codification Leases right-of-use non-lease The Company recognizes amortization of the right-of-use right-of-use right-of-use right-of-use Operating Lease In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use non-lease
Concentration of Credit Risk		Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.
Patent Costs		Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&A, expenses in the accompanying statements of operations and comprehensive loss.
Income Taxes	Income Taxes The Company reports deferred income taxes in accordance with ASC 740, Income Taxes	Income Taxes The Company reports deferred income taxes in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
Indirect Taxes	Indirect Taxes The Company’s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in R&D expenses within discontinued operations, and the related interest and penalties are included in selling, general and administrative, or SG&A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in SG&A in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company’s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed at that time. Indirect tax amounts on commercial sales (product revenue) and asset disposals that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included in inventory within discontinued operations.	Indirect Taxes The Company’s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in R&D expenses within discontinued operations, and the related interest and penalties are included in SG&A expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in SG&A in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company’s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed at that time. Indirect tax amounts on commercial sales (product revenue) and asset disposals that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included in inventory within discontinued operations.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Collaboration Revenue If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or a collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates catch-up For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. See Note 6 and Note 9 for additional information. Product Revenue In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta Therapeutics, LLC, or Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024 (see Note 9 for additional information). The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation. The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company’s product to the customer. Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue.	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Collaboration Revenue If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or a collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates catch-up For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. Potential future payments for variable consideration, such as regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. In July 2022, the Company entered into a License Agreement with Melinta Therapeutics, LLC, or Melinta, or the Melinta License Agreement. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. The Mundipharma Collaboration Agreement and the Melinta License Agreement were terminated upon the effectiveness of the assignment to Napp on April 24, 2024, and the related revenue amounts have been reclassified to discontinued operations. See Note 8 and Note 11 Product Revenue In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024 (see Note 11 The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation. The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company’s product to the customer. Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue.
Cost of Product Revenue	Cost of Product Revenue Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in	Cost of Product Revenue Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in
Acquired In-process Research and Development Expenses	Acquired In-process Acquired in-process The Company evaluates license agreements for IPR&D projects to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the license agreement for IPR&D does not meet the definition of a business and the assets have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&D expense in its condensed consolidated statements of operations and comprehensive loss. In those cases, payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Payments made in connection with regulatory and sales-based milestones will be capitalized and amortized to cost of revenue.
Research and Development Expenses	Research and Development Expenses R&D expenses consist of wages, benefits and stock-based compensation charges for R&D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials. The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.	Research and Development Costs R&D expenses consist of wages, benefits and stock-based compensation charges for R&D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials. The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events. Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses SG&A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.	Selling, General and Administrative Expenses SG&A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.
Preclinical and Clinical Trial Accruals	Preclinical and Clinical Trial Accruals The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.	Preclinical and Clinical Trial Accruals The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company’s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company’s common stock during the equivalent period of the calculated expected term of the Company’s stock-based awards. The Company estimated the expected life of employee stock options using the “simplified” method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met. The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.	Stock-Based Compensation The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company’s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company’s common stock during the equivalent period of the calculated expected term of the Company’s stock-based awards. The Company estimated the expected life of employee stock options using the “simplified” method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met. The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.
Net Earnings (Loss) Per Share	Net Earnings (Loss) Per Share The Company follows the guidance in ASC 260, Earnings Per Share non-forfeitable if-converted two-class Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted two-class In accordance with ASC 260, if a company had a discontinued operation, the company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares): Nine Months Ended September 30,   2024     2023   Common stock warrants 866 866 Series A Convertible Voting Preferred Stock 14,330,750 —  Series X Convertible Preferred Stock 1,052,236 1,052,236 Common stock options, RSUs and PRSUs issued and outstanding 2,454,822 646,233 Total 17,838,674 1,699,335	Net Earnings (Loss) Per Share The Company follows the guidance in ASC 260, Earnings Per Share non-forfeitable if-converted two-class Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted two-class In accordance with ASC 260, if a company had a discontinued operation, the company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares): December 31, 2023 2022 Common stock warrants 866 625,859 Series X Convertible Preferred Stock 1,052,236 909,236 Common stock options, RSUs and PRSUs issued and outstanding 638,037 465,965 Total 1,691,139 2,001,060
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows ASC 820-10, Fair Value Measurements and Disclosures 820-10, The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.	Fair Value of Financial Instruments The Company follows ASC 820-10, Fair Value Measurements and Disclosures 820-10, The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, In December 2023, the FASB issued ASU 2023-09, The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company’s condensed consolidated financial statements or related disclosures, or do not apply to the Company.	Recently Issued and Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company’s consolidated financial statements or related disclosures, or do not apply to the Company.

THE COMPANY AND BASIS OF PRES_2

THE COMPANY AND BASIS OF PRESENTATION (Tables)	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data): Year Ended December 31, 2022 Corrected Consolidated Balance Sheet As Previously Restatement As Restated Operating lease right-of-use $ 1,205 $ (106 ) $ 1,099 Total assets 47,593 (106 ) 47,487 Accrued indirect tax liabilities —  11,534 11,534 Current portion of operating lease liability 1,317 (106 ) 1,211 Total current liabilities 29,972 11,428 41,400 Total liabilities 50,497 11,428 61,925 Accumulated deficit (406,966 ) (11,534 ) (418,500 ) Total stockholders’ deficit (2,904 ) (11,534 ) (14,438 ) Total liabilities and stockholders’ deficit 47,593 (106 ) 47,487 Year Ended December 31, 2022 Corrected Consolidated Statement of Operations and Comprehensive Loss As Previously Restatement As Restated Revenues: Collaboration revenue $ 23,336 $ 160 $ 23,496 Total revenues 23,336 160 23,496 Loss from operations (22,059 ) 160 (21,899 ) Net loss from continuing operations before income tax expense (21,868 ) 160 (21,708 ) Net loss from continuing operations (21,882 ) 160 (21,722 ) Loss from discontinued operations (7,917 ) (3,945 ) (11,862 ) Net loss and comprehensive loss (29,799 ) (3,785 ) (33,584 ) Basic and diluted net loss per common share from continuing operations (6.26 ) (6.22 ) Basic and diluted net loss per common share from discontinued operations (2.27 ) (3.39 ) Basic and diluted net loss per common share (8.53 ) (9.61 ) Shares used to compute basic and diluted net loss per common share 3,492,925 3,492,925 Additional Paid-In Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders’ Equity (Deficit) As Restatement As Restated Balance, December 31, 2021 $ 398,739 $ (720 ) $ 398,019 Issuance costs for underwritten public offering (720 ) 720 —  Balance, December 31, 2022 404,061 —  404,061 Accumulated Deficit As Restatement As Restated Balance, December 31, 2021 $ (377,167 ) $ (7,749 ) $ (384,916 ) Net loss (29,799 ) (3,785 ) (33,584 ) Balance, December 31, 2022 (406,966 ) (11,534 ) (418,500 ) Total Stockholders’ Equity (Deficit) As Restatement As Restated Balance, December 31, 2021 $ 21,573 $ (8,469 ) $ 13,104 Issuance costs for underwritten public offering (720 ) 720 —  Net loss (29,799 ) (3,785 ) (33,584 ) Balance, December 31, 2022 (2,904 ) (11,534 ) (14,438 ) Year Ended December 31, 2022 Corrected Consolidated Statement of Cash Flows As Previously Restatement As Restated Operating activities: Net loss $ (29,799 ) $ (3,785 ) $ (33,584 ) Adjustments to reconcile net loss to net cash used in operating activities: Non-cash 1,082 (101 ) 981 Changes in assets and liabilities: Accrued indirect tax liabilities —  3,945 3,945 Contract liabilities 2,806 (160 ) 2,646 Operating lease liabilities (1,153 ) 101 (1,052 )

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares): Nine Months Ended September 30,   2024     2023   Common stock warrants 866 866 Series A Convertible Voting Preferred Stock 14,330,750 —  Series X Convertible Preferred Stock 1,052,236 1,052,236 Common stock options, RSUs and PRSUs issued and outstanding 2,454,822 646,233 Total 17,838,674 1,699,335	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares): December 31, 2023 2022 Common stock warrants 866 625,859 Series X Convertible Preferred Stock 1,052,236 909,236 Common stock options, RSUs and PRSUs issued and outstanding 638,037 465,965 Total 1,691,139 2,001,060

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	The following tables summarize the Company’s financial instruments measured at fair value on a recurring basis (in thousands): TOTAL LEVEL 1 LEVEL 2 LEVEL 3 September 30, 2024 Assets: Cash and money market accounts $ 127,386 $ 127,386 $ —  $ —  Total assets at fair value $ 127,386 $ 127,386 $ —  $ —  December 31, 2023 Assets: Cash and money market accounts $ 35,778 $ 35,778 $ —  $ —  Total assets at fair value $ 35,778 $ 35,778 $ —  $ —	The following tables summarize the Company’s financial instruments measured at fair value on a recurring basis (in thousands): TOTAL LEVEL 1 LEVEL 2 LEVEL 3 December 31, 2023 Assets: Cash and money market accounts $ 35,778 $ 35,778 $ —  $ —  Total assets at fair value $ 35,778 $ 35,778 $ —  $ —  December 31, 2022 Assets: Cash and money market accounts $ 32,731 $ 32,731 $ —  $ —  Total assets at fair value $ 32,731 $ 32,731 $ —  $ —

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Schedule of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance is as follows (in common stock equivalent shares): September 30, 2024 December 31, 2023 Common stock warrants 866 866 Series A Convertible Preferred Stock 14,330,750 —  Series X Convertible Preferred Stock 1,052,236 1,052,236 Common stock options, RSUs and PRSUs issued and outstanding 2,454,822 638,037 Authorized for future stock awards 1,052,406 170,783 Awards available under the ESPP 67,089 49,623 Total 18,958,169 1,911,545	Common stock reserved for future issuance is as follows (in common stock equivalent shares): December 31, 2023 2022 Common stock warrants 866 625,859 Series X Convertible Preferred Stock 1,052,236 909,236 Common stock options, RSUs and PRSUs issued and outstanding 638,037 465,965 Authorized for future stock awards 170,783 223,713 Awards available under the ESPP 49,623 40,572 Total 1,911,545 2,265,345

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (in thousands): December 31, 2023 2022 Laboratory equipment $ 2,817 $ 2,415 Leasehold improvements 425 425 Computer hardware and software 327 305 Office equipment 36 93 Furniture and fixtures 142 142 3,747 3,380 Less accumulated depreciation and amortization (3,190 ) (3,158 ) Total $ 557 $ 222

EQUITY INCENTIVE PLANS (Tables)

EQUITY INCENTIVE PLANS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity	The following table summarizes RSU and PRSU activity during the nine months ended September 30, 2024: Number of RSUs and Weighted Outstanding at December 31, 2023 104,886 $ 22.83 RSUs and PRSUs granted 153,012 12.30 RSUs and PRSUs vested (43,053 ) 24.24 RSUs and PRSUs canceled (17,705 ) 24.68 Outstanding at September 30, 2024 197,140 $ 14.18	The following table summarizes RSU and PRSU activity during the year ended December 31, 2023: Number of RSUs and PRSUs Weighted Average Outstanding at December 31, 2022 61,149 $ 29.36 RSUs and PRSUs granted 75,778 20.04 RSUs and PRSUs vested (24,487 ) 29.64 RSUs and PRSUs canceled (7,554 ) 25.76 Outstanding at December 31, 2023 104,886 $ 22.83
Schedule of Stock Option Activity	The following table summarizes stock option activity during the nine months ended September 30, 2024: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Total Intrinsic Value Outstanding at December 31, 2023 533,151 $ 44.61 6.72 $ 57 Options granted 1,796,401 11.14 Options exercised —  —  Options canceled (71,870 ) 31.68 Outstanding at September 30, 2024 2,257,682 $ 18.39 9.10 $ 1 Vested and expected to vest at September 30, 2024 2,257,682 $ 18.39 9.10 $ 1 Exercisable at September 30, 2024 420,941 $ 48.19 5.74 $ 1	The following table summarizes stock option activity during the year ended December 31, 2023: Number of Shares Weighted Average Exercise Weighted Average Remaining Contractual in Years Total Intrinsic Outstanding at December 31, 2022 404,816 $ 55.60 6.65 $ 48 Options granted 161,666 20.40 Options exercised (1,287 ) 16.65 Options canceled (32,044 ) 62.40 Outstanding at December 31, 2023 533,151 $ 44.61 6.72 $ 57 Vested and expected to vest at December 31, 2023 533,151 $ 44.61 6.72 $ 57 Exercisable at December 31, 2023 361,644 $ 55.04 5.71 $ 54
Schedule of Black-Scholes Option Pricing Model Assumptions		The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented: For the years ended December 31, 2023 2022 2015 EIP and 2020 IIP Risk-free interest rate 3.58% - 4.61% 1.39% - 4.02% Expected dividend yield 0% 0% Expected volatility 82% - 83% 70% - 75% Expected term (years) 5.50 - 6.08 5.50 - 6.08 2015 ESPP Risk-free interest rate 4.29% - 5.43% 1.57% - 2.65% Expected dividend yield 0% 0% Expected volatility 64% - 147% 75% - 98% Expected term (years) 0.50 - 2.00 0.50 - 2.00
Schedule of Stock-based Compensation Expense	Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Nine Months Ended September 30, 2024 2023 Stock compensation expense: Research and development $ 868 $ 629 Selling, general and administrative 1,150 1,038 Stock compensation expense recorded in continuing operations 2,018 1,667 Stock compensation expense recorded in discontinued operations 231 564 Total stock compensation expense $ 2,249 $ 2,231	Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands): Years ended December 31,   2023     2022   Stock compensation expense: Research and development $ 839 $ 809 Selling, general and administrative 1,469 1,945 Stock compensation expense recorded in continuing operations 2,308 2,754 Stock compensation expense recorded in discontinued operations 753 951 Total stock compensation expense $ 3,061 $ 3,705

SIGNIFICANT AGREEMENTS AND CO_2

SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Agreement And Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition	The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Janssen Collaboration Agreement during the nine months ended September 30, 2024 (in thousands): Opening balance, December 31, 2023 $ 430 Revenue from performance obligations satisfied during reporting period (370 ) Gain on settlement of unsatisfied performance obligations (60 ) Closing balance, September 30, 2024 $ —  The following table presents collaboration revenue under the Janssen Collaboration Agreement (in thousands): Nine Months Ended September 30, 2024 2023 Revenue from Janssen Collaboration Agreement: Point in Time: License of Intellectual Property - upon milestone achieved $ —  $ 2,347 Over Time: Research and Development Services $ 1,273 $ 16,324 Clinical Supply Services 2 1,856 Total Revenue from Janssen Collaboration Agreement $ 1,275 $ 20,527	The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Janssen Collaboration Agreement during the year ended December 31, 2023 (in thousands): Opening balance, December 31, 2022 $ 1,004 Payments received in advance 292 Revenue from performance obligations satisfied during reporting period (866 ) Closing balance, December 31, 2023 $ 430 Current portion of contract liabilities $ 430 Long-term portion of contract liabilities —  Total contract liabilities, December 31, 2023 $ 430 The following table presents collaboration revenue under the Janssen Collaboration Agreement (in thousands): Year Ended Year Ended (As Restated) Revenue from Janssen Collaboration Agreement: Point in Time: License of Intellectual Property - upon milestones achieved $ 2,347 $ 976 Over Time: Research and Development Services 19,011 18,814 Clinical Supply Services 1,925 3,706 Total Revenue from Janssen Collaboration Agreement $ 23,283 $ 23,496

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Amount, Timing and Uncertainty of Cash Flows from Finance Lease	The following table presents information about the amount and timing of cash flows arising from the Company’s finance lease as of September 30, 2024 (in thousands): 2024 $ 75 2025 300 2026 300 2027 25 Total undiscounted finance lease payments 700 Less: Imputed interest (63 ) Present value of finance lease payments $ 637	The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance lease as of December 31, 2023 (in thousands): 2024 $ 275 2025 300 2026 300 2027 25 Total undiscounted finance lease payments 900 Less: Imputed interest (107 ) Present value of finance lease payments $ 793
Schedule of Supplemental Balance Sheet Information For Finance Leases	The balance sheet classification of the Company’s finance lease is as follows (in thousands): Balance Sheet Classification: Finance lease right-of-use $ 788 Accumulated amortization (66 ) Net finance lease right-of-use $ 722 Current portion of finance lease liability $ 259 Long-term finance lease liability 378 Total finance lease liabilities $ 637	The balance sheet classification of the Company’s finance lease is as follows (in thousands): Balance Sheet Classification: Finance lease right-of-use $ 788 Accumulated amortization (6 ) Net finance lease right-of-use $ 782 Current portion of finance lease liability $ 218 Long-term finance lease liability 575 Total finance lease liabilities $ 793
Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease	The following table presents information about the amount and timing of cash flows arising from the Company’s operating lease as of September 30, 2024 (in thousands): 2024 $ 400 2025 1,664 2026 1,731 Total undiscounted operating lease payments 3,795 Less: Imputed interest (489 ) Present value of operating lease payments $ 3,306	The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating lease as of December 31, 2023 (in thousands): 2024 $ 1,600 2025 1,665 2026 1,731 Total undiscounted operating lease payments 4,996 Less: Imputed interest (912 ) Present value of operating lease payments $ 4,084
Schedule of Supplemental Balance Sheet Information	The balance sheet classification of the Company’s operating lease is as follows (in thousands): Balance Sheet Classification: Operating lease right-of-use $ 3,035 Current portion of operating lease liability $ 1,322 Long-term operating lease liability 1,984 Total operating lease liabilities $ 3,306	The balance sheet classification of the Company’s operating lease is as follows (in thousands): Balance Sheet Classification: Operating lease right-of-use $ 3,788 Current portion of operating lease liability $ 1,082 Long-term operating lease liability 3,002 Total operating lease liabilities $ 4,084

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The tax provision for income taxes from continuing operations consisted of the following (in thousands): December 31, 2023 2022 Current tax (benefit) provision: Federal $ (1 ) $ —  State 16 14 Total current tax provision 15 14 Deferred tax provision: Federal —  —  State —  —  Total deferred tax provision —  —  Total tax provision $ 15 $ 14
Schedule of Reconciliation Between Federal Statutory and Provision For Income Taxes	The following table provides a reconciliation between income taxes from continuing operations computed at the federal statutory rate and the provision for income taxes (in thousands): Years Ended December 31,   2023     2022   (As Restated) Federal income taxes at 21% for 2023 and 2022 $ (5,264 ) $ (4,559 ) State income tax, net of federal benefit (241 ) (158 ) Nondeductible expenses 234 365 Tax credits (1,096 ) (1,092 ) Rate change (54 ) 491 Change in valuation allowance 5,861 (22,218 ) Reserve for uncertain tax positions 273 (10,346 ) 162m deferred tax asset limitation 128 82 382 NOL and tax credit limitation —  37,513 Expired stock awards 174 1,052 Other —  (1,116 ) Income tax expense $ 15 $ 14
Schedule of Components of Net Deferred Tax Assets	Significant components of the Company’s net deferred tax assets are as follows (in thousands): December 31, 2023 2022 (As Restated) Deferred tax assets: Net operating losses $ 35,506 $ 42,043 Tax credits 9,747 9,327 Intangibles 136 160 Capitalized R&D 25,871 14,706 Stock compensation 1,424 1,385 Lease liabilities 1,112 275 Deferred revenue 5,951 5,620 Accrued indirect tax liabilities 4,114 2,617 Other 725 1,018 Total deferred tax assets 84,586 77,151 Less valuation allowance (83,086 ) (76,713 ) Deferred tax assets, net of valuation allowance 1,500 438 Deferred tax liabilities: Prepaid expenses (214 ) (189 ) Capitalized inventory costs (244 ) — Right-of-use (1,042 ) (249 ) Total deferred tax liabilities (1,500 ) (438 ) Net deferred tax assets $ —  $ —
Schedule of Reconciliation Amount of Gross Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands): Years Ended December 31,   2023     2022   (As Restated) Balance as of the beginning of the year $ 11,015 $ 23,990 Increases related to current year tax positions 552 497 Decreases related to prior year tax positions (47 ) (13,472 ) Balance as of the end of the year $ 11,520 $ 11,015

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of Discontinued Operations	Assets and liabilities classified as discontinued operations in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023 consist of the following: (In thousands) September 30, 2024 December 31, 2023 Carrying amount of major assets included as part of discontinued operations: Current assets: Accounts receivable $ —  $ 2,171 Inventory —  6,097 Prepaid expenses and other current assets —  1,022 Current assets from discontinued operations —  9,290 Noncurrent assets: Other assets —  934 Noncurrent assets from discontinued operations —  934 Total assets from discontinued operations $ —  $ 10,224 Carrying amount of major liabilities included as part of discontinued operations: Current liabilities: Current contract liabilities —  24,665 Current liabilities from discontinued operations —  24,665 Noncurrent liabilities: Long-term contract liabilities —  4,245 Noncurrent liabilities from discontinued operations —  4,245 Total liabilities from discontinued operations $ —  $ 28,910 Inventory consisted of the following (in thousands): September 30, 2024 December 31, 2023 Raw materials $ —  $ 2,691 Work-in-process —  3,406 Total inventory $ —  $ 6,097 The results of operations from discontinued operations during the nine months ended September 30, 2024 and 2023 have been reflected as income (loss) from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consist of the following: Nine Months Ended September 30, (In thousands) 2024 2023 Major line items constituting pretax income (loss) of discontinued operations Revenues: Total revenues $ 29,263 $ 25,795 Operating expenses: Cost of product revenue 9,030 387 Research and development 10,572 25,061 Selling, general and administrative 7,460 2,795 Total operating expenses 27,062 28,243 Income (loss) from operations 2,201 (2,448 ) Other expense, net: Loss on disposal of discontinued operations (1,799 ) —  Total other expense, net (1,799 ) —  Income (loss) from discontinued operations before income tax expense 402 (2,448 ) Income tax expense —  (371 ) Income (loss) from discontinued operations, net of income taxes $ 402 $ (2,819 )	Assets and liabilities classified as discontinued operations in the condensed consolidated balance sheets as of December 31, 2023 and 2022 consist of the following: December 31, 2023 December 31, 2022 (In thousands) (As Restated) Carrying amount of major assets included as part of discontinued operations: Current assets: Accounts receivable $ 2,171 $ 116 Inventory 6,097 —  Prepaid expenses and other current assets 1,022 952 Current assets from discontinued operations 9,290 1,068 Noncurrent assets: Other assets 934 958 Noncurrent assets from discontinued operations 934 958 Total assets from discontinued operations $ 10,224 $ 2,026 Carrying amount of major liabilities included as part of discontinued operations: Current liabilities: Current contract liabilities $ 24,665 $ 13,610 Current liabilities from discontinued operations 24,665 13,610 Noncurrent liabilities: —  Long-term contract liabilities 4,245 20,525 Noncurrent liabilities from discontinued operations 4,245 20,525 Total liabilities from discontinued operations $ 28,910 $ 34,135 Inventory consisted of the following (in thousands): December 31, 2023 2022 Raw materials $ 2,691 $ —  Work-in-process 3,406 —  Total inventory $ 6,097 $ —  The results of operations from discontinued operations during the years ended December 31, 2023 and 2022 have been reflected as income (loss) from discontinued operations, net of income taxes in the consolidated statements of operations and comprehensive loss and consist of the following: Years ended December 31, (In thousands) 2023 2022 (As Restated) Major line items constituting pretax income (loss) of discontinued operations Revenues: Total revenues $ 40,622 $ 40,952 Operating expenses: Cost of product revenue 1,523 —  Research and development 31,769 47,237 Selling, general and administrative 4,753 5,319 Total operating expenses 38,045 52,556 Income (loss) from discontinued operations before income tax expense 2,577 (11,604 ) Income tax expense (428 ) (258 ) Income (loss) from discontinued operations, net of income taxes $ 2,149 $ (11,862 )
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition	The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Mundipharma Collaboration Agreement and Melinta License Agreement during the nine months ended September 30, 2024 (in thousands): Opening balance, December 31, 2023 $ 28,910 Revenue from performance obligations satisfied during reporting period (28,910 ) Closing balance, September 30, 2024 $ —  Current portion of contract liabilities $ —  Long-term portion of contract liabilities —  Total contract liabilities, September 30, 2024 $ —  The following table presents collaboration revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition (in thousands): Nine Months Ended September 30, 2024 Mundipharma Melinta Revenue from Collaboration, License and Purchase Agreements: Point in Time: Rezafungin Assets, including Sale of IP and Inventory $ 20,833 $ — License of Intellectual Property - upon milestone achieved 813 —  Product Revenue 2,826 —  Royalty Revenue 37 125 Over Time: Research and Development Services 3,895 457 Clinical Supply Services 175 —  Transition Services 102 —  Total Revenue from Collaboration, License and Purchase Agreements $ 28,681 $ 582 Nine Months Ended September 30, 2023 Mundipharma Melinta Revenue from Collaboration, License and Purchase Agreements: Point in Time: License of Intellectual Property - upon milestone achieved $ —  $ 17,257 Clinical Drug Supply 26 —  Product Revenue —  1,468 Royalty Revenue —  70 Over Time: Research and Development Services 4,870 1,859 Clinical Supply Services 245 —  Total Revenue from Collaboration, License and Purchase Agreements $ 5,141 $ 20,654	The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Mundipharma Collaboration Agreement and Melinta License Agreement during the year ended December 31, 2023 (in thousands): Opening balance, December 31, 2022 $ 34,135 Payments received in advance 1,463 Payments receivable 1,488 Revenue from performance obligations satisfied during reporting period (8,176 ) Closing balance, December 31, 2023 $ 28,910 Current portion of contract liabilities $ 24,665 Long-term portion of contract liabilities 4,245 Total contract liabilities, December 31, 2023 $ 28,910 The following table presents collaboration revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition (in thousands): Year Ended December 31, 2023 Mundipharma Melinta Revenue from Collaboration, License and Purchase Agreements: Point in Time: License of Intellectual Property - upon milestones achieved $ 3,252 $ 17,257 Clinical Drug Supply 26 —  Product Revenue 2,867 1,468 Royalty Revenue —  168 Over Time: Research and Development Services 12,303 2,441 Clinical Supply Services 840 —  Total Revenue from Collaboration, License and Purchase Agreements $ 19,288 $ 21,334 Year Ended December 31, 2022 Mundipharma Melinta Revenue from Collaboration and License Agreements: Point in Time: License of Intellectual Property - upon transfer of license $ —  $ 25,885 License of Intellectual Property - upon milestones achieved 3,252 —  Clinical Drug Supply 484 —  Over Time: Research and Development Services 9,595 811 Clinical Supply Services 925 —  Total Revenue from Collaboration and License Agreements $ 14,256 $ 26,696

SELECTED QUARTERLY FINANCIAL _2

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	9 Months Ended
	Sep. 30, 2024
Quarterly Financial Information Disclosure [Abstract]
Schedule of Selected Quarterly Financial Data (Unaudited)	the Company has restated, and recast for the discontinued operations and reverse stock split, its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023. March 31, 2023 March 31, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 47,976 $ —  $ 47,976 $ 36,488 $ —  $ 36,488 Restricted Cash —  —  —  1,482 —  1,482 Accounts receivable 25,703 295 25,998 8,649 —  8,649 Prepaid expenses and other current assets 5,245 (143 ) 5,102 4,038 —  4,038 Current assets from discontinued operations 564 168 732 1,350 —  1,350 Total current assets 79,488 320 79,808 52,007 —  52,007 Property and equipment, net 270 —  270 239 —  239 Operating lease right-of-use 917 (81 ) 836 2,030 (184 ) 1,846 Other assets 102 —  102 155 —  155 Noncurrent assets from discontinued operations 959 —  959 864 —  864 Total assets $ 81,736 $ 239 $ 81,975 $ 55,295 $ (184 ) $ 55,111 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable 3,980 46 4,026 2,861 —  2,861 Accrued liabilities 9,078 30 9,108 9,234 720 9,954 Accrued indirect tax liabilities —  11,795 11,795 —  7,942 7,942 Accrued compensation and benefits 5,843 —  5,843 3,079 —  3,079 Current contract liabilities 699 —  699 4,514 —  4,514 Current portion of operating lease liability 1,001 (81 ) 920 1,190 (100 ) 1,090 Current portion of term loan —  —  —  1,481 —  1,481 Current liabilities from discontinued operations 15,062 29 15,091 9,746 —  9,746 Total current liabilities 35,663 11,819 47,482 32,105 8,562 40,667 Long-term contract liabilities 92 (9 ) 83 337 —  337 Long-term operating lease liability —  —  —  1,004 (84 ) 920 Noncurrent liabilities from discontinued operations 19,144 159 19,303 16,892 —  16,892 Total liabilities 54,899 11,969 66,868 50,338 8,478 58,816 March 31, 2023 March 31, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Commitments and contingencies Stockholders’ equity (deficit): Preferred stock (1) Series X Convertible Preferred stock (2) —  —  —  —  —  —  Common stock (3) 1 —  1 1 —  1 Additional paid-in 430,593 —  430,593 400,404 (720 ) 399,684 Accumulated deficit (403,757 ) (11,730 ) (415,487 ) (395,448 ) (7,942 ) (403,390 ) Total stockholders’ equity (deficit) 26,837 (11,730 ) 15,107 4,957 (8,662 ) (3,705 ) Total liabilities and stockholders’ equity (deficit) $ 81,736 $ 239 $ 81,975 $ 55,295 $ (184 ) $ 55,111 (1) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022 (2) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at March 31, 2023 and March 31, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at March 31, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at March 31, 2022 (3) Common stock, $0.0001 par value; 20,000,000 shares authorized at March 31, 2023 and March 31, 2022; 4,501,256 shares issued and outstanding at March 31, 2023 and 3,452,567 shares issued and outstanding at March 31, 2022 June 30, 2023 June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 50,430 $ —  $ 50,430 $ 24,637 $ —  $ 24,637 Restricted cash —  — —  370 —  370 Accounts receivable 5,310 —  5,310 4,113 —  4,113 Prepaid expenses and other current assets 3,230 —  3,230 5,909 —  5,909 Current assets from discontinued operations 3,270 434 3,704 1,517 —  1,517 Total current assets 62,240 434 62,674 36,546 —  36,546 Property and equipment, net 297 —  297 201 —  201 Operating lease right-of-use 4,388 (81 ) 4,307 1,765 (162 ) 1,603 Other assets 101 —  101 150 —  150 Noncurrent assets from discontinued operations 960 —  960 862 —  862 Total assets $ 67,986 $ 353 $ 68,339 $ 39,524 $ (162 ) $ 39,362 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable 1,899 —  1,899 3,091 —  3,091 Accrued liabilities 10,022 —  10,022 8,567 —  8,567 Accrued indirect tax liabilities —  13,431 13,431 —  10,582 10,582 Accrued compensation and benefits 3,582 —  3,582 3,464 —  3,464 Current contract liabilities 369 —  369 4,444 —  4,444 Current portion of operating lease liability 942 (81 ) 861 1,233 (104 ) 1,129 Current portion of term loan —  —  —  370 —  370 Current liabilities from discontinued operations 14,606 —  14,606 10,286 —  10,286 Total current liabilities 31,420 13,350 44,770 31,455 10,478 41,933 Long-term contract liabilities —  —  —  195 —  195 Long-term operating lease liability 3,601 —  3,601 679 (58 ) 621 Noncurrent liabilities from discontinued operations 17,551 —  17,551 15,156 —  15,156 Total liabilities 52,572 13,350 65,922 47,485 10,420 57,905 June 30, 2023 June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Commitments and contingencies Stockholders’ equity (deficit): Preferred stock (4) Series X Convertible Preferred stock (5) —  —  —  —  —  —  Common stock (6) 1 —  1 1 —  1 Additional paid-in 431,527 —  431,527 400,605 —  400,605 Accumulated deficit (416,114 ) (12,997 ) (429,111 ) (408,567 ) (10,582 ) (419,149 ) Total stockholders’ equity (deficit) 15,414 (12,997 ) 2,417 (7,961 ) (10,582 ) (18,543 ) Total liabilities and stockholders’ equity (deficit) $ 67,986 $ 353 $ 68,339 $ 39,524 $ (162 ) $ 39,362 (4) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and June 30, 2022 (5) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at June 30, 2023 and June 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at June 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at June 30, 2022 (6) Common stock, $0.0001 par value; 20,000,000 shares authorized at June 30, 2023 and June 30, 2022; 4,512,595 shares issued and outstanding at June 30, 2023 and 3,462,024 shares issued and outstanding at June 30, 2022 September 30, 2023 September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 48,670 $ —  $ 48,670 $ 53,078 $ —  $ 53,078 Accounts receivable 2,670 —  2,670 4,917 —  4,917 Prepaid expenses and other current assets 2,794 —  2,794 3,932 —  3,932 Current assets from discontinued operations 3,570 757 4,327 1,972 —  1,972 Total current assets 57,704 757 58,461 63,899 —  63,899 Property and equipment, net 580 —  580 173 —  173 Operating lease right-of-use 4,131 (81 ) 4,050 1,491 (137 ) 1,354 Other assets 103 —  103 132 —  132 Noncurrent assets from discontinued operations 950 —  950 1,163 —  1,163 Total assets $ 63,468 $ 676 $ 64,144 $ 66,858 $ (137 ) $ 66,721 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable 3,661 —  3,661 4,244 —  4,244 Accrued liabilities 11,772 —  11,772 8,162 —  8,162 Accrued indirect tax liabilities —  14,689 14,689 —  11,314 11,314 Accrued compensation and benefits 4,457 —  4,457 4,117 —  4,117 Current contract liabilities 750 —  750 3,254 —  3,254 Current portion of operating lease liability 1,051 (81 ) 970 1,277 (108 ) 1,169 Current liabilities from discontinued operations 13,929 —  13,929 11,995 —  11,995 Total current liabilities 35,620 14,608 50,228 33,049 11,206 44,255 Long-term contract liabilities —  —  —  98 —  98 Long-term operating lease liability 3,306 —  3,306 344 (29 ) 315 Noncurrent liabilities from discontinued operations 16,504 —  16,504 24,300 —  24,300 Total liabilities 55,430 14,608 70,038 57,791 11,177 68,968 September 30, 2023 September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Commitments and contingencies Stockholders’ equity (deficit): Preferred stock (7) Series X Convertible Preferred stock (8) —  —  —  —  —  —  Common stock (9) 1 —  1 1 —  1 Additional paid-in 432,323 —  432,323 402,655 —  402,655 Accumulated deficit (424,286 ) (13,932 ) (438,218 ) (393,589 ) (11,314 ) (404,903 ) Total stockholders’ equity (deficit) 8,038 (13,932 ) (5,894 ) 9,067 (11,314 ) (2,247 ) Total liabilities and stockholders’ equity (deficit) $ 63,468 $ 676 $ 64,144 $ 66,858 $ (137 ) $ 66,721 (7) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and September 30, 2022 (8) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at September 30, 2023 and September 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at September 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at September 30, 2022 (9) Common stock, $0.0001 par value; 20,000,000 shares authorized at September 30, 2023 and September 30, 2022; 4,520,814 shares issued and outstanding at September 30, 2023 and 3,559,141 shares issued and outstanding at September 30, 2022 Three Months Ended March 31, 2023 Three Months Ended March 31, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 5,915 $ 305 $ 6,220 $ 4,583 $ 160 $ 4,743 Total revenues 5,915 305 6,220 4,583 160 4,743 Operating expenses: Research and development 9,415 295 9,710 5,545 —  5,545 General and administrative 3,653 —  3,653 4,675 —  4,675 Total operating expenses 13,068 295 13,363 10,220 —  10,220 Income (loss) from operations (7,153 ) 10 (7,143 ) (5,637 ) 160 (5,477 ) Other income (expense), net: Interest income (expense), net 232 —  232 (20 ) —  (20 ) Total other income (expense), net 232 —  232 (20 ) —  (20 ) Net income (loss) from continuing operations (6,921 ) 10 (6,911 ) (5,657 ) 160 (5,497 ) Income (loss) from discontinued operations 10,130 (206 ) 9,924 (12,624 ) (353 ) (12,977 ) Net income (loss) and comprehensive income (loss) 3,209 (196 ) 3,013 (18,281 ) (193 ) (18,474 ) Allocation of earnings to participating securities (677 ) 41 (636 ) —  —  —  Net income (loss) attributable to common stockholders $ 2,532 $ (155 ) $ 2,377 $ (18,281 ) $ (193 ) $ (18,474 ) Basic and diluted net earnings (loss) per common share from continuing operations (10) $ (1.39 ) $ (1.39 ) $ (1.66 ) $ (1.61 ) Basic and diluted net earnings (loss) per common share from discontinued operations (10) $ 2.03 $ 1.99 $ (3.71 ) $ (3.81 ) Basic and diluted net earnings (loss) per common share (10) $ 0.64 $ 0.60 $ (5.37 ) $ (5.42 ) Shares used to compute basic and diluted net earnings (loss) per common share 3,932,050 3,932,050 3,406,994 3,406,994 (10) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Three Months Ended June 30, 2023 Three Months Ended June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 5,395 $ (305 ) $ 5,090 $ 4,293 $ —  $ 4,293 Total revenues 5,395 (305 ) 5,090 4,293 —  4,293 Operating expenses: Research and development 8,952 (295 ) 8,657 6,276 —  6,276 General and administrative 3,181 —  3,181 3,645 —  3,645 Total operating expenses 12,133 (295 ) 11,838 9,921 —  9,921 Loss from operations (6,738 ) (10 ) (6,748 ) (5,628 ) —  (5,628 ) Other income (expense), net: Interest income (expense), net 623 —  623 (6 ) —  (6 ) Total other income (expense), net 623 —  623 (6 ) —  (6 ) Net loss before income tax expense (6,115 ) (10 ) (6,125 ) (5,634 ) —  (5,634 ) Income tax expense (40 ) —  (40 ) —  —  —  Net income (loss) from continuing operations (6,155 ) (10 ) (6,165 ) (5,634 ) —  (5,634 ) Income (loss) from discontinued operations (6,202 ) (1,257 ) (7,459 ) (7,485 ) (2,640 ) (10,125 ) Net loss and comprehensive loss $ (12,357 ) $ (1,267 ) $ (13,624 ) $ (13,119 ) $ (2,640 ) $ (15,759 ) Basic and diluted net earnings (loss) per common share from continuing operations (11) $ (1.37 ) $ (1.37 ) $ (1.63 ) $ (1.63 ) Basic and diluted net earnings (loss) per common share from discontinued operations (11) $ (1.38 ) $ (1.65 ) $ (2.17 ) $ (2.93 ) Basic and diluted net earnings (loss) per common share (11) $ (2.75 ) $ (3.02 ) $ (3.80 ) $ (4.56 ) Shares used to compute basic and diluted net earnings (loss) per common share 4,505,813 4,505,813 3,456,786 3,456,786 (11) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 11,310 $ —  $ 11,310 $ 8,876 $ 160 $ 9,036 Total revenues 11,310 —  11,310 8,876 160 9,036 Operating expenses: Research and development 18,367 —  18,367 11,821 —  11,821 General and administrative 6,834 —  6,834 8,320 —  8,320 Total operating expenses 25,201 —  25,201 20,141 —  20,141 Loss from operations (13,891 ) —  (13,891 ) (11,265 ) 160 (11,105 ) Other income (expense), net: Interest income (expense), net 855 —  855 (26 ) —  (26 ) Total other income (expense), net 855 —  855 (26 ) —  (26 ) Loss before income tax expense (13,036 ) —  (13,036 ) (11,291 ) 160 (11,131 ) Income tax expense (40 ) —  (40 ) —  —  —  Net income (loss) from continuing operations $ (13,076 ) $ — $ (13,076 ) $ (11,291 ) $ 160 $ (11,131 ) Income (loss) from discontinued operations 3,928 (1,463 ) 2,465 (20,109 ) (2,993 ) (23,102 ) Net loss and comprehensive loss $ (9,148 ) $ (1,463 ) $ (10,611 ) $ (31,400 ) $ (2,833 ) $ (34,233 ) Basic and diluted net earnings (loss) per common share $ (3.10 ) $ (3.10 ) $ (3.29 ) $ (3.24 ) Basic and diluted net earnings (loss) per common share $ 0.93 $ 0.59 $ (5.86 ) $ (6.73 ) Basic and diluted net earnings (loss) per common share (12) $ (2.17 ) $ (2.51 ) $ (9.15 ) $ (9.97 ) Shares used to compute basic and diluted net earnings (loss) per common share 4,220,511 4,220,511 3,432,017 3,432,017 (12) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 9,217 $ —  $ 9,217 $ 6,512 $ —  $ 6,512 Total revenues 9,217 —  9,217 6,512 —  6,512 Operating expenses: Research and development 10,386 —  10,386 8,581 —  8,581 General and administrative 3,299 —  3,299 3,783 —  3,783 Total operating expenses 13,685 —  13,685 12,364 —  12,364 Income (loss) from operations (4,468 ) —  (4,468 ) (5,852 ) —  (5,852 ) Other income, net: Interest income, net 613 —  613 55 —  55 Total other income, net 613 —  613 55 —  55 Net income (loss) before income tax expense (3,855 ) —  (3,855 ) (5,797 ) —  (5,797 ) Income tax expense 32 —  32 —  —  —  Net income (loss) from continuing operations (3,823 ) —  (3,823 ) (5,797 ) —  (5,797 ) Income (loss) from discontinued operations (4,349 ) (935 ) (5,284 ) 20,775 (732 ) 20,043 Net income (loss) and comprehensive income (loss) (8,172 ) (935 ) (9,107 ) 14,978 (732 ) 14,246 Allocation of earnings to participating securities —  —  —  (3,081 ) 150 (2,931 ) Net income (loss) attributable to common stockholders $ (8,172 ) $ (935 ) $ (9,107 ) $ 11,897 $ (582 ) $ 11,315 Basic and diluted net earnings (loss) per common share from continuing operations (13) $ (0.85 ) $ (0.85 ) $ (1.31 ) $ (1.31 ) Basic and diluted net earnings (loss) per common share from discontinued operations (13) $ (0.96 ) $ (1.17 ) $ 4.70 $ 4.53 Basic and diluted net earnings (loss) per common share (13) $ (1.81 ) $ (2.02 ) $ 3.39 $ 3.22 Shares used to compute basic and diluted net earnings (loss) per common share 4,514,381 4,514,381 3,510,974 3,510,974 (13) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Corrected Condensed Consolidated As Restatement As Restated As Restatement As Restated Revenues: Collaboration revenue $ 20,527 $ —  $ 20,527 $ 15,388 $ 160 $ 15,548 Product revenue —  —  —  —  —  —  Total revenues 20,527 —  20,527 15,388 160 15,548 Operating expenses: Cost of product revenue —  —  —  —  —  —  Research and development 28,753 —  28,753 20,402 —  20,402 General and administrative 10,133 —  10,133 12,103 —  12,103 Total operating expenses 38,886 —  38,886 32,505 —  32,505 Loss from operations (18,359 ) —  (18,359 ) (17,117 ) 160 (16,957 ) Other income, net: Interest income, net 1,468 —  1,468 29 —  29 Total other income, net 1,468 —  1,468 29 —  29 Net loss before income tax expense (16,891 ) —  (16,891 ) (17,088 ) 160 (16,928 ) Income tax expense (8 ) —  (8 ) —  —  —  Net income (loss) from continuing operations (16,899 ) — (16,899 ) (17,088 ) 160 (16,928 ) Income (loss) from discontinued operations (421 ) (2,398 ) (2,819 ) 666 (3,725 ) (3,059 ) Net income (loss) and comprehensive income (loss) $ (17,320 ) $ (2,398 ) $ (19,718 ) $ (16,422 ) $ (3,565 ) $ (19,987 ) Basic and diluted net earnings (loss) per common share $ (3.91 ) $ (3.91 ) $ (4.94 ) $ (4.89 ) Basic and diluted net earnings (loss) per common share $ (0.10 ) $ (0.65 ) $ 0.19 $ (0.89 ) Basic and diluted net earnings (loss) per common share (14) $ (4.01 ) $ (4.56 ) $ (4.75 ) $ (5.78 ) Shares used to compute basic and diluted net earnings (loss) per common share 4,319,536 4,319,536 3,458,608 3,458,608 (14) As the Company had a discontinued operation, the company used income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations. Because there is a loss from continuing operations, the potentially dilutive shares are antidilutive and diluted net earnings (loss) per share is the same as basic net earnings (loss) per share. Three Months Ended March 31, 2023 Three Months Ended March 31, 2022 Corrected Condensed Consolidated Statement of As Restatement As As Restatement As Operating activities: Net income (loss) $ 3,209 $ (196 ) $ 3,013 $ (18,281 ) $ (193 ) $ (18,474 ) Adjustments to reconcile net loss to net cash used in operating Stock-based compensation 640 —  640 1,338 —  1,338 Non-cash 288 (26 ) 262 258 (24 ) 234 Depreciation and amortization 32 —  32 39 —  39 Amortization of costs to obtain a contract with a customer 475 —  475 —  —  —  Non-cash —  —  —  1 —  1 Changes in assets and liabilities: Accounts receivable (19,993 ) (295 ) (20,288 ) (3,427 ) —  (3,427 ) Prepaid expenses, other current assets, and other assets 872 (24 ) 848 (1,120 ) —  (1,120 ) Accounts payable and accrued liabilities 3,116 76 3,192 657 —  657 Accrued indirect tax liabilities —  261 261 —  353 353 Accrued compensation and benefits 921 —  921 (1,953 ) —  (1,953 ) Contract liabilities (142 ) 178 36 (844 ) (160 ) (1,004 ) Operating lease liabilities (316 ) 26 (290 ) (276 ) 24 (252 ) Net cash used in operating activities (10,898 ) —  (10,898 ) (23,608 ) —  (23,608 ) Investing activities: Purchases of property and equipment (94 ) —  (94 ) (84 ) —  (84 ) Net cash used in investing activities (94 ) —  (94 ) (84 ) —  (84 ) Financing activities: Proceeds from underwritten public offering, net of issuance costs 17,593 —  17,593 —  —  —  Proceeds from public offering of common stock, net of issuance costs 8,630 —  8,630 500 —  500 Proceeds from exercise of stock options 14 —  14 —  —  —  Principal repayments of Term Loan —  —  —  (1,111 ) —  (1,111 ) Net cash provided by (used in) financing activities 26,237 —  26,237 (611 ) —  (611 ) Net increase (decrease) in cash and cash equivalents 15,245 —  15,245 (24,303 ) —  (24,303 ) Cash and cash equivalents at beginning of period 32,731 —  32,731 62,273 — 62,273 Cash and cash equivalents at end of period $ 47,976 $ —  $ 47,976 $ 37,970 $ — $ 37,970 Supplemental disclosure of cash flows: Interest paid $ —  $ —  $ —  $ 25 $ —  $ 25 Non-cash Purchases of property and equipment, included in accounts payable $ 55 $ —  $ 55 $ 16 $ —  $ 16 Non-cash Issuance costs incurred but not yet paid, included in accounts payable $ 337 $ —  $ 337 $ —  $ 720 $ 720 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 Corrected Condensed Consolidated Statement of As Restatement As As Restatement As Operating activities: Net loss $ (9,148 ) $ (1,463 ) $ (10,611 ) $ (31,400 ) $ (2,833 ) $ (34,233 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 1,435 —  1,435 2,016 —  2,016 Non-cash 664 (25 ) 639 523 (47 ) 476 Depreciation and amortization 57 —  57 77 —  77 Amortization of costs to obtain a contract with a customer 40 —  40 —  —  —  Non-cash —  —  —  1 —  1 Changes in assets and liabilities: Accounts receivable 350 —  350 524 —  524 Inventory (1,954 ) (434 ) (2,388 ) —  —  —  Prepaid expenses, other current assets, and other assets 2,120 —  2,120 (2,567 ) —  (2,567 ) Accounts payable and accrued liabilities 2,870 —  2,870 (483 ) —  (483 ) Accrued indirect tax liabilities —  1,897 1,897 —  2,993 2,993 Accrued compensation and benefits (1,277 ) —  (1,277 ) (1,324 ) —  (1,324 ) Contract liabilities (2,613 ) —  (2,613 ) (2,252 ) (160 ) (2,412 ) Operating lease liabilities (620 ) 25 (595 ) (559 ) 47 (512 ) Net cash used in operating activities (8,076 ) —  (8,076 ) (35,444 ) —  (35,444 ) Investing activities: Purchases of property and equipment (201 ) —  (201 ) (100 ) —  (100 ) Net cash used in investing activities (201 ) —  (201 ) (100 ) —  (100 ) Financing activities: Proceeds from underwritten public offering, net of issuance costs 17,256 —  17,256 —  —  —  Proceeds from public offering of common stock, net of issuance costs 8,706 —  8,706 500 —  500 Proceeds from exercise of stock options 14 —  14 —  —  —  Principal repayments of Term Loan —  —  —  (2,222 ) —  (2,222 ) Net cash provided by (used in) financing activities 25,976 —  25,976 (1,722 ) —  (1,722 ) Net increase (decrease) in cash and cash equivalents 17,699 —  17,699 (37,266 ) —  (37,266 ) Cash and cash equivalents at beginning of period 32,731 — 32,731 62,273 — 62,273 Cash and cash equivalents at end of period $ 50,430 $ — $ 50,430 $ 25,007 $ — $ 25,007 Supplemental disclosure of cash flows: Interest paid $ —  $ —  $ —  $ 38 $ —  $ 38 Income taxes paid $ 588 $ —  $ 588 $ —  $ —  $ —  Non-cash Operating lease right-of-use $ 3,847 $ —  $ 3,847 $ —  $ —  $ —  Non-cash Purchase of shares pursuant to Employee Stock Purchase Plan $ 63 $ —  $ 63 $ 69 $ —  $ 69 Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities $ —  $ —  $ —  $ 720 $ —  $ 720 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Corrected Condensed Consolidated Statement As  Restatement  As As  Restatement  As Operating activities: Net loss $ (17,320 ) $ (2,398 ) $ (19,718 ) $ (16,422 ) $ (3,565 ) $ (19,987 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 2,231 —  2,231 2,859 —  2,859 Non-cash 921 (26 ) 895 796 (72 ) 724 Depreciation and amortization 79 —  79 114 —  114 Amortization of costs to obtain a contract with a customer 53 —  53 1,772 —  1,772 Non-cash —  —  —  1 —  1 Changes in assets and liabilities: Accounts receivable 2,978 (323 ) 2,655 314 —  314 Inventory (2,467 ) (434 ) (2,901 ) —  —  —  Prepaid expenses, other current assets, and other assets 2,776 —  2,776 (1,662 ) —  (1,662 ) Accounts payable and accrued liabilities 6,204 —  6,204 (1,037 ) —  (1,037 ) Accrued indirect tax liabilities —  3,155 3,155 —  3,725 3,725 Accrued compensation and benefits (402 ) —  (402 ) (670 ) —  (670 ) Contract liabilities (3,956 ) —  (3,956 ) 7,314 (160 ) 7,154 Operating lease liabilities (807 ) 26 (781 ) (850 ) 72 (778 ) Net cash used in operating activities (9,710 ) —  (9,710 ) (7,471 ) —  (7,471 ) Investing activities: Purchases of property and equipment (327 ) —  (327 ) (109 ) —  (109 ) Net cash used in investing activities (327 ) —  (327 ) (109 ) —  (109 ) Financing activities: Proceeds from underwritten public offering, net of issuance costs 17,256 —  17,256 —  —  —  Proceeds from public offering of common stock, net of issuance costs 8,706 —  8,706 1,698 —  1,698 Proceeds from exercise of stock options 14 —  14 —  —  —  Issuance costs for underwritten public offering —  —  —  (720 ) —  (720 ) Principal repayments of Term Loan —  —  —  (2,593 ) —  (2,593 ) Net cash provided by (used in) financing activities 25,976 —  25,976 (1,615 ) —  (1,615 ) Net increase (decrease) in cash and cash equivalents 15,939 —  15,939 (9,195 ) —  (9,195 ) Cash and cash equivalents at beginning of period 32,731 —  32,731 62,273 —  62,273 Cash and cash equivalents at end of period $ 48,670 $ —  $ 48,670 $ 53,078 $ —  $ 53,078 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Corrected Condensed Consolidated Statement As  Restatement  As As  Restatement  As Supplemental disclosure of cash flows: Interest paid $ —  $ —  $ —  $ 40 $ —  $ 40 Income taxes paid $ 651 $ —  $ 651 $ —  $ —  $ —  Non-cash Purchases of property and equipment, included in accounts payable and accrued liabilities $ 178 $ —  $ 178 $ —  $ —  $ —  Operating lease right-of-use $ 3,847 $ —  $ 3,847 $ —  $ —  $ —  Non-cash Purchase of shares pursuant to Employee Stock Purchase Plan $ 63 $ —  $ 63 $ 69 $ —  $ 69 Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets $ — $ —  $ —  $ 10 $ —  $ 10 Corrected Condensed Consolidated Statements of Convertible Preferred Stock and Series X Convertible Common Stock Additional Paid-In Accumulated (As Total (As Restated) (In thousands, except share data) Shares Amount Shares Amount Balance, December 31, 2022 (As Restated) 1,818,472 $ —  3,623,591 $ 1 $ 404,061 $ (418,500 ) $ (14,438 ) Underwritten public offering, net of issuance costs 286,000 —  554,300 —  17,256 —  17,256 Public offering of common stock, net of issuance costs —  —  307,936 —  8,622 —  8,622 Issuance of common stock for exercise of options —  —  812 —  14 —  14 Issuance of common stock for restricted share units vested —  —  14,617 —  —  —  —  Stock-based compensation —  —  —  —  640 —  640 Net income (As Restated) —  —  —  —  —  3,013 3,013 Balance, March 31, 2023 (As Restated) 2,104,472 —  4,501,256 1 430,593 (415,487 ) 15,107 Public offering of common stock, net of issuance costs —  —  3,047 —  76 —  76 Issuance of common stock for restricted share units vested —  —  232 —  —  —  —  Issuance of common stock under Employee Stock Purchase Plan —  —  8,060 —  63 —  63 Stock-based compensation —  —  —  —  795 —  795 Net loss (As Restated) —  —  —  —  —  (13,624 ) (13,624 ) Balance, June 30, 2023 (As Restated) 2,104,472 —  4,512,595 1 431,527 (429,111 ) 2,417 Issuance of common stock for restricted share units vested —  —  8,219 —  —  —  —  Stock-based compensation —  —  —  —  796 —  796 Net loss (As Restated) —  —  —  —  —  (9,107 ) (9,107 ) Balance, September 30, 2023 (As Restated) 2,104,472 $ —  4,520,814 $ 1 $ 432,323 $ (438,218 ) $ (5,894 ) Corrected Condensed Consolidated Statements of Convertible Preferred Stock and Series X Convertible Common Stock Additional Paid-In (As Accumulated (As Total (As Restated) (In thousands, except share data) Shares Amount Shares Amount Balance, December 31, 2021 (As Restated) 1,818,472 $ —  3,393,320 $ 1 $ 398,019 $ (384,916 ) $ 13,104 Public offering of common stock, net of issuance costs —  —  32,208 —  500 —  500 Issuance of common stock for restricted share units vested —  —  27,039 —  —  —  —  Stock-based compensation —  —  —  —  1,165 —  1,165 Net loss (As Restated) —  —  —  —  —  (18,474 ) (18,474 ) Balance, March 31, 2022 (As Restated) 1,818,472 —  3,452,567 1 399,684 (403,390 ) (3,705 ) Issuance of common stock for restricted share units vested —  —  252 —  —  —  —  Issuance of common stock under Employee Stock Purchase Plan —  —  9,205 —  69 —  69 Stock-based compensation —  —  —  —  852 —  852 Issuance costs for underwritten public offering (As Restated) —  —  —  —  —  —  —  Net loss (As Restated) —  —  —  —  —  (15,759 ) (15,759 ) Balance, June 30, 2022 (As Restated) 1,818,472 —  3,462,024 1 400,605 (419,149 ) (18,543 ) Public offering of common stock, net of issuance costs —  —  83,197 —  1,208 —  1,208 Issuance of common stock for restricted share units vested —  —  13,920 —  —  —  —  Stock-based compensation —  —  —  —  842 —  842 Net income (As Restated) —  —  —  —  —  14,246 14,246 Balance, September 30, 2022 (As Restated) 1,818,472 $ —  3,559,141 $ 1 $ 402,655 $ (404,903 ) $ (2,247 )

THE COMPANY AND BASIS OF PRES_3

THE COMPANY AND BASIS OF PRESENTATION (Details) $ in Thousands			1 Months Ended		3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Apr. 24, 2024 USD ($)	Apr. 23, 2024	Nov. 30, 2024 USD ($)	Apr. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2023 USD ($) segment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit					$ 438,218	$ 429,111	$ 415,487	$ 404,903	$ 419,149	$ 403,390	$ 429,111	$ 419,149	$ 558,951	$ 438,218	$ 404,903	$ 441,431	$ 418,500
Cash and cash equivalents					48,670	50,430	47,976	53,078	25,007	37,970	50,430	25,007	$ 127,386	48,670	53,078	$ 35,778	32,731	$ 62,273
Reverse stock split		0.05
Number of operating segments | segment													1			1
Accrued indirect tax liabilities					14,689	13,431	11,795	11,314	10,582	7,942	13,431	10,582	$ 26,289	14,689	11,314	$ 18,040	11,534
Operating expenses					$ 13,685	$ 11,838	$ 13,363	$ 12,364	$ 9,921	$ 10,220	$ 25,201	$ 20,141	$ 123,195	$ 38,886	$ 32,505	$ 50,343	45,395
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit																	7,600	3,900
Accrued indirect tax liabilities																	11,500	7,600
Operating expenses																	$ 3,900	$ 3,700
2024 Private Placement | Series A Convertible Voting Preferred Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sale of stock, gross	$ 240,000
Subsequent event | 2024 Private Placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sale of stock, gross			$ 105,000
Subsequent event | 2024 Private Placement | Series A Convertible Voting Preferred Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sale of stock, gross				$ 240,000

THE COMPANY AND BASIS OF PRES_4

THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating lease right-of-use asset	$ 3,035	$ 3,788	$ 4,050	$ 4,307	$ 836	$ 1,099	$ 1,354	$ 1,603	$ 1,846
Total assets	162,331	67,030	64,144	68,339	81,975	47,487	66,721	39,362	55,111
Accrued indirect tax liabilities	26,289	18,040	14,689	13,431	11,795	11,534	11,314	10,582	7,942
Current portion of operating lease liability	1,322	1,082	970	861	920	1,211	1,169	1,129	1,090
Total current liabilities	44,339	67,418	50,228	44,770	47,482	41,400	44,255	41,933	40,667
Total liabilities	46,701	75,240	70,038	65,922	66,868	61,925	68,968	57,905	58,816
Accumulated deficit	(558,951)	(441,431)	(438,218)	(429,111)	(415,487)	(418,500)	(404,903)	(419,149)	(403,390)
Total stockholders' deficit	115,630	(8,210)	(5,894)	2,417	15,107	(14,438)	(2,247)	(18,543)	(3,705)	$ 13,104
Total liabilities and stockholders' deficit	$ 162,331	$ 67,030	64,144	68,339	81,975	47,487	66,721	39,362	55,111
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating lease right-of-use asset			4,131	4,388	917	1,205	1,491	1,765	2,030
Total assets			63,468	67,986	81,736	47,593	66,858	39,524	55,295
Accrued indirect tax liabilities			0	0	0	0	0	0	0
Current portion of operating lease liability			1,051	942	1,001	1,317	1,277	1,233	1,190
Total current liabilities			35,620	31,420	35,663	29,972	33,049	31,455	32,105
Total liabilities			55,430	52,572	54,899	50,497	57,791	47,485	50,338
Accumulated deficit			(424,286)	(416,114)	(403,757)	(406,966)	(393,589)	(408,567)	(395,448)
Total stockholders' deficit			8,038	15,414	26,837	(2,904)	9,067	(7,961)	4,957	21,573
Total liabilities and stockholders' deficit			63,468	67,986	81,736	47,593	66,858	39,524	55,295
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating lease right-of-use asset			(81)	(81)	(81)	(106)	(137)	(162)	(184)
Total assets			676	353	239	(106)	(137)	(162)	(184)
Accrued indirect tax liabilities			14,689	13,431	11,795	11,534	11,314	10,582	7,942
Current portion of operating lease liability			(81)	(81)	(81)	(106)	(108)	(104)	(100)
Total current liabilities			14,608	13,350	11,819	11,428	11,206	10,478	8,562
Total liabilities			14,608	13,350	11,969	11,428	11,177	10,420	8,478
Accumulated deficit			(13,932)	(12,997)	(11,730)	(11,534)	(11,314)	(10,582)	(7,942)
Total stockholders' deficit			(13,932)	(12,997)	(11,730)	(11,534)	(11,314)	(10,582)	(8,662)	$ (8,469)
Total liabilities and stockholders' deficit			$ 676	$ 353	$ 239	$ (106)	$ (137)	$ (162)	$ (184)

THE COMPANY AND BASIS OF PRES_5

THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Collaboration revenue	$ 9,217	$ 5,090	$ 6,220	$ 6,512	$ 4,293	$ 4,743	$ 11,310	$ 9,036	$ 1,275	$ 20,527	$ 15,548	$ 23,283	$ 23,496
Total revenues	9,217	5,090	6,220	6,512	4,293	4,743	11,310	9,036	1,275	20,527	15,548	23,283	23,496
Loss from operations	(4,468)	(6,748)	(7,143)	(5,852)	(5,628)	(5,477)	(13,891)	(11,105)	(121,920)	(18,359)	(16,957)	(27,060)	(21,899)
Net loss from continuing operations before income tax expense	(3,855)	(6,125)	(6,911)	(5,797)	(5,634)	(5,497)	(13,036)	(11,131)	(117,922)	(16,891)	(16,928)	(25,065)	(21,708)
Net loss from continuing operations									(117,922)	(16,899)		(25,080)	(21,722)
Loss from discontinued operations									402	(2,819)		2,149	(11,862)
Net loss and comprehensive loss	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)	(10,611)	(34,233)	(117,520)	(19,718)	(19,987)	(22,931)	(33,584)
Net loss and comprehensive loss	$ (9,107)	$ (13,624)	$ 3,013	$ 14,246	$ (15,759)	$ (18,474)	$ (10,611)	$ (34,233)	$ (117,520)	$ (19,718)	$ (19,987)	$ (22,931)	$ (33,584)
Basic net loss per common share from continuing operations (in dollars per share)									$ (22.61)	$ (3.91)		$ (5.74)	$ (6.22)
Diluted net loss per common share from continuing operations (in dollars per share)									(22.61)	(3.91)		(5.74)	(6.22)
Basic net loss per common share from discontinued operations (in dollars per share)									0.08	(0.65)		0.49	(3.39)
Diluted net loss per common share from discontinued operations (in dollars per share)									0.08	(0.65)		0.49	(3.39)
Basic net loss per common share (in dollars per share)	$ (2.02)	$ (1.65)	$ 0.6	$ 3.22	$ (2.93)	$ (5.42)	$ (2.51)	$ (9.97)	(22.53)	(4.56)	$ (5.78)	(5.25)	(9.61)
Diluted net loss per common share (in dollars per share)	$ (2.02)	$ (1.65)	$ 0.6	$ 3.22	$ (2.93)	$ (5.42)	$ (2.51)	$ (9.97)	$ (22.53)	$ (4.56)	$ (5.78)	$ (5.25)	$ (9.61)
Shares used to compute basic net loss per common share (in shares)	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017	5,215,365	4,319,536	3,458,608	4,371,375	3,492,925
Shares used to compute diluted net loss per common share (in shares)	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017	5,215,365	4,319,536	3,458,608	4,371,375	3,492,925
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Collaboration revenue	$ 9,217	$ 5,395	$ 5,915	$ 6,512	$ 4,293	$ 4,583	$ 11,310	$ 8,876		$ 20,527	$ 15,388		$ 23,336
Total revenues	9,217	5,395	5,915	6,512	4,293	4,583	11,310	8,876		20,527	15,388		23,336
Loss from operations	(4,468)	(6,738)	(7,153)	(5,852)	(5,628)	(5,637)	(13,891)	(11,265)		(18,359)	(17,117)		(22,059)
Net loss from continuing operations before income tax expense	(3,855)	(6,115)	(6,921)	(5,797)	(5,634)	(5,657)	(13,036)	(11,291)		(16,891)	(17,088)		(21,868)
Net loss from continuing operations													(21,882)
Loss from discontinued operations													(7,917)
Net loss and comprehensive loss	(8,172)	(12,357)	3,209	14,978	(13,119)	(18,281)	(9,148)	(31,400)		(17,320)	(16,422)		(29,799)
Net loss and comprehensive loss	$ (8,172)	$ (12,357)	$ 3,209	$ 14,978	$ (13,119)	$ (18,281)	$ (9,148)	$ (31,400)		$ (17,320)	$ (16,422)		$ (29,799)
Basic net loss per common share from continuing operations (in dollars per share)													$ (6.26)
Diluted net loss per common share from continuing operations (in dollars per share)													(6.26)
Basic net loss per common share from discontinued operations (in dollars per share)													(2.27)
Diluted net loss per common share from discontinued operations (in dollars per share)													(2.27)
Basic net loss per common share (in dollars per share)	$ (1.81)	$ (1.38)	$ 0.64	$ 3.39	$ (2.17)	$ (5.37)	$ (2.17)	$ (9.15)		$ (4.01)	$ (4.75)		(8.53)
Diluted net loss per common share (in dollars per share)	$ (1.81)	$ (1.38)	$ 0.64	$ 3.39	$ (2.17)	$ (5.37)	$ (2.17)	$ (9.15)		$ (4.01)	$ (4.75)		$ (8.53)
Shares used to compute basic net loss per common share (in shares)	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017		4,319,536	3,458,608		3,492,925
Shares used to compute diluted net loss per common share (in shares)	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017		4,319,536	3,458,608		3,492,925
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Collaboration revenue	$ 0	$ (305)	$ 305	$ 0	$ 0	$ 160	$ 0	$ 160		$ 0	$ 160		$ 160
Total revenues	0	(305)	305	0	0	160	0	160		0	160		160
Loss from operations	0	(10)	10	0	0	160	0	160		0	160		160
Net loss from continuing operations before income tax expense	0	(10)	10	0	0	160	0	160		0	160		160
Net loss from continuing operations													160
Loss from discontinued operations													(3,945)
Net loss and comprehensive loss	(935)	(1,267)	(196)	(732)	(2,640)	(193)	(1,463)	(2,833)		(2,398)	(3,565)		(3,785)
Net loss and comprehensive loss	$ (935)	$ (1,267)	$ (196)	$ (732)	$ (2,640)	$ (193)	$ (1,463)	$ (2,833)		$ (2,398)	$ (3,565)		$ (3,785)

THE COMPANY AND BASIS OF PRES_6

THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	$ 2,417	$ 15,107	$ (14,438)	$ (18,543)	$ (3,705)	$ 13,104	$ (14,438)	$ 13,104	$ (8,210)	$ (14,438)	$ 13,104	$ (14,438)	$ 13,104
Net loss	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)	(10,611)	(34,233)	(117,520)	(19,718)	(19,987)	(22,931)	(33,584)
Balance, ending	(5,894)	2,417	15,107	(2,247)	(18,543)	(3,705)	2,417	(18,543)	115,630	(5,894)	(2,247)	(8,210)	(14,438)
Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs for underwritten public offering													0
Additional Paid-In Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	431,527	430,593	404,061	400,605	399,684	398,019	404,061	398,019	433,220	404,061	398,019	404,061	398,019
Balance, ending	432,323	431,527	430,593	402,655	400,605	399,684	431,527	400,605	674,580	432,323	402,655	433,220	404,061
Additional Paid-In Capital | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs for underwritten public offering													0
Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	(429,111)	(415,487)	(418,500)	(419,149)	(403,390)	(384,916)	(418,500)	(384,916)	(441,431)	(418,500)	(384,916)	(418,500)	(384,916)
Net loss	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)			(117,520)	(19,718)		(22,931)	(33,584)
Balance, ending	(438,218)	(429,111)	(415,487)	(404,903)	(419,149)	(403,390)	(429,111)	(419,149)	$ (558,951)	(438,218)	(404,903)	(441,431)	(418,500)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	15,414	26,837	(2,904)	(7,961)	4,957	21,573	(2,904)	21,573		(2,904)	21,573	(2,904)	21,573
Net loss	(8,172)	(12,357)	3,209	14,978	(13,119)	(18,281)	(9,148)	(31,400)		(17,320)	(16,422)		(29,799)
Balance, ending	8,038	15,414	26,837	9,067	(7,961)	4,957	15,414	(7,961)		8,038	9,067		(2,904)
As Previously Reported | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs for underwritten public offering													(720)
As Previously Reported | Additional Paid-In Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning			404,061			398,739	404,061	398,739		404,061	398,739	404,061	398,739
Balance, ending													404,061
As Previously Reported | Additional Paid-In Capital | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs for underwritten public offering													(720)
As Previously Reported | Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning			(406,966)			(377,167)	(406,966)	(377,167)		(406,966)	(377,167)	(406,966)	(377,167)
Net loss													(29,799)
Balance, ending													(406,966)
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	(12,997)	(11,730)	(11,534)	(10,582)	(8,662)	(8,469)	(11,534)	(8,469)		(11,534)	(8,469)	(11,534)	(8,469)
Net loss	(935)	(1,267)	(196)	(732)	(2,640)	(193)	(1,463)	(2,833)		(2,398)	(3,565)		(3,785)
Balance, ending	$ (13,932)	$ (12,997)	(11,730)	$ (11,314)	$ (10,582)	(8,662)	(12,997)	(10,582)		(13,932)	(11,314)		(11,534)
Restatement Adjustment | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs for underwritten public offering													720
Restatement Adjustment | Additional Paid-In Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning			0			(720)	0	(720)		0	(720)	0	(720)
Balance, ending													0
Restatement Adjustment | Additional Paid-In Capital | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs for underwritten public offering													720
Restatement Adjustment | Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning			$ (11,534)			$ (7,749)	$ (11,534)	$ (7,749)		$ (11,534)	$ (7,749)	$ (11,534)	(7,749)
Net loss													(3,785)
Balance, ending													$ (11,534)

THE COMPANY AND BASIS OF PRES_7

THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (9,107)	$ (13,624)	$ 3,013	$ 14,246	$ (15,759)	$ (18,474)	$ (10,611)	$ (34,233)	$ (117,520)	$ (19,718)	$ (19,987)	$ (22,931)	$ (33,584)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash operating lease expense			262			234	639	476	753	895	724	1,158	981
Changes in assets and liabilities:
Accrued indirect tax liabilities			261			353	1,897	2,993		3,155	3,725		3,945
Contract liabilities			36			(1,004)	(2,613)	(2,412)	(29,340)	(3,956)	7,154	(5,799)	2,646
Operating lease liabilities			(290)			(252)	(595)	(512)	$ (778)	(781)	(778)	$ (973)	(1,052)
As Previously Reported
Operating activities:
Net loss	(8,172)	(12,357)	3,209	14,978	(13,119)	(18,281)	(9,148)	(31,400)		(17,320)	(16,422)		(29,799)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash operating lease expense			288			258	664	523		921	796		1,082
Changes in assets and liabilities:
Accrued indirect tax liabilities			0			0	0	0		0	0		0
Contract liabilities			(142)			(844)	(2,613)	(2,252)		(3,956)	7,314		2,806
Operating lease liabilities			(316)			(276)	(620)	(559)		(807)	(850)		(1,153)
Restatement Adjustment
Operating activities:
Net loss	$ (935)	$ (1,267)	(196)	$ (732)	$ (2,640)	(193)	(1,463)	(2,833)		(2,398)	(3,565)		(3,785)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash operating lease expense			(26)			(24)	(25)	(47)		(26)	(72)		(101)
Changes in assets and liabilities:
Accrued indirect tax liabilities			261			353	1,897	2,993		3,155	3,725		3,945
Contract liabilities			178			(160)	0	(160)		0	(160)		(160)
Operating lease liabilities			$ 26			$ 24	$ 25	$ 47		$ 26	$ 72		$ 101

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 31, 2022 obligation	Mar. 31, 2021 obligation	Sep. 30, 2019 obligation
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Credit losses | $	$ 0	$ 0
Expected dividend rate (as a percent)	0%	0%
Janssen Pharmaceuticals, Inc.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of performance obligations				1
Janssen Pharmaceuticals, Inc. | Janssen Collaboration Agreement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of performance obligations				3
Mundipharma Medical Company
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of performance obligations					3
Melinta Therapeutics Inc
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of performance obligations			3
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life (in years)	3 years	3 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life (in years)	7 years	7 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)	17,838,674	1,699,335	1,691,139	2,001,060
Common stock warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)	866	866	866	625,859
Convertible Preferred Stock | Series A Convertible Voting Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)	14,330,750	0
Convertible Preferred Stock | Series X Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)	1,052,236	1,052,236	1,052,236	909,236
Common stock options, RSUs and PRSUs issued and outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)	2,454,822	646,233	638,037	465,965

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets:
Cash and money market accounts	$ 127,386	$ 35,778	$ 32,731
Total assets at fair value	127,386	35,778	32,731
LEVEL 1
Assets:
Cash and money market accounts	127,386	35,778	32,731
Total assets at fair value	127,386	35,778	32,731
LEVEL 2
Assets:
Cash and money market accounts	0	0	0
Total assets at fair value	0	0	0
LEVEL 3
Assets:
Cash and money market accounts	0	0	0
Total assets at fair value	$ 0	$ 0	$ 0

STOCKHOLDERS' EQUITY - Addition

STOCKHOLDERS' EQUITY - Additional Information (Details)							1 Months Ended		9 Months Ended		12 Months Ended		15 Months Ended
	Jul. 19, 2024 shares	Jul. 18, 2024 shares	Apr. 24, 2024 USD ($)	Apr. 23, 2024 $ / shares shares	Mar. 07, 2023 USD ($) $ / shares shares	Aug. 12, 2020 shares	Apr. 30, 2024 $ / shares shares	May 31, 2018 $ / shares shares	Sep. 30, 2024 USD ($) vote $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) vote $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Jul. 17, 2024 shares	Apr. 22, 2024 shares	Jun. 30, 2023 $ / shares shares	Mar. 31, 2023 $ / shares shares	Sep. 30, 2022 $ / shares shares	Jun. 30, 2022 $ / shares shares	Mar. 31, 2022 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)		50,000,000		20,000,000					50,000,000	20,000,000	20,000,000	20,000,000	50,000,000	20,000,000	200,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000
Preferred stock, par value (in dollars per share) | $ / shares									$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)									10,000,000	10,000,000	10,000,000	10,000,000	10,000,000			10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Dividends in arrears or default | $									$ 0		$ 0
Common Stock Warrant
Class of Stock [Line Items]
Warrants outstanding (in shares)									866		866	625,859	866
Warrants expired (in shares)											624,993
Warrants, aggregate intrinsic value, outstanding | $									$ 0		$ 0	$ 0	$ 0
Common Stock Warrant | Weighted Average
Class of Stock [Line Items]
Exercise price of warrant (in dollars per share) | $ / shares									$ 230.95		$ 230.95	$ 136.33	$ 230.95
Common Stock
Class of Stock [Line Items]
Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)						26,120
Number of votes for each share held | vote									1		1
Series X Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares								$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)								5,000,000	4,947,759	4,947,759	4,947,759	4,947,759	4,947,759			4,947,759	4,947,759	4,947,759	4,947,759	4,947,759
Maximum ownership following conversion (more than) (as a percent)								9.99%
Preferred stock, shares outstanding (in shares)									2,104,472	2,104,472	2,104,472	1,818,472	2,104,472			2,104,472	2,104,472	1,818,472	1,818,472	1,818,472
Common stock issued for each preferred stock (in shares)								0.5
Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)						52,241
Number of votes for each share held | vote									0
Series A Convertible Voting Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares									$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized (in shares)									204,725				204,725
Preferred stock, shares outstanding (in shares)									204,725		0		204,725
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares							$ 0.0001
Preferred stock, shares authorized (in shares)							240,000
Conversion of stock, shares issued (in shares)	2,469,250
Conversion of stock, shares converted (in shares)	35,275
Maximum ownership following conversion (more than) (as a percent)	9.99%						9.99%
Preferred stock, shares outstanding (in shares)									204,725				204,725
Common stock issued for each preferred stock (in shares)							70
Controlled Equity Sales Agreement, Cantor Fitzgerald and Company
Class of Stock [Line Items]
Shares sold (in shares)									0	310,983	310,983	170,723	0
Sale of stock, net | $										$ 8,700,000	$ 8,700,000	$ 2,400,000
Consideration remaining on transaction | $									$ 37,100,000		$ 37,100,000		$ 37,100,000
2023 Underwritten Public Offering
Class of Stock [Line Items]
Sale of stock, net | $					$ 17,300,000
Sale of stock, gross | $					$ 19,500,000
2023 Underwritten Public Offering | Common Stock
Class of Stock [Line Items]
Shares sold (in shares)					554,300
Offering price (in dollars per share) | $ / shares					$ 25.34
2023 Underwritten Public Offering | Series X Convertible Preferred Stock
Class of Stock [Line Items]
Shares sold (in shares)					286,000
Offering price (in dollars per share) | $ / shares					$ 12.67
Over-Allotment Option | Common Stock
Class of Stock [Line Items]
Shares sold (in shares)					72,300
2024 Private Placement | Series A Convertible Voting Preferred Stock
Class of Stock [Line Items]
Shares sold (in shares)				240,000
Sale of stock, net | $			$ 239,100,000
Sale of stock, gross | $			$ 240,000,000
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001
2024 Private Placement | Series A Convertible Preferred Stock
Class of Stock [Line Items]
Offering price (in dollars per share) | $ / shares				$ 1,000
Conversion of stock, shares issued (in shares)		16,800,000
Conversion of stock, shares converted (in shares)		240,000

STOCKHOLDERS' EQUITY - Schedule

STOCKHOLDERS' EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Total (in shares)	18,958,169	1,911,545	2,265,345
Common stock warrants
Class of Stock [Line Items]
Total (in shares)	866	866	625,859
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Total (in shares)	14,330,750	0
Series X Convertible Preferred Stock
Class of Stock [Line Items]
Total (in shares)	1,052,236	1,052,236	909,236
Common stock options, RSUs and PRSUs issued and outstanding
Class of Stock [Line Items]
Total (in shares)	2,454,822	638,037	465,965
Authorized for future stock awards
Class of Stock [Line Items]
Total (in shares)	1,052,406	170,783	223,713
Awards available under the ESPP
Class of Stock [Line Items]
Total (in shares)	67,089	49,623	40,572

PROPERTY AND EQUIPMENT - Summar

PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 3,747				$ 3,380
Less accumulated depreciation and amortization		(3,190)				(3,158)
Total	$ 561	557	$ 580	$ 297	$ 270	222	$ 173	$ 201	$ 239
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		2,817				2,415
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		425				425
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		327				305
Office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		36				93
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 142				$ 142

PROPERTY AND EQUIPMENT - Additi

PROPERTY AND EQUIPMENT - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended			12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization of property and equipment	$ 32	$ 39	$ 57	$ 77	$ 114	$ 79	$ 114	$ 112	$ 143

EQUITY INCENTIVE PLANS - Additi

EQUITY INCENTIVE PLANS - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	9 Months Ended		12 Months Ended
	Jul. 18, 2024	Mar. 31, 2015	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of employee stock options granted (in dollars per share)			$ 8.05	$ 14.45	$ 14.45	$ 10.14
Unrecognized share-based compensation expense, options			$ 15.2		$ 2.4
RSU and PRSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional awards were granted (in shares)			153,012		75,778
Weighted-average period to recognize unrecognized compensation cost (in years)			2 years 7 months 6 days		2 years
RSUs and PRSUs granted (in dollars per share)			$ 12.3	$ 20.1	$ 20.04	$ 16.64
Fair value of RSUs and PRSUs			$ 1	$ 0.7	$ 0.7	$ 1.6
Estimated unrecognized share-based compensation expense			$ 2.3		$ 1.7
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period to recognize unrecognized compensation cost (in years)			2 years 10 months 24 days		1 year 10 months 24 days
2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional awards were granted (in shares)	0
Term for stock options to be granted (in years)	10 years
Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)	100%
Voting power threshold (as a percent)	10%
2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan | More than 10% of Voting Power
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)	110%
2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	3 years
2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	4 years
2015 EIP and 2020 IIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term for stock options to be granted (in years)		10 years
Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)		100%
Voting power threshold (as a percent)		10%
Automatic annual increase in shares authorized for issuance in equity incentive plan (as a percent)		4%
2015 EIP and 2020 IIP | More than 10% of Voting Power
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)		110%
2015 EIP and 2020 IIP | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		3 years
2015 EIP and 2020 IIP | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		4 years
2015 Employee Stock Purchase Plan | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)		85%
Automatic annual increase in shares authorized for issuance in equity incentive plan (as a percent)		1%
Employee payroll deduction under the stock plan (as a percent)		15%
Issuance of common stock under Employee Stock Purchase Plan (in shares)			7,050	8,060	15,465	18,168
Total unrecognized compensation expense related to the ESPP			$ 0.1
Weighted-average period to recognize unrecognized compensation cost (in years)			7 months 6 days		4 months 24 days
2015 Employee Stock Purchase Plan | Maximum | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares outstanding (in shares)		24,516

EQUITY INCENTIVE PLANS - Schedu

EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details) - RSU and PRSU - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Number of RSUs and PRSUs
Outstanding, beginning balance (in shares)	104,886	61,149	61,149
RSUs and PRSUs granted (in shares)	153,012		75,778
RSUs and PRSUs vested (in shares)	(43,053)		(24,487)
RSUs and PRSUs canceled (in shares)	(17,705)		(7,554)
Outstanding, ending balance (in shares)	197,140		104,886	61,149
Weighted Average Grant Date Fair Value
Outstanding, beginning balance (in dollars per share)	$ 22.83	$ 29.36	$ 29.36
RSUs and PRSUs granted (in dollars per share)	12.3	$ 20.1	20.04	$ 16.64
RSUs and PRSUs vested (in dollars per share)	24.24		29.64
RSUs and PRSUs canceled (in dollars per share)	24.68		25.76
Outstanding, ending balance (in dollars per share)	$ 14.18		$ 22.83	$ 29.36

EQUITY INCENTIVE PLANS - Sche_2

EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Number of Shares
Outstanding, beginning balance (in shares)	533,151	404,816
Options granted (in shares)	1,796,401	161,666
Options exercised (in shares)	0	(1,287)
Options canceled (in shares)	(71,870)	(32,044)
Outstanding, ending balance (in shares)	2,257,682	533,151	404,816
Vested and expected to vest (in shares)	2,257,682	533,151
Exercisable (in shares)	420,941	361,644
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 44.61	$ 55.6
Options granted (in dollars per share)	11.14	20.4
Options exercised (in dollars per share)	0	16.65
Options canceled (in dollars per share)	31.68	62.4
Outstanding, ending balance (in dollars per share)	18.39	44.61	$ 55.6
Vested and expected to vest (in dollars per share)	18.39	44.61
Exercisable (in dollars per share)	$ 48.19	$ 55.04
Weighted Average Remaining Contractual Life in Years
Outstanding (in years)	9 years 1 month 6 days	6 years 8 months 19 days	6 years 7 months 24 days
Vested and expected to vest (in years)	9 years 1 month 6 days	6 years 8 months 19 days
Exercisable (in years)	5 years 8 months 26 days	5 years 8 months 15 days
Total Aggregate Intrinsic Value (in thousands)
Outstanding	$ 1	$ 57	$ 48
Vested and expected to vest	1	57
Exercisable	$ 1	$ 54

EQUITY INCENTIVE PLANS - Sche_3

EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield (as a percent)	0%	0%
2015 EIP and 2020 IIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum (as a percent)		3.58%	1.39%
Risk-free interest rate, maximum (as a percent)		4.61%	4.02%
Expected dividend yield (as a percent)		0%	0%
Expected volatility, minimum (as a percent)		82%	70%
Expected volatility, maximum (as a percent)		83%	75%
2015 EIP and 2020 IIP | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		5 years 6 months	5 years 6 months
2015 EIP and 2020 IIP | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		6 years 29 days	6 years 29 days
2015 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum (as a percent)		4.29%	1.57%
Risk-free interest rate, maximum (as a percent)		5.43%	2.65%
Expected dividend yield (as a percent)		0%	0%
Expected volatility, minimum (as a percent)		64%	75%
Expected volatility, maximum (as a percent)		147%	98%
2015 ESPP | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		6 months	6 months
2015 ESPP | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		2 years	2 years

EQUITY INCENTIVE PLANS - Summar

EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock compensation expense	$ 2,249	$ 2,231	$ 3,061	$ 3,705
Continuing Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock compensation expense	2,018	1,667	2,308	2,754
Discontinued Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock compensation expense	231	564	753	951
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock compensation expense	868	629	839	809
Selling, general and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock compensation expense	$ 1,150	$ 1,038	$ 1,469	$ 1,945

DEBT (Details)

DEBT (Details) - Term Loan - Term A Loan	Oct. 03, 2016 USD ($)
Debt Instrument [Line Items]
Borrowed from the lender	$ 10,000,000
Variable annual rate (as a percent)	4.50%
Prime interest rate (as a percent)	0.75%

SIGNIFICANT AGREEMENTS AND CO_3

SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended			3 Months Ended							6 Months Ended		9 Months Ended			12 Months Ended		37 Months Ended
	Apr. 24, 2024	Mar. 31, 2021	Sep. 30, 2023	Mar. 31, 2022	May 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Apr. 23, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement							$ 9,217	$ 5,090	$ 6,220	$ 6,512	$ 4,293	$ 4,743	$ 11,310	$ 9,036	$ 1,275	$ 20,527	$ 15,548	$ 23,283	$ 23,496
Accounts receivable			$ 2,670	$ 8,649		$ 1,699	2,670	$ 5,310	$ 25,998	$ 4,917	$ 4,113	$ 8,649	$ 5,310	$ 4,113	1,699	2,670	$ 4,917	14,075	5,718
Acquired in-process research and development															84,883	0
Contract liability																		430
Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract liability																		430	1,004
Janssen Pharmaceuticals, Inc. | Related Party | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, maximum cost share																		49,800		$ 47,800
Payments related to collaborative agreement																		27,000		27,000
Revenue from collaborative agreement															1,275	20,527		23,283	23,496
Revenue, remaining performance obligation, amount						0									0
Accounts receivable						0									0			1,900	5,600
Contract liability						0									0			430
Janssen Pharmaceuticals, Inc. | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, amount																		$ 3,800
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)																		6 months
Janssen Pharmaceuticals, Inc. | Related Party | Upfront Payment | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement		$ 27,000
Janssen Pharmaceuticals, Inc. | Related Party | R&D Funding | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value		58,200
Janssen Pharmaceuticals, Inc. | Related Party | Development, Regulatory, and Commercial Milestones | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value		$ 695,000
Janssen Pharmaceuticals, Inc. | Related Party | Milestone Achievement | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement			$ 7,000	$ 3,000														$ 10,000		10,000
Janssen Pharmaceuticals, Inc. | Related Party | License Of Intellectual Property | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement					$ 26,800
Janssen Pharmaceuticals, Inc. | Related Party | Royalty Revenue | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement						0	$ 0								0	$ 0		$ 0	$ 0
Janssen Pharmaceuticals, Inc. | Related Party | License Agreement | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development						85,400									85,400
Direct transaction costs						$ 400									$ 400
Janssen Pharmaceuticals, Inc. | Related Party | License Agreement | Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement	$ 85,000
Janssen Pharmaceuticals, Inc. | Related Party | License Agreement | Upfront Payment | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement	85,000
Acquired in-process research and development	84,900
Contract liability																				$ 500
Janssen Pharmaceuticals, Inc. | Related Party | License Agreement | Development, Regulatory, and Commercial Milestones | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value	150,000
Janssen Pharmaceuticals, Inc. | Related Party | License Agreement | Commercialization Milestone | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value	$ 455,000
Janssen Pharmaceuticals, Inc. | Related Party | Licenses of Intellectual Property | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement					$ 26,800

SIGNIFICANT AGREEMENTS AND CO_4

SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Contract Liability Activity (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]
Opening balance	$ 430
Closing balance		$ 430
Current portion of contract liabilities	0	430	$ 750	$ 369	$ 699	$ 1,004	$ 3,254	$ 4,444	$ 4,514
Long-term portion of contract liabilities		0	$ 0	$ 0	$ 83		$ 98	$ 195	$ 337
Related Party
Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]
Opening balance	430	1,004
Payments received in advance		292
Revenue from performance obligations satisfied during reporting period		(866)
Closing balance		430
Related Party | Janssen Pharmaceuticals, Inc. | Collaborative Arrangement
Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]
Opening balance	430
Revenue from performance obligations satisfied during reporting period	(370)
Gain on settlement of unsatisfied performance obligations	(60)
Closing balance	$ 0	$ 430

SIGNIFICANT AGREEMENTS AND CO_5

SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue from Janssen Collaboration Agreement	$ 9,217	$ 5,090	$ 6,220	$ 6,512	$ 4,293	$ 4,743	$ 11,310	$ 9,036	$ 1,275	$ 20,527	$ 15,548	$ 23,283	$ 23,496
Related Party | Janssen Pharmaceuticals, Inc. | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue from Janssen Collaboration Agreement									1,275	20,527		23,283	23,496
Related Party | Janssen Pharmaceuticals, Inc. | License of Intellectual Property - upon milestones achieved | Point in Time: | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue from Janssen Collaboration Agreement									0	2,347		2,347	976
Related Party | Janssen Pharmaceuticals, Inc. | Research and Development Services | Over Time: | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue from Janssen Collaboration Agreement									1,273	16,324		19,011	18,814
Related Party | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Over Time: | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue from Janssen Collaboration Agreement									$ 2	$ 1,856		$ 1,925	$ 3,706

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details)			1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 09, 2024 employee	Apr. 20, 2023 USD ($) option	Nov. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) claim	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of claims and actions pending | claim							0
Finance Lease Obligations
Lessee, finance lease, term of contract (in months)			36 months
Lessee, finance lease, monthly rate			$ 25,009
Lessee, finance lease, option, purchase equipment			$ 1
Lessee, finance lease, discount rate (as a percent)				8%	8%		8%
Finance lease, weighted average remaining lease term (in years)				2 years 3 months 18 days	2 years 3 months 18 days		3 years 1 month 6 days
Finance lease payments					$ 200,000		$ 0
Finance lease costs				$ 100,000	$ 100,000
Operating Lease Obligations
Renewal term (in months)		36 months
Base rent per month		$ 133,371
Percentage increase in base rent annual (as a percent)		4%
Number of options to extend | option		2
Option renewal term (in years)		2 years
Incremental borrowing rate (as a percent)		12%					12%
Weighted average remaining lease term (in years)				2 years 3 months 18 days	2 years 3 months 18 days		3 years
Lease payments					$ 1,200,000	$ 1,000,000	$ 1,300,000	$ 1,200,000
Lease cost					$ 1,300,000	$ 1,200,000	$ 1,600,000	$ 1,300,000
Variable lease and short-term lease term included within operating lease cost (in days)					30 days		30 days
Reduction in Force
Number of employees eliminated | employee	20
Reduction in force (as a percent)	0.30
Severance payments and employee benefits					$ 1,200,000
Equipment
Finance Lease Obligations
Useful life (in years)				10 years	10 years

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
2024	$ 75
2024/2025	300	$ 275
2025/2026	300	300
2026/2027	25	300
2027		25
Total undiscounted finance lease payments	700	900
Less: Imputed interest	(63)	(107)
Present value of finance lease payments	$ 637	$ 793

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information For Finance Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Finance lease right-of-use asset	$ 788	$ 788
Accumulated amortization	(66)	(6)
Net finance lease right-of-use asset	722	782	$ 0
Current portion of finance lease liability	259	218	0
Long-term finance lease liability	378	575	$ 0
Total finance lease liabilities	$ 637	$ 793

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
2024	$ 400
2024/2025	1,664	$ 1,600
2025/2026	1,731	1,665
2026		1,731
Total undiscounted operating lease payments	3,795	4,996
Less: Imputed interest	(489)	(912)
Present value of operating lease payments	$ 3,306	$ 4,084

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 3,035	$ 3,788	$ 4,050	$ 4,307	$ 836	$ 1,099	$ 1,354	$ 1,603	$ 1,846
Current portion of operating lease liability	1,322	1,082	970	861	920	1,211	1,169	1,129	1,090
Long-term operating lease liability	1,984	3,002	$ 3,306	$ 3,601	$ 0	$ 0	$ 315	$ 621	$ 920
Total operating lease liabilities	$ 3,306	$ 4,084

INCOME TAXES - Summary of Compo

INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Current tax provision:
Federal			$ (1,000)	$ 0
State			16,000	14,000
Total current tax provision			15,000	14,000
Deferred tax provision:
Federal			0	0
State			0	0
Total deferred tax provision			0	0
Income tax expense	$ 0	$ 8,000	$ 15,000	$ 14,000

INCOME TAXES - Summary of Recon

INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal income taxes at 21% for 2023 and 2022			$ (5,264,000)	$ (4,559,000)
Federal statutory income tax rate (as a percent)			21%	21%	21%
State income tax, net of federal benefit			$ (241,000)	$ (158,000)
Nondeductible expenses			234,000	365,000
Tax credits			(1,096,000)	(1,092,000)
Rate change			(54,000)	491,000
Change in valuation allowance			5,861,000	(22,218,000)
Reserve for uncertain tax positions			273,000	(10,346,000)
162m deferred tax asset limitation			128,000	82,000
382 NOL and tax credit limitation			0	37,513,000
Expired stock awards			174,000	1,052,000
Other			0	(1,116,000)
Income tax expense	$ 0	$ 8,000	$ 15,000	$ 14,000

INCOME TAXES - Summary of Signi

INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating losses	$ 35,506	$ 42,043
Tax credits	9,747	9,327
Intangibles	136	160
Capitalized R&D	25,871	14,706
Stock compensation	1,424	1,385
Lease liabilities	1,112	275
Deferred revenue	5,951	5,620
Accrued indirect tax liabilities	4,114	2,617
Other	725	1,018
Total deferred tax assets	84,586	77,151
Less valuation allowance	(83,086)	(76,713)
Deferred tax assets, net of valuation allowance	1,500	438
Deferred tax liabilities:
Prepaid expenses	(214)	(189)
Capitalized inventory costs	(244)	0
Right-of-use assets	(1,042)	(249)
Total deferred tax liabilities	(1,500)	(438)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Income tax expense from discontinued operations			$ 400,000	$ 300,000
Research and development credit carryforwards, no subject to expiration			5,300,000
Increase (decrease) in deferred tax assets, valuation allowance			6,400,000	19,700,000
Unrecognized tax benefits			11,520,000	11,015,000	$ 23,990,000
Unrecognized tax benefits that would impact on effective tax rate			9,700,000
Income tax benefit (expense)	$ 0	$ (8,000)	(15,000)	$ (14,000)
Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards			153,800,000
Tax credit carryforwards, research and development			9,500,000
State
Income Tax Contingency [Line Items]
Net operating loss carryforwards			131,200,000
Tax credit carryforwards, research and development			$ 5,300,000

INCOME TAXES - Summary of Rec_2

INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Unrecognized tax benefits
Balance as of the beginning of the year	$ 11,015	$ 23,990
Increases related to current year tax positions	552	497
Decreases related to prior year tax positions	(47)	(13,472)
Balance as of the end of the year	$ 11,520	$ 11,015

DISCONTINUED OPERATIONS - Addit

DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($)				1 Months Ended						3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended		21 Months Ended	62 Months Ended
	Apr. 24, 2024	Jul. 26, 2022	Sep. 03, 2019	Jan. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Aug. 31, 2022	Dec. 31, 2021	Sep. 30, 2019	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Apr. 23, 2024	Apr. 23, 2024	Jul. 31, 2024	Nov. 30, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposal of discontinued operations																		$ (1,799,000)	$ 0
Revenue from collaborative agreement										$ 9,217,000	$ 5,090,000	$ 6,220,000	$ 6,512,000	$ 4,293,000	$ 4,743,000	$ 11,310,000	$ 9,036,000	1,275,000	20,527,000	$ 15,548,000	$ 23,283,000	$ 23,496,000
Contract liability					$ 430,000																430,000
Capitalized contract cost, amortization												475,000			0	40,000	0	184,000	53,000	1,772,000	77,000	0
Accounts receivable					14,075,000	$ 25,998,000				$ 2,670,000	$ 5,310,000	$ 25,998,000	$ 4,917,000	$ 4,113,000	$ 8,649,000	$ 5,310,000	$ 4,113,000	1,699,000	2,670,000	$ 4,917,000	14,075,000	5,718,000
Related Party
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contract liability					430,000																430,000	1,004,000
Discontinued Operations, Disposed of by Sale | Rezafungin
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory write-down																		0			0
Cash provided by (used in) operating activities, discontinued operations																		18,100,000	9,300,000		10,500,000	3,900,000
Cash provided by (used in) investing activities, discontinued operations																		0	0		0	0
Cash provided by (used in) financing activities, discontinued operations																		0	0		0	0
Revenue																		29,263,000	25,795,000		40,622,000	40,952,000
Loss on disposal of discontinued operations																		(1,799,000)	0
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Remaining performance obligation, amount																		0
Contract liability					28,910,000													0			28,910,000	34,135,000
Accounts receivable																		0
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Napp Pharmaceutical Group Limited
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Collaborative agreement, maximum cost share, forgiveness amount	$ 11,100,000
Collaborative arrangement, carry over services agreement term (in days)	45 days
Collaborative arrangement, other services agreement term (in days)	75 days
Collaborative agreement, maximum cost share, forgiveness, not satisfied, refund period (in days)	10 days
Collaborative arrangement, transaction, value	$ 21,200,000
Contract liabilities, forgiveness amount	25,300,000
Transition services	600,000
Payments related to collaborative agreement	2,100,000
Accounts receivable, forgiveness amount	2,600,000
Revenue																		100,000
Loss on disposal of discontinued operations	$ 300,000
Collaborative arrangement, transitions services term (in days)	76 days
Remaining performance obligation, amount																		0
Accounts receivable																		1,700,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Napp Pharmaceutical Group Limited | Rezafungin Assets, including Sale of IP and Inventory
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 20,800,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Mundipharma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contract liabilities, forgiveness amount																									$ 11,100,000
Payments related to collaborative agreement																								$ 30,000,000
Remaining performance obligation, amount					11,500,000																11,500,000
Cost sharing percentage (as a percent)			50%
Collaborative agreement, maximum cost share			$ 31,200,000																					31,200,000
Collaborative agreement, potential transaction value			$ 568,400,000
Revenue from collaborative agreement				$ 2,800,000	11,100,000		$ 11,100,000	$ 2,800,000	$ 17,900,000									28,681,000	5,141,000		19,288,000	14,256,000		$ 27,900,000
Contract liability																										$ 11,100,000
Accounts receivable					13,900,000																13,900,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Mundipharma | Licenses of Intellectual Property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable					1,700,000																1,700,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Mundipharma | Royalty Revenue
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from collaborative agreement																		0	0		0	0
Accounts receivable					200,000																200,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Melinta
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payments related to collaborative agreement																							$ 30,000,000
Remaining performance obligation, amount					3,700,000																3,700,000
Collaborative agreement, potential transaction value		$ 460,000,000
Revenue from collaborative agreement						$ 20,000,000	$ 25,900,000											582,000	20,654,000		21,334,000	26,696,000	$ 20,000,000
Accounts receivable					400,000																400,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Melinta | Upfront Payment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payments related to collaborative agreement		30,000,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Melinta | Development, Regulatory, and Commercial Milestones
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Collaborative agreement, potential transaction value		$ 430,000,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Melinta | Milestone Achievement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capitalized contract cost, gross					500,000													500,000			500,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Melinta | Licenses of Intellectual Property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capitalized contract cost, gross					2,000,000													2,000,000			2,000,000
Capitalized contract cost, amortization																		200,000	500,000		500,000	1,800,000
Capitalized contract cost, net					200,000													0			200,000
Accounts receivable					400,000																400,000
Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement | Related Party | Melinta | Royalty Revenue
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from collaborative agreement																		$ 100,000	$ 0		200,000	$ 0
Accounts receivable					$ 100,000																$ 100,000

DISCONTINUED OPERATIONS - Sched

DISCONTINUED OPERATIONS - Schedule of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Current assets from discontinued operations	$ 0	$ 9,290	$ 1,068
Noncurrent assets:
Noncurrent assets from discontinued operations	0	934	958
Current liabilities:
Current liabilities from discontinued operations	0	24,665	13,610
Noncurrent liabilities:
Noncurrent liabilities from discontinued operations	0	4,245	20,525
Discontinued Operations, Disposed of by Sale | Rezafungin
Current assets:
Accounts receivable	0	2,171	116
Inventory	0	6,097	0
Prepaid expenses and other current assets	0	1,022	952
Current assets from discontinued operations	0	9,290	1,068
Noncurrent assets:
Other assets	0	934	958
Noncurrent assets from discontinued operations	0	934	958
Total assets from discontinued operations	0	10,224	2,026
Current liabilities:
Current contract liabilities	0	24,665	13,610
Current liabilities from discontinued operations	0	24,665	13,610
Noncurrent liabilities:
Long-term contract liabilities	0	4,245	20,525
Noncurrent liabilities from discontinued operations	0	4,245	20,525
Total liabilities from discontinued operations	$ 0	$ 28,910	$ 34,135

DISCONTINUED OPERATIONS - Sch_2

DISCONTINUED OPERATIONS - Schedule of Inventory (Details) - Discontinued Operations, Disposed of by Sale - Rezafungin - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Raw materials	$ 0	$ 2,691	$ 0
Work-in-process	0	3,406	0
Total inventory	$ 0	$ 6,097	$ 0

DISCONTINUED OPERATIONS - Sch_3

DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Other expense, net:
Loss on disposal of discontinued operations	$ (1,799)	$ 0
Discontinued Operations, Disposed of by Sale | Rezafungin
Revenues:
Total revenues	29,263	25,795	$ 40,622	$ 40,952
Operating expenses:
Cost of product revenue	9,030	387	1,523	0
Research and development	10,572	25,061	31,769	47,237
Selling, general and administrative	7,460	2,795	4,753	5,319
Total operating expenses	27,062	28,243	38,045	52,556
Income (loss) from operations	2,201	(2,448)
Other expense, net:
Loss on disposal of discontinued operations	(1,799)	0
Total other expense, net	(1,799)	0
Income (loss) from discontinued operations before income tax expense	402	(2,448)	2,577	(11,604)
Income tax expense	0	371	(428)	(258)
Income (loss) from discontinued operations, net of income taxes	$ 402	$ (2,819)	$ 2,149	$ (11,862)

DISCONTINUED OPERATIONS - Sch_4

DISCONTINUED OPERATIONS - Schedule of Contract Liability Activity (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]
Opening balance	$ 430
Closing balance		$ 430
Current portion of contract liabilities	0	430	$ 750	$ 369	$ 699	$ 1,004	$ 3,254	$ 4,444	$ 4,514
Long-term portion of contract liabilities		0	$ 0	$ 0	$ 83		$ 98	$ 195	$ 337
Related Party
Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]
Opening balance	430	1,004
Revenue from performance obligations satisfied during reporting period		(866)
Payments received in advance		292
Closing balance		430
Related Party | Discontinued Operations, Disposed of by Sale | Rezafungin | Collaborative Arrangement
Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]
Opening balance	28,910	34,135
Revenue from performance obligations satisfied during reporting period	(28,910)	(8,176)
Payments received in advance		1,463
Payments receivable		1,488
Closing balance	0	28,910
Current portion of contract liabilities	0	24,665
Long-term portion of contract liabilities	$ 0	$ 4,245

DISCONTINUED OPERATIONS - Sch_5

DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)	1 Months Ended						3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended		21 Months Ended	62 Months Ended
	Jan. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Aug. 31, 2022	Dec. 31, 2021	Sep. 30, 2019	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Apr. 23, 2024	Apr. 23, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue							$ 9,217,000	$ 5,090,000	$ 6,220,000	$ 6,512,000	$ 4,293,000	$ 4,743,000	$ 11,310,000	$ 9,036,000	$ 1,275,000	$ 20,527,000	$ 15,548,000	$ 23,283,000	$ 23,496,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue	$ 2,800,000	$ 11,100,000		$ 11,100,000	$ 2,800,000	$ 17,900,000									28,681,000	5,141,000		19,288,000	14,256,000		$ 27,900,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue			$ 20,000,000	$ 25,900,000											582,000	20,654,000		21,334,000	26,696,000	$ 20,000,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Royalty Revenue | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															0	0		0	0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Royalty Revenue | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															100,000	0		200,000	0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Rezafungin Assets, including Sale of IP and Inventory | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															20,833,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Rezafungin Assets, including Sale of IP and Inventory | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | License of Intellectual Property - upon transfer of license | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																			0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | License of Intellectual Property - upon transfer of license | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																			25,885,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | License of Intellectual Property - upon milestone achieved | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															813,000	0		3,252,000	3,252,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | License of Intellectual Property - upon milestone achieved | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															0	17,257,000		17,257,000	0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Clinical Drug Supply | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																26,000		26,000	484,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Clinical Drug Supply | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																0		0	0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Product Revenue | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															2,826,000	0		2,867,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Product Revenue | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															0	1,468,000		1,468,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Royalty Revenue | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															37,000	0		0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Point in Time: | Royalty Revenue | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															125,000	70,000		168,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Over Time: | Research and Development Services | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															3,895,000	4,870,000		12,303,000	9,595,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Over Time: | Research and Development Services | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															457,000	1,859,000		2,441,000	811,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Over Time: | Clinical Supply Services | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															175,000	245,000		840,000	925,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Over Time: | Clinical Supply Services | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															0	$ 0		$ 0	$ 0
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Over Time: | Transition Services | Mundipharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															102,000
Rezafungin | Discontinued Operations, Disposed of by Sale | Related Party | Collaborative Arrangement | Over Time: | Transition Services | Melinta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue															$ 0

SELECTED QUARTERLY FINANCIAL _3

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 127,386	$ 35,778	$ 48,670	$ 50,430	$ 47,976	$ 32,731	$ 53,078	$ 24,637	$ 36,488
Restricted Cash				0	0			370	1,482
Accounts receivable	1,699	14,075	2,670	5,310	25,998	5,718	4,917	4,113	8,649
Prepaid expenses and other current assets	27,686	1,712	2,794	3,230	5,102	5,577	3,932	5,909	4,038
Current assets from discontinued operations			4,327	3,704	732		1,972	1,517	1,350
Total current assets	156,771	60,855	58,461	62,674	79,808	45,094	63,899	36,546	52,007
Property and equipment, net	561	557	580	297	270	222	173	201	239
Operating lease right-of-use asset	3,035	3,788	4,050	4,307	836	1,099	1,354	1,603	1,846
Other assets	1,242	114	103	101	102	114	132	150	155
Noncurrent assets from discontinued operations			950	960	959		1,163	862	864
Total assets	162,331	67,030	64,144	68,339	81,975	47,487	66,721	39,362	55,111
Current liabilities:
Accounts payable	2,967	3,772	3,661	1,899	4,026	1,447	4,244	3,091	2,861
Accrued liabilities	8,569	14,177	11,772	10,022	9,108	7,672	8,162	8,567	9,954
Accrued indirect tax liabilities	26,289	18,040	14,689	13,431	11,795	11,534	11,314	10,582	7,942
Accrued compensation and benefits	4,933	5,034	4,457	3,582	5,843	4,922	4,117	3,464	3,079
Current contract liabilities	0	430	750	369	699	1,004	3,254	4,444	4,514
Current portion of operating lease liability	1,322	1,082	970	861	920	1,211	1,169	1,129	1,090
Current portion of term loan				0	0			370	1,481
Current liabilities from discontinued operations			13,929	14,606	15,091		11,995	10,286	9,746
Total current liabilities	44,339	67,418	50,228	44,770	47,482	41,400	44,255	41,933	40,667
Long-term contract liabilities		0	0	0	83		98	195	337
Long-term operating lease liability	1,984	3,002	3,306	3,601	0	0	315	621	920
Noncurrent liabilities from discontinued operations			16,504	17,551	19,303		24,300	15,156	16,892
Total liabilities	46,701	75,240	70,038	65,922	66,868	61,925	68,968	57,905	58,816
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock
Common stock	1	1	1	1	1	1	1	1	1
Additional paid-in capital	674,580	433,220	432,323	431,527	430,593	404,061	402,655	400,605	399,684
Accumulated deficit	(558,951)	(441,431)	(438,218)	(429,111)	(415,487)	(418,500)	(404,903)	(419,149)	(403,390)
Total stockholders' deficit	115,630	(8,210)	(5,894)	2,417	15,107	(14,438)	(2,247)	(18,543)	(3,705)	$ 13,104
Total liabilities and stockholders' deficit	162,331	67,030	64,144	68,339	81,975	47,487	66,721	39,362	55,111
Series X Convertible Preferred Stock
Stockholders' equity (deficit):
Preferred stock	$ 0	$ 0	0	0	0	0	0	0	0
As Previously Reported
Current assets:
Cash and cash equivalents			48,670	50,430	47,976		53,078	24,637	36,488
Restricted Cash				0	0			370	1,482
Accounts receivable			2,670	5,310	25,703		4,917	4,113	8,649
Prepaid expenses and other current assets			2,794	3,230	5,245		3,932	5,909	4,038
Current assets from discontinued operations			3,570	3,270	564		1,972	1,517	1,350
Total current assets			57,704	62,240	79,488		63,899	36,546	52,007
Property and equipment, net			580	297	270		173	201	239
Operating lease right-of-use asset			4,131	4,388	917	1,205	1,491	1,765	2,030
Other assets			103	101	102		132	150	155
Noncurrent assets from discontinued operations			950	960	959		1,163	862	864
Total assets			63,468	67,986	81,736	47,593	66,858	39,524	55,295
Current liabilities:
Accounts payable			3,661	1,899	3,980		4,244	3,091	2,861
Accrued liabilities			11,772	10,022	9,078		8,162	8,567	9,234
Accrued indirect tax liabilities			0	0	0	0	0	0	0
Accrued compensation and benefits			4,457	3,582	5,843		4,117	3,464	3,079
Current contract liabilities			750	369	699		3,254	4,444	4,514
Current portion of operating lease liability			1,051	942	1,001	1,317	1,277	1,233	1,190
Current portion of term loan				0	0			370	1,481
Current liabilities from discontinued operations			13,929	14,606	15,062		11,995	10,286	9,746
Total current liabilities			35,620	31,420	35,663	29,972	33,049	31,455	32,105
Long-term contract liabilities			0	0	92		98	195	337
Long-term operating lease liability			3,306	3,601	0		344	679	1,004
Noncurrent liabilities from discontinued operations			16,504	17,551	19,144		24,300	15,156	16,892
Total liabilities			55,430	52,572	54,899	50,497	57,791	47,485	50,338
Commitments and contingencies
Stockholders' equity (deficit):
Common stock			1	1	1		1	1	1
Additional paid-in capital			432,323	431,527	430,593		402,655	400,605	400,404
Accumulated deficit			(424,286)	(416,114)	(403,757)	(406,966)	(393,589)	(408,567)	(395,448)
Total stockholders' deficit			8,038	15,414	26,837	(2,904)	9,067	(7,961)	4,957	21,573
Total liabilities and stockholders' deficit			63,468	67,986	81,736	47,593	66,858	39,524	55,295
As Previously Reported | Series X Convertible Preferred Stock
Stockholders' equity (deficit):
Preferred stock			0	0	0		0	0	0
Restatement Adjustment
Current assets:
Cash and cash equivalents			0	0	0		0	0	0
Restricted Cash				0	0			0	0
Accounts receivable			0	0	295		0	0	0
Prepaid expenses and other current assets			0	0	(143)		0	0	0
Current assets from discontinued operations			757	434	168		0	0	0
Total current assets			757	434	320		0	0	0
Property and equipment, net			0	0	0		0	0	0
Operating lease right-of-use asset			(81)	(81)	(81)	(106)	(137)	(162)	(184)
Other assets			0	0	0		0	0	0
Noncurrent assets from discontinued operations			0	0	0		0	0	0
Total assets			676	353	239	(106)	(137)	(162)	(184)
Current liabilities:
Accounts payable			0	0	46		0	0	0
Accrued liabilities			0	0	30		0	0	720
Accrued indirect tax liabilities			14,689	13,431	11,795	11,534	11,314	10,582	7,942
Accrued compensation and benefits			0	0	0		0	0	0
Current contract liabilities			0	0	0		0	0	0
Current portion of operating lease liability			(81)	(81)	(81)	(106)	(108)	(104)	(100)
Current portion of term loan				0	0			0	0
Current liabilities from discontinued operations			0	0	29		0	0	0
Total current liabilities			14,608	13,350	11,819	11,428	11,206	10,478	8,562
Long-term contract liabilities			0	0	(9)		0	0	0
Long-term operating lease liability			0	0	0		(29)	(58)	(84)
Noncurrent liabilities from discontinued operations			0	0	159		0	0	0
Total liabilities			14,608	13,350	11,969	11,428	11,177	10,420	8,478
Commitments and contingencies
Stockholders' equity (deficit):
Common stock			0	0	0		0	0	0
Additional paid-in capital			0	0	0		0	0	(720)
Accumulated deficit			(13,932)	(12,997)	(11,730)	(11,534)	(11,314)	(10,582)	(7,942)
Total stockholders' deficit			(13,932)	(12,997)	(11,730)	(11,534)	(11,314)	(10,582)	(8,662)	$ (8,469)
Total liabilities and stockholders' deficit			676	353	239	$ (106)	(137)	(162)	(184)
Restatement Adjustment | Series X Convertible Preferred Stock
Stockholders' equity (deficit):
Preferred stock			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0

SELECTED QUARTERLY FINANCIAL _4

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details) - $ / shares	Sep. 30, 2024	Jul. 18, 2024	Jul. 17, 2024	Apr. 23, 2024	Apr. 22, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	May 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock, par value (USD per share)	$ 0.0001					$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000					10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Common stock, par value (USD per share)	$ 0.0001					$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000	20,000,000	20,000,000	200,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000
Common stock, shares issued (in shares)	7,046,633					4,530,113	4,520,814	4,512,595	4,501,256	3,623,591	3,559,141	3,462,024	3,452,567
Common stock, shares outstanding (in shares)	7,046,633					4,530,113	4,520,814	4,512,595	4,501,256	3,623,591	3,559,141	3,462,024	3,452,567
Series X Convertible Preferred Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock, par value (USD per share)	$ 0.0001					$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	4,947,759					4,947,759	4,947,759	4,947,759	4,947,759	4,947,759	4,947,759	4,947,759	4,947,759	5,000,000
Preferred stock, shares issued (in shares)	2,156,713					2,156,713	2,156,713	2,156,713	2,156,713	1,870,713	1,870,713	1,870,713	1,870,713
Preferred stock, shares outstanding (in shares)	2,104,472					2,104,472	2,104,472	2,104,472	2,104,472	1,818,472	1,818,472	1,818,472	1,818,472

SELECTED QUARTERLY FINANCIAL _5

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Collaboration revenue	$ 9,217	$ 5,090	$ 6,220	$ 6,512	$ 4,293	$ 4,743	$ 11,310	$ 9,036	$ 1,275	$ 20,527	$ 15,548	$ 23,283	$ 23,496
Product revenue										0	0
Total revenues	9,217	5,090	6,220	6,512	4,293	4,743	11,310	9,036	1,275	20,527	15,548	23,283	23,496
Operating expenses:
Cost of product revenue										0	0
Research and development	10,386	8,657	9,710	8,581	6,276	5,545	18,367	11,821	25,005	28,753	20,402	36,763	30,168
Selling, general and administrative	3,299	3,181	3,653	3,783	3,645	4,675	6,834	8,320	13,307	10,133	12,103	13,580	15,227
Total operating expenses	13,685	11,838	13,363	12,364	9,921	10,220	25,201	20,141	123,195	38,886	32,505	50,343	45,395
Loss from operations	(4,468)	(6,748)	(7,143)	(5,852)	(5,628)	(5,477)	(13,891)	(11,105)	(121,920)	(18,359)	(16,957)	(27,060)	(21,899)
Other income, net:
Interest income (expense), net	613	623	232	55	(6)	(20)	855	(26)	3,998	1,468	29	1,995	191
Total other income, net	613	623	232	55	(6)	(20)	855	(26)	3,998	1,468	29	1,995	191
Loss before income tax expense	(3,855)	(6,125)	(6,911)	(5,797)	(5,634)	(5,497)	(13,036)	(11,131)	(117,922)	(16,891)	(16,928)	(25,065)	(21,708)
Income tax expense	32	(40)	9,924	0	0	(12,977)	(40)	0		(8)	0
Net income (loss)	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)	(10,611)	(34,233)	(117,520)	(19,718)	(19,987)	(22,931)	(33,584)
Comprehensive Income (Loss)	(9,107)	$ (13,624)	3,013	14,246	$ (15,759)	(18,474)	$ (10,611)	$ (34,233)	$ (117,520)	$ (19,718)	$ (19,987)	$ (22,931)	$ (33,584)
Allocation of earnings to participating securities, Basic	0		(636)	(2,931)		0
Allocation of earnings to participating securities, Diluted	0		(636)	(2,931)		0
Net income (loss) attributable to common stockholders	$ (9,107)		$ 2,377	$ 11,315		$ (18,474)
Basic	$ (2.02)	$ (1.65)	$ 0.6	$ 3.22	$ (2.93)	$ (5.42)	$ (2.51)	$ (9.97)	$ (22.53)	$ (4.56)	$ (5.78)	$ (5.25)	$ (9.61)
Diluted	$ (2.02)	$ (1.65)	$ 0.6	$ 3.22	$ (2.93)	$ (5.42)	$ (2.51)	$ (9.97)	$ (22.53)	$ (4.56)	$ (5.78)	$ (5.25)	$ (9.61)
Shares, Basic	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017	5,215,365	4,319,536	3,458,608	4,371,375	3,492,925
Shares, Diluted	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017	5,215,365	4,319,536	3,458,608	4,371,375	3,492,925
Continuing Operations [Member]
Other income, net:
Loss before income tax expense	$ (3,823)	$ (6,165)		$ (5,797)	$ (5,634)		$ (13,076)	$ (11,131)		$ (16,899)	$ (16,928)
Basic	$ (0.85)	$ (1.37)	$ (1.39)	$ (1.31)	$ (1.63)	$ (1.61)	$ (3.1)	$ (3.24)		$ (3.91)	$ (4.89)
Diluted	$ (0.85)	$ (1.37)	(1.39)	$ (1.31)	$ (1.63)	(1.61)	$ (3.1)	$ (3.24)		$ (3.91)	$ (4.89)
Discontinued Operations [Member]
Other income, net:
Loss before income tax expense	$ (5,284)	$ (7,459)		$ 20,043	$ (10,125)		$ 2,465	$ (23,102)		$ (2,819)	$ (3,059)
Basic	$ (1.17)	$ (3.02)	1.99	$ 4.53	$ (4.56)	(3.81)	$ 0.59	$ (6.73)		$ (0.65)	$ (0.89)
Diluted	$ (1.17)	$ (3.02)	$ 1.99	$ 4.53	$ (4.56)	$ (3.81)	$ 0.59	$ (6.73)		$ (0.65)	$ (0.89)
As Previously Reported
Revenues:
Collaboration revenue	$ 9,217	$ 5,395	$ 5,915	$ 6,512	$ 4,293	$ 4,583	$ 11,310	$ 8,876		$ 20,527	$ 15,388		$ 23,336
Product revenue										0	0
Total revenues	9,217	5,395	5,915	6,512	4,293	4,583	11,310	8,876		20,527	15,388		23,336
Operating expenses:
Cost of product revenue										0	0
Research and development	10,386	8,952	9,415	8,581	6,276	5,545	18,367	11,821		28,753	20,402
Selling, general and administrative	3,299	3,181	3,653	3,783	3,645	4,675	6,834	8,320		10,133	12,103
Total operating expenses	13,685	12,133	13,068	12,364	9,921	10,220	25,201	20,141		38,886	32,505
Loss from operations	(4,468)	(6,738)	(7,153)	(5,852)	(5,628)	(5,637)	(13,891)	(11,265)		(18,359)	(17,117)		(22,059)
Other income, net:
Interest income (expense), net	613	623	232	55	(6)	(20)	855	(26)		1,468	29
Total other income, net	613	623	232	55	(6)	(20)	855	(26)		1,468	29
Loss before income tax expense	(3,855)	(6,115)	(6,921)	(5,797)	(5,634)	(5,657)	(13,036)	(11,291)		(16,891)	(17,088)		(21,868)
Income tax expense	32	(40)	10,130	0	0	(12,624)	(40)	0		(8)	0
Net income (loss)	(8,172)	(12,357)	3,209	14,978	(13,119)	(18,281)	(9,148)	(31,400)		(17,320)	(16,422)		(29,799)
Comprehensive Income (Loss)	(8,172)	$ (12,357)	3,209	14,978	$ (13,119)	(18,281)	$ (9,148)	$ (31,400)		$ (17,320)	$ (16,422)		$ (29,799)
Allocation of earnings to participating securities, Basic	0		(677)	(3,081)		0
Allocation of earnings to participating securities, Diluted	0		(677)	(3,081)		0
Net income (loss) attributable to common stockholders	$ (8,172)		$ 2,532	$ 11,897		$ (18,281)
Basic	$ (1.81)	$ (1.38)	$ 0.64	$ 3.39	$ (2.17)	$ (5.37)	$ (2.17)	$ (9.15)		$ (4.01)	$ (4.75)		$ (8.53)
Diluted	$ (1.81)	$ (1.38)	$ 0.64	$ 3.39	$ (2.17)	$ (5.37)	$ (2.17)	$ (9.15)		$ (4.01)	$ (4.75)		$ (8.53)
Shares, Basic	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017		4,319,536	3,458,608		3,492,925
Shares, Diluted	4,514,381	4,505,813	3,932,050	3,510,974	3,456,786	3,406,994	4,220,511	3,432,017		4,319,536	3,458,608		3,492,925
As Previously Reported | Continuing Operations [Member]
Other income, net:
Loss before income tax expense	$ (3,823)	$ (6,155)		$ (5,797)	$ (5,634)		$ (13,076)	$ (11,291)		$ (16,899)	$ (17,088)
Basic	$ (0.85)	$ (1.37)	$ (1.39)	$ (1.31)	$ (1.63)	$ (1.66)	$ (3.1)	$ (3.29)		$ (3.91)	$ (4.94)
Diluted	$ (0.85)	$ (1.37)	(1.39)	$ (1.31)	$ (1.63)	(1.66)	$ (3.1)	$ (3.29)		$ (3.91)	$ (4.94)
As Previously Reported | Discontinued Operations [Member]
Other income, net:
Loss before income tax expense	$ (4,349)	$ (6,202)		$ 20,775	$ (7,485)		$ 3,928	$ (20,109)		$ (421)	$ 666
Basic	$ (0.96)	$ (2.75)	2.03	$ 4.7	$ (3.8)	(3.71)	$ 0.93	$ (5.86)		$ (0.1)	$ 0.19
Diluted	$ (0.96)	$ (2.75)	$ 2.03	$ 4.7	$ (3.8)	$ (3.71)	$ 0.93	$ (5.86)		$ (0.1)	$ 0.19
Restatement Adjustment
Revenues:
Collaboration revenue	$ 0	$ (305)	$ 305	$ 0	$ 0	$ 160	$ 0	$ 160		$ 0	$ 160		$ 160
Product revenue										0	0
Total revenues	0	(305)	305	0	0	160	0	160		0	160		160
Operating expenses:
Cost of product revenue										0	0
Research and development	0	(295)	295	0	0	0	0	0		0	0
Selling, general and administrative	0	0	0	0	0	0	0	0		0	0
Total operating expenses	0	(295)	295	0	0	0	0	0		0	0
Loss from operations	0	(10)	10	0	0	160	0	160		0	160		160
Other income, net:
Interest income (expense), net	0	0	0	0	0	0	0	0		0	0
Total other income, net	0	0	0	0	0	0	0	0		0	0
Loss before income tax expense	0	(10)	10	0	0	160	0	160		0	160		160
Income tax expense	0	0	(206)	0	0	(353)	0	0		0	0
Net income (loss)	(935)	(1,267)	(196)	(732)	(2,640)	(193)	(1,463)	(2,833)		(2,398)	(3,565)		(3,785)
Comprehensive Income (Loss)	(935)	(1,267)	(196)	(732)	(2,640)	(193)	(1,463)	(2,833)		(2,398)	(3,565)		$ (3,785)
Allocation of earnings to participating securities, Basic	0		41	150		0
Allocation of earnings to participating securities, Diluted	0		41	150		0
Net income (loss) attributable to common stockholders	(935)		$ (155)	(582)		$ (193)
Restatement Adjustment | Continuing Operations [Member]
Other income, net:
Loss before income tax expense		(10)			0		0	160			160
Restatement Adjustment | Discontinued Operations [Member]
Other income, net:
Loss before income tax expense	$ (935)	$ (1,257)		$ (732)	$ (2,640)		$ (1,463)	$ (2,993)		$ (2,398)	$ (3,725)

SELECTED QUARTERLY FINANCIAL _6

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (9,107)	$ (13,624)	$ 3,013	$ 14,246	$ (15,759)	$ (18,474)	$ (10,611)	$ (34,233)	$ (117,520)	$ (19,718)	$ (19,987)	$ (22,931)	$ (33,584)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			640			1,338	1,435	2,016	2,249	2,231	2,859	3,061	3,532
Non-cash operating lease expense			262			234	639	476	753	895	724	1,158	981
Depreciation and amortization			32			39	57	77	114	79	114	112	143
Amortization of costs to obtain a contract with a customer			475			0	40	0	184	53	1,772	77	0
Non-cash interest expense			0			1	0	1	44	0	1	5	1
Changes in assets and liabilities:
Accounts receivable			(20,288)			(3,427)	350	524	14,270	2,655	314	(10,413)	(477)
Inventory							(2,388)	0	6,097	(2,901)	0	(6,097)	0
Prepaid expenses, other current assets, and other assets			848			(1,120)	2,120	(2,567)	(26,832)	2,776	(1,662)	3,735	(2,440)
Accounts payable and accrued liabilities			3,192			657	2,870	(483)	(6,422)	6,204	(1,037)	8,886	(2,371)
Accrued indirect tax liabilities			261			353	1,897	2,993		3,155	3,725		3,945
Accrued compensation and benefits			921			(1,953)	(1,277)	(1,324)	(46)	(402)	(670)	235	203
Contract liabilities			36			(1,004)	(2,613)	(2,412)	(29,340)	(3,956)	7,154	(5,799)	2,646
Operating lease liabilities			(290)			(252)	(595)	(512)	(778)	(781)	(778)	(973)	(1,052)
Net cash used in operating activities			(10,898)			(23,608)	(8,076)	(35,444)	(147,119)	(9,710)	(7,471)	(22,432)	(28,473)
Investing activities:
Purchases of property and equipment			(94)			(84)	(201)	(100)	(129)	(327)	(109)	(505)	(118)
Net cash used in investing activities			(94)			(84)	(201)	(100)	(129)	(327)	(109)	(505)	(118)
Financing activities:
Proceeds from underwritten public offering, net of issuance costs			17,593			0	17,256	0	0	17,256	0	17,256	0
Proceeds from public offering of common stock, net of issuance costs			8,630			500	8,706	500		8,706	1,698
Proceeds from exercise of stock options			14			0	14	0	0	14	0	21	0
Issuance costs for underwritten public offering										0	(720)	0	(720)
Principal repayments of Term Loan			0			(1,111)	0	(2,222)		0	(2,593)	0	(2,593)
Net cash provided by (used in) financing activities			26,237			(611)	25,976	(1,722)	238,856	25,976	(1,615)	25,984	(951)
Net increase (decrease) in cash and cash equivalents			15,245			(24,303)	17,699	(37,266)	91,608	15,939	(9,195)	3,047	(29,542)
Cash and cash equivalents at beginning of period	50,430	47,976	32,731	25,007	37,970	62,273	32,731	62,273	35,778	32,731	62,273	32,731	62,273
Cash and cash equivalents at end of period	48,670	50,430	47,976	53,078	25,007	37,970	50,430	25,007	127,386	48,670	53,078	35,778	32,731
Supplemental disclosure of cash flows:
Interest paid			0			25	0	38		0	40	0	40
Income taxes paid							588	0	95	651	0	797	0
Non-cash investing activities:
Purchases of property and equipment, included in accounts payable and accrued liabilities			55			16			0	178	0	11	69
Operating lease right-of-use asset obtained in exchange for lease liability							3,847	0	0	3,847	0	3,847	0
Non-cash financing activities:
Purchase of shares pursuant to Employee Stock Purchase Plan		63			69		63	69	$ 55	63	69	122	140
Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities			337			720	0	720
Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets										0	10	0	8
As Previously Reported
Operating activities:
Net loss	(8,172)	(12,357)	3,209	14,978	(13,119)	(18,281)	(9,148)	(31,400)		(17,320)	(16,422)		(29,799)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			640			1,338	1,435	2,016		2,231	2,859
Non-cash operating lease expense			288			258	664	523		921	796		1,082
Depreciation and amortization			32			39	57	77		79	114
Amortization of costs to obtain a contract with a customer			475			0	40	0		53	1,772
Non-cash interest expense			0			1	0	1		0	1
Changes in assets and liabilities:
Accounts receivable			(19,993)			(3,427)	350	524		2,978	314
Inventory							(1,954)	0		(2,467)	0
Prepaid expenses, other current assets, and other assets			872			(1,120)	2,120	(2,567)		2,776	(1,662)
Accounts payable and accrued liabilities			3,116			657	2,870	(483)		6,204	(1,037)
Accrued indirect tax liabilities			0			0	0	0		0	0		0
Accrued compensation and benefits			921			(1,953)	(1,277)	(1,324)		(402)	(670)
Contract liabilities			(142)			(844)	(2,613)	(2,252)		(3,956)	7,314		2,806
Operating lease liabilities			(316)			(276)	(620)	(559)		(807)	(850)		(1,153)
Net cash used in operating activities			(10,898)			(23,608)	(8,076)	(35,444)		(9,710)	(7,471)
Investing activities:
Purchases of property and equipment			(94)			(84)	(201)	(100)		(327)	(109)
Net cash used in investing activities			(94)			(84)	(201)	(100)		(327)	(109)
Financing activities:
Proceeds from underwritten public offering, net of issuance costs			17,593			0	17,256	0		17,256	0
Proceeds from public offering of common stock, net of issuance costs			8,630			500	8,706	500		8,706	1,698
Proceeds from exercise of stock options			14			0	14	0		14	0
Issuance costs for underwritten public offering										0	(720)
Principal repayments of Term Loan			0			(1,111)	0	(2,222)		0	(2,593)
Net cash provided by (used in) financing activities			26,237			(611)	25,976	(1,722)		25,976	(1,615)
Net increase (decrease) in cash and cash equivalents			15,245			(24,303)	17,699	(37,266)		15,939	(9,195)
Cash and cash equivalents at beginning of period	50,430	47,976	32,731	25,007	37,970	62,273	32,731	62,273		32,731	62,273	32,731	62,273
Cash and cash equivalents at end of period	48,670	50,430	47,976	53,078	25,007	37,970	50,430	25,007		48,670	53,078		32,731
Supplemental disclosure of cash flows:
Interest paid			0			25	0	38		0	40
Income taxes paid							588	0		651	0
Non-cash investing activities:
Purchases of property and equipment, included in accounts payable and accrued liabilities			55			16				178	0
Operating lease right-of-use asset obtained in exchange for lease liability							3,847	0		3,847	0
Non-cash financing activities:
Purchase of shares pursuant to Employee Stock Purchase Plan							63	69		63	69
Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities			337			0	0	720
Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets										0	10
Restatement Adjustment
Operating activities:
Net loss	(935)	(1,267)	(196)	(732)	(2,640)	(193)	(1,463)	(2,833)		(2,398)	(3,565)		(3,785)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			0			0	0	0		0	0
Non-cash operating lease expense			(26)			(24)	(25)	(47)		(26)	(72)		(101)
Depreciation and amortization			0			0	0	0		0	0
Amortization of costs to obtain a contract with a customer			0			0	0	0		0	0
Non-cash interest expense			0			0	0	0		0	0
Changes in assets and liabilities:
Accounts receivable			(295)			0	0	0		(323)	0
Inventory							(434)	0		(434)	0
Prepaid expenses, other current assets, and other assets			(24)			0	0	0		0	0
Accounts payable and accrued liabilities			76			0	0	0		0	0
Accrued indirect tax liabilities			261			353	1,897	2,993		3,155	3,725		3,945
Accrued compensation and benefits			0			0	0	0		0	0
Contract liabilities			178			(160)	0	(160)		0	(160)		(160)
Operating lease liabilities			26			24	25	47		26	72		101
Net cash used in operating activities			0			0	0	0		0	0
Investing activities:
Purchases of property and equipment			0			0	0	0		0	0
Net cash used in investing activities			0			0	0	0		0	0
Financing activities:
Proceeds from underwritten public offering, net of issuance costs			0			0	0	0		0	0
Proceeds from public offering of common stock, net of issuance costs			0			0	0	0		0	0
Proceeds from exercise of stock options			0			0	0	0		0	0
Issuance costs for underwritten public offering										0	0
Principal repayments of Term Loan			0			0	0	0		0	0
Net cash provided by (used in) financing activities			0			0	0	0		0	0
Net increase (decrease) in cash and cash equivalents			0			0	0	0		0	0
Cash and cash equivalents at beginning of period	0	0	0	0	0	0	0	0		0	0	$ 0	0
Cash and cash equivalents at end of period	$ 0	$ 0	0	$ 0	$ 0	0	0	0		0	0		$ 0
Supplemental disclosure of cash flows:
Interest paid			0			0	0	0		0	0
Income taxes paid							0	0		0	0
Non-cash investing activities:
Purchases of property and equipment, included in accounts payable and accrued liabilities			0			0				0	0
Operating lease right-of-use asset obtained in exchange for lease liability							0	0		0	0
Non-cash financing activities:
Purchase of shares pursuant to Employee Stock Purchase Plan							0	0		0	0
Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities			$ 0			$ 720	$ 0	$ 0
Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets										$ 0	$ 0

SELECTED QUARTERLY FINANCIAL _7

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	$ 2,417	$ 15,107	$ (14,438)	$ (18,543)	$ (3,705)	$ 13,104	$ (14,438)	$ 13,104	$ (8,210)	$ (14,438)	$ 13,104	$ (14,438)	$ 13,104
Balance, beginning (in shares)	4,512,595	4,501,256	3,623,591	3,462,024	3,452,567		3,623,591		4,530,113	3,623,591		3,623,591
Issuance of common stock for exercise of stock options (in shares)									0			1,287
Issuance of common stock for exercise of stock options			$ 14							$ 14		$ 21
Issuance of common stock under Employee Stock Purchase Plan		$ 63			$ 69		$ 63	69	$ 55	63	69	122	140
Stock-based compensation	$ 796	795	640	$ 842	852	1,165			2,249	2,231		3,061	3,532
Net loss	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)	(10,611)	(34,233)	(117,520)	(19,718)	(19,987)	(22,931)	(33,584)
Balance, ending	$ (5,894)	$ 2,417	$ 15,107	$ (2,247)	$ (18,543)	$ (3,705)	$ 2,417	$ (18,543)	$ 115,630	$ (5,894)	$ (2,247)	$ (8,210)	$ (14,438)
Balance, ending (in shares)	4,520,814	4,512,595	4,501,256	3,559,141	3,462,024	3,452,567	4,512,595	3,462,024	7,046,633	4,520,814	3,559,141	4,530,113	3,623,591
Series X Convertible Preferred Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning (in shares)	2,104,472	2,104,472	1,818,472	1,818,472	1,818,472		1,818,472		2,104,472	1,818,472		1,818,472
Balance, ending (in shares)	2,104,472	2,104,472	2,104,472	1,818,472	1,818,472	1,818,472	2,104,472	1,818,472	2,104,472	2,104,472	1,818,472	2,104,472	1,818,472
Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs			$ 17,256							$ 17,256		$ 17,256
Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs			8,622	$ 1,208		$ 500				8,698		8,699	$ 2,370
Net loss		$ 76
Additional Paid-In Capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	$ 431,527	430,593	404,061	400,605	$ 399,684	398,019	$ 404,061	$ 398,019	$ 433,220	404,061	$ 398,019	404,061	398,019
Issuance of common stock for exercise of stock options			14							14		21
Issuance of common stock under Employee Stock Purchase Plan		63			69				55	63		122	140
Stock-based compensation	796	795	640	842	852	1,165			2,249	2,231		3,061	3,532
Balance, ending	432,323	431,527	430,593	402,655	400,605	399,684	431,527	400,605	674,580	432,323	402,655	433,220	404,061
Additional Paid-In Capital | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs			17,256							17,256		17,256
Additional Paid-In Capital | Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs		76	8,622	1,208		500				8,698		8,699	2,370
Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	(429,111)	(415,487)	(418,500)	(419,149)	(403,390)	(384,916)	(418,500)	(384,916)	(441,431)	(418,500)	(384,916)	(418,500)	(384,916)
Net loss	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)			(117,520)	(19,718)		(22,931)	(33,584)
Balance, ending	$ (438,218)	$ (429,111)	$ (415,487)	$ (404,903)	$ (419,149)	$ (403,390)	$ (429,111)	$ (419,149)	$ (558,951)	$ (438,218)	$ (404,903)	$ (441,431)	$ (418,500)
Preferred Stock | Series X Convertible Preferred Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning (in shares)	2,104,472	2,104,472	1,818,472	1,818,472	1,818,472	1,818,472	1,818,472	1,818,472	2,104,472	1,818,472	1,818,472	1,818,472	1,818,472
Balance, beginning	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Balance, ending (in shares)	2,104,472	2,104,472	2,104,472	1,818,472	1,818,472	1,818,472	2,104,472	1,818,472	2,104,472	2,104,472	1,818,472	2,104,472	1,818,472
Balance, ending	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Preferred Stock | Underwritten Public Offering | Series X Convertible Preferred Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs (in shares)			286,000							286,000		286,000
Common Stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance, beginning	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Balance, beginning (in shares)	4,512,595	4,501,256	3,623,591	3,462,024	3,452,567	3,393,320	3,623,591	3,393,320	4,530,113	3,623,591	3,393,320	3,623,591	3,393,320
Issuance of common stock for exercise of stock options (in shares)			812							812		1,287
Issuance of common stock for restricted share units vested (in shares)	8,219	232	14,617	13,920	252	27,039			40,220	23,068		24,487	41,380
Issuance of common stock under Employee Stock Purchase Plan (in shares)		8,060			9,205				7,050	8,060		15,465	18,168
Balance, ending	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Balance, ending (in shares)	4,520,814	4,512,595	4,501,256	3,559,141	3,462,024	3,452,567	4,512,595	3,462,024	7,046,633	4,520,814	3,559,141	4,530,113	3,623,591
Common Stock | Underwritten Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs (in shares)			554,300							554,300		554,300
Common Stock | Public Offering
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of stock, net of issuance costs (in shares)		3,047	307,936	83,197		32,208				310,983		310,983	170,723

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) $ / shares in Units, $ in Thousands

1 Months Ended

9 Months Ended

12 Months Ended

37 Months Ended

Nov. 26, 2024 USD ($)

Nov. 20, 2024 $ / shares shares

Sep. 09, 2024 employee

Jul. 19, 2024 shares

Jul. 18, 2024 shares

Apr. 24, 2024 USD ($)

Apr. 23, 2024 $ / shares shares

Mar. 31, 2021 USD ($)

Nov. 30, 2024 USD ($)

Apr. 30, 2024 USD ($) $ / shares

Sep. 30, 2024 USD ($) $ / shares shares

Sep. 30, 2023 USD ($) $ / shares shares

Dec. 31, 2023 USD ($) $ / shares shares

Apr. 23, 2024 USD ($) $ / shares shares

Jul. 17, 2024 shares

Apr. 22, 2024 shares

Jun. 30, 2023 $ / shares shares

Mar. 31, 2023 $ / shares shares

Dec. 31, 2022 $ / shares shares

Sep. 30, 2022 $ / shares shares

Jun. 30, 2022 $ / shares shares

Mar. 31, 2022 $ / shares shares

Subsequent Event [Line Items]

Common stock, shares authorized (in shares) | shares

50,000,000

20,000,000

50,000,000

20,000,000

20,000,000

20,000,000

20,000,000

200,000,000

20,000,000

20,000,000

20,000,000

20,000,000

20,000,000

20,000,000

Proceeds from private placement, net of issuance costs

$ 239,095

$ 0

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

Number of employees eliminated | employee

20

Reduction in force (as a percent)

0.30

Series A Convertible Voting Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Series A Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.0001

Maximum ownership following conversion (more than) (as a percent)

9.99%

9.99%

Conversion of stock, shares issued (in shares) | shares

2,469,250

Conversion of stock, shares converted (in shares) | shares

35,275

Private Placement | Series A Convertible Voting Preferred Stock [Member]

Subsequent Event [Line Items]

Shares sold (in shares) | shares

240,000

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Sale of stock, gross

$ 240,000

Private Placement | Series A Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share | $ / shares

$ 1,000

$ 1,000

Conversion of stock, shares issued (in shares) | shares

16,800,000

Conversion of stock, shares converted (in shares) | shares

240,000

Related Party [Member] | License [Member] | Janssen Pharmaceuticals, Inc. [Member] | Upfront Payment [Member]

Subsequent Event [Line Items]

Payments related to collaborative agreement

85,000

Related Party [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | Janssen Pharmaceuticals, Inc. [Member]

Subsequent Event [Line Items]

Payments related to collaborative agreement

$ 27,000

$ 27,000

Related Party [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | Janssen Pharmaceuticals, Inc. [Member] | Upfront Payment [Member]

Subsequent Event [Line Items]

Payments related to collaborative agreement

$ 27,000

Related Party [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | Janssen Pharmaceuticals, Inc. [Member] | Development, Regulatory, And Commercial Milestones [Member]

Subsequent Event [Line Items]

Collaborative agreement, potential transaction value

$ 695,000

Related Party [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | License [Member] | Janssen Pharmaceuticals, Inc. [Member] | Upfront Payment [Member]

Subsequent Event [Line Items]

Payments related to collaborative agreement

85,000

Related Party [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | License [Member] | Janssen Pharmaceuticals, Inc. [Member] | Development, Regulatory, And Commercial Milestones [Member]

Subsequent Event [Line Items]

Collaborative agreement, potential transaction value

150,000

Related Party [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | License [Member] | Janssen Pharmaceuticals, Inc. [Member] | Commercialization Milestone [Member]

Subsequent Event [Line Items]

Collaborative agreement, potential transaction value

$ 455,000

Subsequent event | Private Placement

Subsequent Event [Line Items]

Proceeds from private placement, net of issuance costs

$ 105,000

Sale of stock, gross

$ 105,000

Subsequent event | Private Placement | Common Stock

Subsequent Event [Line Items]

Shares sold (in shares) | shares

3,892,274

Sale of Stock, Price Per Share | $ / shares

$ 0.0001

Subsequent event | Private Placement | Common Stock | Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share | $ / shares

$ 14.912

Subsequent event | Private Placement | Series A Convertible Voting Preferred Stock [Member]

Subsequent Event [Line Items]

Sale of stock, gross

$ 240,000

Subsequent event | Pre Funded Warrants | Common Stock

Subsequent Event [Line Items]

Shares sold (in shares) | shares

3,149,035

Sale of Stock, Price Per Share | $ / shares

$ 14.9119

Warrant, Exercise Price, Increase | $ / shares

0.0001

Subsequent event | Pre Funded Warrants | Common Stock | Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share | $ / shares

$ 14.912

Subsequent event | Beneficial Owner [Member]

Subsequent Event [Line Items]

Beneficial Ownership Service Term

61 days

Subsequent event | Maximum | Beneficial Owner [Member]

Subsequent Event [Line Items]

Percentage Of Beneficially Owner In The Company

19.99%

Subsequent event | Minimum | Beneficial Owner [Member]

Subsequent Event [Line Items]

Percentage Of Beneficially Owner In The Company

9.99%